BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399-401. [PMID: 19684573 DOI: 10.1038/nature08309] [Cited by in Crossref: 2730] [Cited by in F6Publishing: 2920] [Article Influence: 195.0] [Reference Citation Analysis]
Number Citing Articles
1 Sy A, McCabe L, Hudson E, Ansari AM, Pedergnana V, Lin SK, Santana S, Fiorino M, Ala A, Stone B, Smith M, Nelson M, Barclay ST, McPherson S, Ryder SD, Collier J, Barnes E, Walker AS, Pett SL, Cooke G; STOP-HCV-1 trial team. Utility of a buccal swab point-of-care test for the IFNL4 genotype in the era of direct acting antivirals for hepatitis C virus. PLoS One 2023;18:e0280551. [PMID: 36689413 DOI: 10.1371/journal.pone.0280551] [Reference Citation Analysis]
2 Abdelrahman M, Ibrahim MK, Tawfik S, Omran D, Bendary MM, Hassanin SO, Elbatae H. The relation between SNPs in the NME1 gene and response to sofosbuvir in Egyptian patients with chronic HCV. Beni-Suef Univ J Basic Appl Sci 2023;12:2. [DOI: 10.1186/s43088-022-00337-6] [Reference Citation Analysis]
3 Duchen D, Vergara C, Thio CL, Kundu P, Chatterjee N, Thomas DL, Wojcik GL, Duggal P. Pathogen exposure misclassification can bias association signals in GWAS of infectious diseases when using population-based common control subjects. Am J Hum Genet 2023:S0002-9297(22)00547-X. [PMID: 36649706 DOI: 10.1016/j.ajhg.2022.12.013] [Reference Citation Analysis]
4 Mouterde M, Daali Y, Rollason V, Čížková M, Mulugeta A, Al Balushi KA, Fakis G, Constantinidis TC, Al-Thihli K, Černá M, Makonnen E, Boukouvala S, Al-Yahyaee S, Yimer G, Černý V, Desmeules J, Poloni ES. Joint Analysis of Phenotypic and Genomic Diversity Sheds Light on the Evolution of Xenobiotic Metabolism in Humans. Genome Biol Evol 2022;14. [PMID: 36445690 DOI: 10.1093/gbe/evac167] [Reference Citation Analysis]
5 Redondo N, Rodríguez-goncer I, Parra P, Albert E, Giménez E, Ruiz-merlo T, López-medrano F, San Juan R, González E, Sevillano Á, Andrés A, Navarro D, Aguado JM, Fernández-ruiz M. Impact of polymorphisms in genes orchestrating innate immune responses on replication kinetics of Torque teno virus after kidney transplantation. Front Genet 2022;13. [DOI: 10.3389/fgene.2022.1069890] [Reference Citation Analysis]
6 Santer DM, Li D, Ghosheh Y, Zahoor MA, Prajapati D, Hansen BE, Tyrrell DLJ, Feld JJ, Gehring AJ. Interferon-λ treatment accelerates SARS-CoV-2 clearance despite age-related delays in the induction of T cell immunity. Nat Commun 2022;13:6992. [PMID: 36385011 DOI: 10.1038/s41467-022-34709-4] [Reference Citation Analysis]
7 Casey JL, Dore GJ, Grebely J, Matthews GV, Cherepanov V, Martinello M, Marks P, Janssen HLA, Hansen BE, Kaul R, MacParland SA, Gehring AJ, Feld JJ. Hepatitis C virus-specific immune responses following direct-acting antivirals administered during recent hepatitis C virus infection. J Viral Hepat 2022. [PMID: 36302162 DOI: 10.1111/jvh.13761] [Reference Citation Analysis]
8 Casanova JL, Abel L. From rare disorders of immunity to common determinants of infection: Following the mechanistic thread. Cell 2022;185:3086-103. [PMID: 35985287 DOI: 10.1016/j.cell.2022.07.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
9 Biczo A, Bereczki F, Koch K, Varga PP, Lazary A; Genodisc Consortium. Genetic variants of interleukin 1B and 6 are associated with clinical outcome of surgically treated lumbar degenerative disc disease. BMC Musculoskelet Disord 2022;23:774. [PMID: 35964023 DOI: 10.1186/s12891-022-05711-0] [Reference Citation Analysis]
10 Oluyomi AO, El-Serag HB, Olayode A, Thrift AP. Neighborhood-Level Factors Contribute to Disparities in Hepatocellular Carcinoma Incidence in Texas. Clin Gastroenterol Hepatol 2022:S1542-3565(22)00711-X. [PMID: 35933074 DOI: 10.1016/j.cgh.2022.06.031] [Reference Citation Analysis]
11 Granatov EV, Abashev AR, Khabirov FA, Dykhanov AY, Khaibullin TI. Review of human interferons and the potential of their use in the complex therapy of a new coronavirus infection COVID-19. RJTAO 2022;14:38-44. [DOI: 10.14412/2074-2711-2022-1s-38-44] [Reference Citation Analysis]
12 Kazmierski J, Elsner C, Döhner K, Xu S, Ducroux A, Pott F, Jansen J, Thorball CW, Zeymer O, Zhou X, Fedorov R, Fellay J, Löffler MW, Weber ANR, Sodeik B, Goffinet C. A Baseline Cellular Antiviral State Is Maintained by cGAS and Its Most Frequent Naturally Occurring Variant rs610913. The Journal of Immunology 2022;209:535-547. [DOI: 10.4049/jimmunol.2100685] [Reference Citation Analysis]
13 Yin S, Yu Y. An adoption-implementation framework of digital green knowledge to improve the performance of digital green innovation practices for industry 5.0. Journal of Cleaner Production 2022;363:132608. [DOI: 10.1016/j.jclepro.2022.132608] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
14 Hayes CN, Imamura M, Tanaka J, Chayama K. Road to elimination of HCV: Clinical challenges in HCV management. Liver Int 2022;42:1935-44. [PMID: 34967486 DOI: 10.1111/liv.15150] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
15 Duchen D, Vergara C, Thio CL, Kundu P, Chatterjee N, Thomas DL, Wojcik GL, Duggal P. Pathogen exposure misclassification can bias association signals in GWAS of infectious diseases when using population-based common controls.. [DOI: 10.1101/2022.07.14.22276656] [Reference Citation Analysis]
16 Schäfer A, Leist SR, Gralinski LE, Martinez DR, Winkler ES, Okuda K, Hawkins PE, Gully KL, Graham RL, Scobey DT, Bell TA, Hock P, Shaw GD, Loome JF, Madden EA, Anderson E, Baxter VK, Taft-benz SA, Zweigart MR, May SR, Dong S, Clark M, Miller DR, Lynch RM, Heise MT, Tisch R, Boucher RC, Pardo Manuel de Villena F, Montgomery SA, Diamond MS, Ferris MT, Baric RS, Lednicky JA. A Multitrait Locus Regulates Sarbecovirus Pathogenesis. mBio. [DOI: 10.1128/mbio.01454-22] [Reference Citation Analysis]
17 Oluyomi AO, Mohammadi KA, El-Serag HB, Thrift AP. Mediating Effects of Neighborhood-Level Socioeconomic Deprivation on the Association Between Race/Ethnicity and Advanced Hepatocellular Carcinoma. Cancer Epidemiol Biomarkers Prev 2022;31:1402-9. [PMID: 35314860 DOI: 10.1158/1055-9965.EPI-21-1396] [Reference Citation Analysis]
18 Hanton AJ, Scott F, Stenzel K, Nausch N, Zdesenko G, Mduluza T, Mutapi F. Frequency distribution of cytokine and associated transcription factor single nucleotide polymorphisms in Zimbabweans: Impact on schistosome infection and cytokine levels. PLoS Negl Trop Dis 2022;16:e0010536. [DOI: 10.1371/journal.pntd.0010536] [Reference Citation Analysis]
19 Xu T, Peng B, Liu M, Liu Q, Yang J, Qu M, Liu N, Lin L, Wu J. Favorable Genotypes of Type III Interferon Confer Risk of Dyslipidemia in the Population With Obesity. Front Endocrinol 2022;13:871352. [DOI: 10.3389/fendo.2022.871352] [Reference Citation Analysis]
20 Borde JP, Zajkowska J. Chapter 5: TBE in adults. Tick-borne encephalitis - The Book 2022. [DOI: 10.33442/26613980_5-5] [Reference Citation Analysis]
21 Møhlenberg M, O'Brien TR, Hartmann R. The role of IFNL4 in liver inflammation and progression of fibrosis. Genes Immun 2022;23:111-7. [PMID: 35585257 DOI: 10.1038/s41435-022-00173-9] [Reference Citation Analysis]
22 Anstee QM, Castera L, Loomba R. Impact of non-invasive biomarkers on hepatology practice: Past, present and future. J Hepatol 2022;76:1362-78. [PMID: 35589256 DOI: 10.1016/j.jhep.2022.03.026] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
23 Cherepnin MA, Tsukanov VV, Savchenko AA, Vasyutin AV, Kasparov EV, Tonkikh JL, Borisov AG. Comparison of clinical and laboratory characteristics and frequency of liver fibrosis in patients with chronic viral hepatitis C of the first and third genotypes. Medicinskij sovet 2022. [DOI: 10.21518/2079-701x-2022-16-7-98-103] [Reference Citation Analysis]
24 Սարգսյան Ս. ՔՐՈՆԻԿ ՎԻՐՈՒՍԱՅԻՆ C ՀԵՊԱՏԻՏ. ՀԱԿԱՎԻՐՈՒՍԱՅԻՆ ԲՈՒԺՄԱՆ ՓՈՒԼԵՐԸ (ՎԵՐԼՈՒԾՈՒԹՅՈՒՆ). MSEJ 2022. [DOI: 10.56936/18291775-2022.33-22] [Reference Citation Analysis]
25 Kim WR, Telep LE, Jump B, Lu M, Ramroth H, Flaherty J, Gaggar A, Chokkalingam AP, Gordon SC. Risk of hepatocellular carcinoma in treatment-naïve chronic hepatitis B patients receiving tenofovir disoproxil fumarate versus entecavir in the United States. Aliment Pharmacol Ther 2022;55:828-35. [PMID: 35137422 DOI: 10.1111/apt.16786] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Santer DM, Li D, Ghosheh Y, Zahoor MA, Prajapati D, Tyrrell DLJ, Feld JJ, Gehring AJ. Pegylated-interferon-λ treatment-induced peripheral interferon stimulated genes are associated with SARS-CoV-2 viral load decline despite delayed T cell response in older individuals.. [DOI: 10.1101/2022.02.24.22271438] [Reference Citation Analysis]
27 Guan J, Ren Y, Wang J, Zhu H. The Knowledge on HCV: From the Discovery to the Elimination. Infectious Microbes and Diseases 2022;4:1-6. [DOI: 10.1097/im9.0000000000000085] [Reference Citation Analysis]
28 Zheng M, Lin Y, Wang W, Zhao Y, Bao X. Application of nucleoside or nucleotide analogues in RNA dynamics and RNA ‐binding protein analysis. WIREs RNA 2022. [DOI: 10.1002/wrna.1722] [Reference Citation Analysis]
29 Sorrentino L, Silvestri V, Oliveto G, Scordio M, Frasca F, Fracella M, Bitossi C, D’auria A, Santinelli L, Gabriele L, Pierangeli A, Mastroianni CM, d’Ettorre G, Antonelli G, Caruz A, Ottini L, Scagnolari C. Distribution of Interferon Lambda 4 Single Nucleotide Polymorphism rs11322783 Genotypes in Patients with COVID-19. Microorganisms 2022;10:363. [DOI: 10.3390/microorganisms10020363] [Reference Citation Analysis]
30 Yilmaz B, Çakmak Genç G, Karakaş Çelik S, Solak Tekin N, Can M, Dursun A. Association between Psoriasis Disease and IFN-λ Gene Polymorphisms. Immunol Invest 2022;:1-13. [PMID: 35118914 DOI: 10.1080/08820139.2022.2036187] [Reference Citation Analysis]
31 Luna-Cuadros MA, Chen HW, Hanif H, Ali MJ, Khan MM, Lau DTY. Risk of hepatocellular carcinoma after hepatitis C virus cure. World J Gastroenterol 2022; 28(1): 96-107 [DOI: 10.3748/wjg.v28.i1.96] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
32 Villamil FG, Massenzio NE, Baré PC, Cocco PA, Cairo FM, Picchio GR. Twenty-year follow-up of an outbreak of hepatitis C in a small rural town of Argentina: The O'Brien Project. Ann Hepatol 2022;27 Suppl 1:100577. [PMID: 34740846 DOI: 10.1016/j.aohep.2021.100577] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Ramamoorthy A, Sissung T, Pacanowski M. Clinical pharmacogenetics. Atkinson's Principles of Clinical Pharmacology 2022. [DOI: 10.1016/b978-0-12-819869-8.00016-1] [Reference Citation Analysis]
34 Manns MP, Maasoumy B. Breakthroughs in hepatitis C research: from discovery to cure. Nat Rev Gastroenterol Hepatol 2022;19:533-50. [PMID: 35595834 DOI: 10.1038/s41575-022-00608-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
35 Ferwerda B, Abdellaoui A, Nieuwdorp M, Zwinderman K. A Genetic Map of the Modern Urban Society of Amsterdam. Front Genet 2021;12:727269. [PMID: 34917125 DOI: 10.3389/fgene.2021.727269] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Manivasagam S, Klein RS. Type III Interferons: Emerging Roles in Autoimmunity. Front Immunol 2021;12:764062. [PMID: 34899712 DOI: 10.3389/fimmu.2021.764062] [Reference Citation Analysis]
37 Li J, Chen H, Chen J, Zhou B, Hou J, Jiang DK. A Missense Variant in Granulysin is Associated with the Efficacy of Pegylated-Interferon-Alpha Therapy in Chinese Patients with HBeAg-Positive Chronic Hepatitis B. Pharmgenomics Pers Med 2021;14:1505-15. [PMID: 34848996 DOI: 10.2147/PGPM.S337962] [Reference Citation Analysis]
38 Ibrahim MK, AbdElrahman M, Bader El Din NG, Tawfik S, Abd-Elsalam S, Omran D, Barakat AZ, Farouk S, Elbatae H, El Awady MK. The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients. Microb Pathog 2021;162:105311. [PMID: 34843922 DOI: 10.1016/j.micpath.2021.105311] [Reference Citation Analysis]
39 Møhlenberg M, Monrad I, Vibholm LK, Nielsen SSF, Frattari GS, Schleimann MH, Olesen R, Kjolby M, Gunst JD, Søgaard OS, O'Brien TR, Tolstrup M, Hartmann R. The Impact of IFNλ4 on the Adaptive Immune Response to SARS-CoV-2 Infection. J Interferon Cytokine Res 2021;41:407-14. [PMID: 34788130 DOI: 10.1089/jir.2021.0106] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
40 Saponi-Cortes JMR, Rivas MD, Calle-Alonso F, Sanchez JF, Costo A, Martin C, Zamorano J. IFNL4 genetic variant can predispose to COVID-19. Sci Rep 2021;11:21185. [PMID: 34707167 DOI: 10.1038/s41598-021-00747-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
41 Jin Z, Zheng E, Sareli C, Kolattukudy PE, Niu J. Monocyte Chemotactic Protein-Induced Protein 1 (MCPIP-1): A Key Player of Host Defense and Immune Regulation. Front Immunol 2021;12:727861. [PMID: 34659213 DOI: 10.3389/fimmu.2021.727861] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
42 Redondo N, Navarro D, Aguado JM, Fernández-Ruiz M. Human genetic polymorphisms and risk of viral infection after solid organ transplantation. Transplant Rev (Orlando) 2021;36:100669. [PMID: 34688126 DOI: 10.1016/j.trre.2021.100669] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
43 Rich HE, Antos D, McCourt CC, Zheng WQ, Devito LJ, McHugh KJ, Gopal R, Wang J, Alcorn JF. Murine Type III interferons are functionally redundant and correlate with bacterial burden during influenza/bacterial super-infection. PLoS One 2021;16:e0255309. [PMID: 34618816 DOI: 10.1371/journal.pone.0255309] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Gozman L, Perry K, Nikogosov D, Klabukov I, Shevlyakov A, Baranova A. A Role of Variance in Interferon Genes to Disease Severity in COVID-19 Patients. Front Genet 2021;12:709388. [PMID: 34603376 DOI: 10.3389/fgene.2021.709388] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
45 Ridruejo E, Pereson MJ, Flichman DM, Di Lello FA. Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions. World J Hepatol 2021; 13(9): 1069-1078 [PMID: 34630875 DOI: 10.4254/wjh.v13.i9.1069] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
46 Ye J, Chen J. Interferon and Hepatitis B: Current and Future Perspectives. Front Immunol 2021;12:733364. [PMID: 34557195 DOI: 10.3389/fimmu.2021.733364] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
47 Cai Y. Comment on "Safe use of livers from deceased donors older than 70 years in recipients with HCV cirrhosis treated with direct-action antivirals. Retrospective cohort study" (Int J Surg 2021:105981). Int J Surg 2021;94:106096. [PMID: 34537398 DOI: 10.1016/j.ijsu.2021.106096] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
48 Onabajo OO, Wang F, Lee MH, Florez-Vargas O, Obajemu A, Tanikawa C, Vargas JM, Liao SF, Song C, Huang YH, Shen CY, Banday AR, O'Brien TR, Hu Z, Matsuda K, Prokunina-Olsson L. Intracellular Accumulation of IFN-λ4 Induces ER Stress and Results in Anti-Cirrhotic but Pro-HCV Effects. Front Immunol 2021;12:692263. [PMID: 34497603 DOI: 10.3389/fimmu.2021.692263] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
49 Gui Y, Grzyb K, Thomas MH, Ohnmacht J, Garcia P, Buttini M, Skupin A, Sauter T, Sinkkonen L. Single-nuclei chromatin profiling of ventral midbrain reveals cell identity transcription factors and cell-type-specific gene regulatory variation. Epigenetics Chromatin 2021;14:43. [PMID: 34503558 DOI: 10.1186/s13072-021-00418-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
50 Ferraris P, Wichit S, Cordel N, Missé D. Human host genetics and susceptibility to ZIKV infection. Infect Genet Evol 2021;95:105066. [PMID: 34487865 DOI: 10.1016/j.meegid.2021.105066] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
51 Kumar N, Prabhu SS, Monga I, Banerjee I. Influence of IL28B gene polymorphisms on PegINF-RBV-mediated HCV clearance in HIV-HCV co-infected patients: A meta-analysis. Meta Gene 2021;29:100909. [DOI: 10.1016/j.mgene.2021.100909] [Reference Citation Analysis]
52 Erdei E, Torgerson D, O’leary R, Spear M, Shedden M, O’leary M, Enright K, Best L. Respiratory syncytial virus-specific immunoglobulin G (IgG) concentrations associate with environmental and genetic factors: the Factors Influencing Pediatric Asthma Study.. [DOI: 10.1101/2021.08.17.21262198] [Reference Citation Analysis]
53 Liu JJ. Disparity in the Care of Black Inflammatory Bowel Disease Patients. Inflamm Bowel Dis 2021;27:1548-9. [PMID: 34037231 DOI: 10.1093/ibd/izab100] [Reference Citation Analysis]
54 Gokhale NS, Smith JR, Van Gelder RD, Savan R. RNA regulatory mechanisms that control antiviral innate immunity. Immunol Rev 2021;304:77-96. [PMID: 34405416 DOI: 10.1111/imr.13019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
55 Plotnikova M, Lozhkov A, Romanovskaya-Romanko E, Baranovskaya I, Sergeeva M, Kаа K, Klotchenko S, Vasin A. IFN-λ1 Displays Various Levels of Antiviral Activity In Vitro in a Select Panel of RNA Viruses. Viruses 2021;13:1602. [PMID: 34452467 DOI: 10.3390/v13081602] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
56 Chen Q, Coto-Llerena M, Suslov A, Teixeira RD, Fofana I, Nuciforo S, Hofmann M, Thimme R, Hensel N, Lohmann V, Ng CKY, Rosenberger G, Wieland S, Heim MH. Interferon lambda 4 impairs hepatitis C viral antigen presentation and attenuates T cell responses. Nat Commun 2021;12:4882. [PMID: 34385466 DOI: 10.1038/s41467-021-25218-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
57 Elsheredy AG, Almaeen AH, Ghazy AA, Helaly GF, Amer I, Ghazy HA, Haydara T. Impact of Interleukin 28B and ICAM-1 Genetic Polymorphisms on Response to Direct Antiviral Treatment Among HCV Infected Patients. Endocr Metab Immune Disord Drug Targets 2020;20:1328-35. [PMID: 32368983 DOI: 10.2174/1871530320666200505113619] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
58 Béziat V, Jouanguy E. Human inborn errors of immunity to oncogenic viruses. Curr Opin Immunol 2021;72:277-85. [PMID: 34364035 DOI: 10.1016/j.coi.2021.06.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
59 Wang Y, Li L, Dong Z, Yu Y, Zhou A, Zhao X, Zhang J. Ultrasensitive electrochemical detection of hepatitis C virus core antigen using terminal deoxynucleotidyl transferase amplification coupled with DNA nanowires. Mikrochim Acta 2021;188:285. [PMID: 34347172 DOI: 10.1007/s00604-021-04939-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
60 Kitab B, Kohara M, Tsukiyama-kohara K. Host-Targeting Antivirals for Treatment of Hepatitis C. Advances in Hepatology 2021. [DOI: 10.5772/intechopen.95373] [Reference Citation Analysis]
61 Kulkeaw K, Pengsart W. Progress and Challenges in the Use of a Liver-on-a-Chip for Hepatotropic Infectious Diseases. Micromachines (Basel) 2021;12:842. [PMID: 34357252 DOI: 10.3390/mi12070842] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
62 McInnes G, Yee SW, Pershad Y, Altman RB. Genomewide Association Studies in Pharmacogenomics. Clin Pharmacol Ther 2021;110:637-48. [PMID: 34185318 DOI: 10.1002/cpt.2349] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
63 Szczotka-Flynn LB, Shovlin JP, Schnider CM, Caffery BE, Alfonso EC, Carnt NA, Chalmers RL, Collier S, Jacobs DS, Joslin CE, Kroken AR, Lakkis C, Pearlman E, Schein OD, Stapleton F, Tu E, Willcox MDP. American Academy of Optometry Microbial Keratitis Think Tank. Optom Vis Sci 2021;98:182-98. [PMID: 33771951 DOI: 10.1097/OPX.0000000000001664] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
64 da Silva AMV, Alvarado-Arnez LE, Azamor T, Batista-Silva LR, Leal-Calvo T, Bezerra OCL, Ribeiro-Alves M, Kehdy FSG, Neves PCDC, Bayma C, da Silva J, de Souza AF, Muller M, de Andrade EF, Andrade ACM, Dos Santos EM, Xavier JR, Maia MLS, Meireles RP, Cuni HN, Sander GB, Picon PD, Matos DCS, Moraes MO. Interferon-lambda 3 and 4 Polymorphisms Increase Sustained Virological Responses and Regulate Innate Immunity in Antiviral Therapy With Pegylated Interferon-Alpha. Front Cell Infect Microbiol 2021;11:656393. [PMID: 34307188 DOI: 10.3389/fcimb.2021.656393] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
65 Waldenström J, Kåberg M, Alanko Blomé M, Widell A, Björkman P, Nilsson S, Hammarberg A, Weiland O, Nyström K, Lagging M. Absence of interferon-λ 4 enhances spontaneous clearance of acute hepatitis C virus genotypes 1-3 infection. Scand J Gastroenterol 2021;56:855-61. [PMID: 34034600 DOI: 10.1080/00365521.2021.1925956] [Reference Citation Analysis]
66 Waldenström J, Hellstrand K, Westin J, Nilsson S, Christensen P, Färkkilä M, Mørch K, Langeland N, Norkrans G, Lagging M. Presence of interferon-λ 4, male gender, absent/mild steatosis and low viral load augment antibody levels to hepatitis C virus. Scand J Gastroenterol 2021;56:849-54. [PMID: 34078234 DOI: 10.1080/00365521.2021.1922750] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
67 McLaren PJ, Fellay J. HIV-1 and human genetic variation. Nat Rev Genet 2021. [PMID: 34168330 DOI: 10.1038/s41576-021-00378-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
68 Boldeanu MV, Siloşi I, Bărbulescu AL, Sandu RE, Geormăneanu C, Pădureanu V, Popescu-Drigă MV, Poenariu IS, Siloşi CA, Ungureanu AM, Dijmărescu AL, Boldeanu L. Host immune response in chronic hepatitis C infection: involvement of cytokines and inflammasomes. Rom J Morphol Embryol 2020;61:33-43. [PMID: 32747893 DOI: 10.47162/RJME.61.1.04] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
69 Novotny LA, Evans JG, Su L, Guo H, Meissner EG. Review of Lambda Interferons in Hepatitis B Virus Infection: Outcomes and Therapeutic Strategies. Viruses 2021;13:1090. [PMID: 34207487 DOI: 10.3390/v13061090] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
70 Borde JP, Zajkowska J. Chapter 5: TBE in adults. Tick-borne encephalitis - The Book 2021. [DOI: 10.33442/26613980_5-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
71 Jäger R, Gisslinger H, Fuchs E, Bogner E, Milosevic Feenstra JD, Weinzierl J, Schischlik F, Gisslinger B, Schalling M, Zörer M, Krejcy K, Klade C, Kralovics R. Germline genetic factors influence the outcome of interferon-α therapy in polycythemia vera. Blood 2021;137:387-91. [PMID: 32814349 DOI: 10.1182/blood.2020005792] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
72 Johnson AM, Barigye R, Saminathan H. Perspectives on the use and risk of adverse events associated with cytokine-storm targeting antibodies and challenges associated with development of novel monoclonal antibodies for the treatment of COVID-19 clinical cases. Hum Vaccin Immunother 2021;17:2824-40. [PMID: 33974497 DOI: 10.1080/21645515.2021.1908060] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
73 Henden AS, Koyama M, Robb RJ, Forero A, Kuns RD, Chang K, Ensbey KS, Varelias A, Kazakoff SH, Waddell N, Clouston AD, Giri R, Begun J, Blazar BR, Degli-Esposti MA, Kotenko SV, Lane SW, Bowerman K, Savan R, Hugenholtz P, Gartlan KH, Hill GR. IFNλ Therapy Prevents Severe Gastrointestinal Graft-versus-Host Disease. Blood 2021:blood. [PMID: 33951730 DOI: 10.1182/blood.2020006375] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
74 Wang SQ, Shen Y, Li J, Liu Y, Cheng LS, Wu SD, She WM, Jiang W. Entecavir-induced interferon-λ1 suppresses type 2 innate lymphoid cells in patients with hepatitis B virus-related liver cirrhosis. J Viral Hepat 2021;28:795-808. [PMID: 33482039 DOI: 10.1111/jvh.13476] [Reference Citation Analysis]
75 Ly KN, Miniño AM, Liu SJ, Roberts H, Hughes EM, Ward JW, Jiles RB. Deaths Associated With Hepatitis C Virus Infection Among Residents in 50 States and the District of Columbia, 2016-2017. Clin Infect Dis 2020;71:1149-60. [PMID: 31586173 DOI: 10.1093/cid/ciz976] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
76 Fazylov VK, Manapova ER, Akifev VO. Сatamnestic data on the effect of interferon therapy on the course of combined HIV/HCV-infection. VIČ-infekc immunosupr 2021;13:45-52. [DOI: 10.22328/2077-9828-2021-13-1-45-52] [Reference Citation Analysis]
77 Thorball CW, Fellay J, Borghesi A. Immunological lessons from genome-wide association studies of infections. Curr Opin Immunol 2021;72:87-93. [PMID: 33878603 DOI: 10.1016/j.coi.2021.03.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
78 Prokunina-Olsson L, Morrison RD, Obajemu A, Mahamar A, Kim S, Attaher O, Florez-Vargas O, Sidibe Y, Onabajo OO, Hutchinson AA, Manning M, Kwan J, Brand N, Dicko A, Fried M, Albert PS, Mbulaiteye SM, Duffy PE. IFN-λ4 is associated with increased risk and earlier occurrence of several common infections in African children. Genes Immun 2021;22:44-55. [PMID: 33850301 DOI: 10.1038/s41435-021-00127-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
79 Hahn WO, Pepper M, Liles WC. B cell intrinsic expression of IFNλ receptor suppresses the acute humoral immune response to experimental blood-stage malaria. Virulence 2020;11:594-606. [PMID: 32407154 DOI: 10.1080/21505594.2020.1768329] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
80 IL28B遺伝子多型の発見から臨床応用①ゲノムワイド関連解析(GWAS). Acta hepatologica Japonica 2021;62:206-208. [DOI: 10.2957/kanzo.62.206] [Reference Citation Analysis]
81 Jeyarajan AJ, Chung RT. Insights Into the Pathophysiology of Liver Disease in HCV/HIV: Does it End With HCV Cure? J Infect Dis 2020;222:S802-13. [PMID: 33245355 DOI: 10.1093/infdis/jiaa279] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
82 Hassanien KS, El-Sayed EM, Ismail RS, Zakarya ZM, Helal GK. Association between interleukin 28B polymorphism and sustained virological response to sofosbuvir plus daclatasvir in chronic hepatitis C genotype 4 Egyptian patients. J Clin Pharm Ther 2021;46:942-9. [PMID: 33768560 DOI: 10.1111/jcpt.13417] [Reference Citation Analysis]
83 Roy S, Guha Roy D, Bhushan A, Bharatiya S, Chinnaswamy S. Functional genetic variants of the IFN-λ3 (IL28B) gene and transcription factor interactions on its promoter. Cytokine 2021;142:155491. [PMID: 33725487 DOI: 10.1016/j.cyto.2021.155491] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
84 Chang ML, Chang SW, Chen SC, Chien RN, Hsu CL, Chang MY, Fann CSJ. Genetic Association of Hepatitis C-Related Mixed Cryoglobulinemia: A 10-Year Prospective Study of Asians Treated with Antivirals. Viruses 2021;13:464. [PMID: 33799903 DOI: 10.3390/v13030464] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
85 Lunova M, Kubovciak J, Smolková B, Uzhytchak M, Michalova K, Dejneka A, Strnad P, Lunov O, Jirsa M. Expression of Interferons Lambda 3 and 4 Induces Identical Response in Human Liver Cell Lines Depending Exclusively on Canonical Signaling. Int J Mol Sci 2021;22:2560. [PMID: 33806448 DOI: 10.3390/ijms22052560] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
86 Saponi-cortes JMR, Rivas MD, Calle F, Sanchez Muñoz-torrero JF, Costo A, Martin C, Zamorano J. IFNL4 genetic variant can predispose to COVID-19.. [DOI: 10.1101/2021.03.01.21252696] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
87 Meissner EG, Chung D, Tsao B, Haas DW, Utay NS. IFNL4 Genotype Does Not Associate with CD4 T-Cell Recovery in People Living with Human Immunodeficiency Virus. AIDS Res Hum Retroviruses 2021;37:184-8. [PMID: 33066718 DOI: 10.1089/AID.2020.0104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
88 Støy S, Terczynska-Dyla E, Veidal SS, Rigbolt K, Vilstrup H, Grønbaek H, Hartmann R, Sandahl TD. Interferon lambda 4 genotype and pathway in alcoholic hepatitis. Scand J Gastroenterol 2021;56:304-11. [PMID: 33602032 DOI: 10.1080/00365521.2021.1874046] [Reference Citation Analysis]
89 Rüeger S, Hammer C, Loetscher A, McLaren PJ, Lawless D, Naret O, Khanna N, Bernasconi E, Cavassini M, Günthard HF, Kahlert CR, Rauch A, Depledge DP, Morfopoulou S, Breuer J, Zdobnov E, Fellay J; Swiss HIV Cohort Study. The influence of human genetic variation on Epstein-Barr virus sequence diversity. Sci Rep 2021;11:4586. [PMID: 33633271 DOI: 10.1038/s41598-021-84070-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
90 Chihab H, Badre W, Tahiri M, Jadid FZ, Zaidane I, Elfihry R, Marchio A, Pineau P, Ezzikouri S, Benjelloun S. IFNL4 rs12979860 polymorphism influences HBV DNA viral loads but not the outcome of HBV infection in Moroccan patients. Microbes Infect 2021;23:104802. [PMID: 33607264 DOI: 10.1016/j.micinf.2021.104802] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
91 Rotimi CN, Bentley AR, Doumatey AP, Chen G, Shriner D, Adeyemo A. Insights into the Genomic Landscape of African Ancestry Populations. The Science of Health Disparities Research 2021. [DOI: 10.1002/9781119374855.ch9] [Reference Citation Analysis]
92 Волынец Г. Features of Lipid Metabolism in HCV Infection. Клиническая инфектология и паразитология 2021. [DOI: 10.34883/pi.2020.9.4.028] [Reference Citation Analysis]
93 Feld JJ, Kandel C, Biondi MJ, Kozak RA, Zahoor MA, Lemieux C, Borgia SM, Boggild AK, Powis J, McCready J, Tan DHS, Chan T, Coburn B, Kumar D, Humar A, Chan A, O'Neil B, Noureldin S, Booth J, Hong R, Smookler D, Aleyadeh W, Patel A, Barber B, Casey J, Hiebert R, Mistry H, Choong I, Hislop C, Santer DM, Lorne Tyrrell D, Glenn JS, Gehring AJ, Janssen HLA, Hansen BE. Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial. Lancet Respir Med 2021;9:498-510. [PMID: 33556319 DOI: 10.1016/S2213-2600(20)30566-X] [Cited by in Crossref: 105] [Cited by in F6Publishing: 116] [Article Influence: 52.5] [Reference Citation Analysis]
94 Hashempour T, Dehghani B, Mousavi Z, Akbari T, Hasanshahi Z, Moayedi J, Yahaghi M, Davarpanah MA. Association of Mutations in the NS5A-PKRBD Region and IFNL4 Genotypes with Hepatitis C Interferon Responsiveness and its Functional and Structural Analysis. CP 2021;18:38-49. [DOI: 10.2174/1570164617666200107091124] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
95 Rauff B, Amar A, Chudhary SA, Mahmood S, Tayyab GUN, Hanif R. Interferon-λ rs12979860 genotype association with liver fibrosis in chronic hepatitis C (CHC) patients in the Pakistani population. Arch Virol 2021;166:1047-56. [PMID: 33528661 DOI: 10.1007/s00705-020-04901-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
96 Schwerk J, Negash A, Savan R, Gale M Jr. Innate Immunity in Hepatitis C Virus Infection. Cold Spring Harb Perspect Med 2021;11:a036988. [PMID: 32341066 DOI: 10.1101/cshperspect.a036988] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
97 de Bitencorte JT, Rech TF, Lunge VR, dos Santos DC, Álvares-da-Silva MR, Simon D. Association of interferon lambda-4 rs12979860 polymorphism with hepatocellular carcinoma in patients with chronic hepatitis C infection. World J Hepatol 2021; 13(1): 109-119 [PMID: 33584990 DOI: 10.4254/wjh.v13.i1.109] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
98 Polyak SJ, Crispe IN, Baumert TF. Liver Abnormalities after Elimination of HCV Infection: Persistent Epigenetic and Immunological Perturbations Post-Cure. Pathogens 2021;10:44. [PMID: 33430338 DOI: 10.3390/pathogens10010044] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
99 Al-busafi SA, Alnaamani K. Hepatitis C-Induced Hepatocellular Carcinoma in the Middle East. Liver Cancer in the Middle East 2021. [DOI: 10.1007/978-3-030-78737-0_17] [Reference Citation Analysis]
100 Degasperi E, Colombo M. Natural History of Hepatitis C Infection. Hepatitis C: Epidemiology, Prevention and Elimination 2021. [DOI: 10.1007/978-3-030-64649-3_7] [Reference Citation Analysis]
101 Bove G, Mehnert A, Dao Thi VL. iPSCs for modeling hepatotropic pathogen infections. iPSCs for Studying Infectious Diseases 2021. [DOI: 10.1016/b978-0-12-823808-0.00013-4] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
102 Takaoka A. Interferons. Handbook of Hormones 2021. [DOI: 10.1016/b978-0-12-820649-2.00115-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
103 Fawaz R, Jonas MM. Acute and Chronic Hepatitis. Pediatric Gastrointestinal and Liver Disease 2021. [DOI: 10.1016/b978-0-323-67293-1.00075-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
104 Fernandez T. Genome-wide Association. Encyclopedia of Autism Spectrum Disorders 2021. [DOI: 10.1007/978-3-319-91280-6_1996] [Reference Citation Analysis]
105 Voight BF. What HaveWe Learned fromGWAS? Human Population Genomics 2021. [DOI: 10.1007/978-3-030-61646-5_7] [Reference Citation Analysis]
106 Im YR, Hunter H, de Gracia Hahn D, Duret A, Cheah Q, Dong J, Fairey M, Hjalmarsson C, Li A, Lim HK, Mckeown L, Mitrofan C, Rao R, Utukuri M, Rowe IA, Mann JP. A systematic analysis of rodent models implicates adipogenesis and innate immunity in pathogenesis of fatty liver disease.. [DOI: 10.1101/2020.12.15.422799] [Reference Citation Analysis]
107 Kwok AJ, Mentzer A, Knight JC. Host genetics and infectious disease: new tools, insights and translational opportunities. Nat Rev Genet 2021;22:137-53. [PMID: 33277640 DOI: 10.1038/s41576-020-00297-6] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 16.3] [Reference Citation Analysis]
108 Rüeger S, Hammer C, Loetscher A, Mclaren PJ, Lawless D, Naret O, Depledge DP, Morfopoulou S, Breuer J, Zdobnov E, Fellay J, Swiss HIV Cohort Study. The influence of human genetic variation on Epstein-Barr virus sequence diversity.. [DOI: 10.1101/2020.12.02.20242370] [Reference Citation Analysis]
109 Hassan R, Allali I, Agamah FE, Elsheikh SSM, Thomford NE, Dandara C, Chimusa ER. Drug response in association with pharmacogenomics and pharmacomicrobiomics: towards a better personalized medicine. Brief Bioinform 2021;22:bbaa292. [PMID: 33253350 DOI: 10.1093/bib/bbaa292] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
110 Lozhkov AA, Klotchenko SA, Ramsay ES, Moshkoff HD, Moshkoff DA, Vasin AV, Salvato MS. The Key Roles of Interferon Lambda in Human Molecular Defense against Respiratory Viral Infections. Pathogens 2020;9:E989. [PMID: 33255985 DOI: 10.3390/pathogens9120989] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
111 Kubota N, Fujiwara N, Hoshida Y. Clinical and Molecular Prediction of Hepatocellular Carcinoma Risk. J Clin Med 2020;9:E3843. [PMID: 33256232 DOI: 10.3390/jcm9123843] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
112 Feld JJ, Kandel C, Biondi MJ, Kozak RA, Zahoor MA, Lemieux C, Borgia SM, Boggild AK, Powis J, Mccready J, Tan DHS, Chan T, Coburn B, Kumar D, Humar A, Chan A, O’neil B, Noureldin S, Booth J, Hong R, Smookler D, Aleyadeh W, Patel A, Barber B, Casey J, Hiebert R, Mistry H, Choong I, Hislop C, Santer DM, Tyrrell DL, Glenn JS, Gehring AJ, Janssen HL, Hansen B. Peginterferon-lambda for the treatment of COVID-19 in outpatients.. [DOI: 10.1101/2020.11.09.20228098] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
113 Walter MR. The Role of Structure in the Biology of Interferon Signaling. Front Immunol 2020;11:606489. [PMID: 33281831 DOI: 10.3389/fimmu.2020.606489] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 9.7] [Reference Citation Analysis]
114 Wang F, Huang S, Gao R, Zhou Y, Lai C, Li Z, Xian W, Qian X, Huang Y, Tang Q, Liu P, Chen R, Liu R, Li X, Tong X, Zhou X, Bai Y, Duan G, Zhang T, Xu X, Wang J, Yang H, Liu S, He Q, Jin X, Liu L. Initial whole-genome sequencing and analysis of the host genetic contribution to COVID-19 severity and susceptibility. Cell Discov. 2020;6:83. [PMID: 33298875 DOI: 10.1038/s41421-020-00231-4] [Cited by in Crossref: 89] [Cited by in F6Publishing: 96] [Article Influence: 29.7] [Reference Citation Analysis]
115 Sakr AA, Ahmed AE, Abd El-Maksoud MDE, Gamal A, El-Garem H, Ahmed OM. Interferon lambda 4 gene polymorphisms as a predicting tool of response to hepatitis C virus genotype 4 patients treated with Sofosbuvir and Ribavirin. Infect Genet Evol 2020;86:104606. [PMID: 33127459 DOI: 10.1016/j.meegid.2020.104606] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
116 Szczotka-Flynn L. Contact Lens-Related Microbial Keratitis and Host Genetics. Eye Contact Lens 2020;46:327-8. [PMID: 33119983 DOI: 10.1097/ICL.0000000000000735] [Reference Citation Analysis]
117 Onabajo OO, Wang F, Lee M, Florez-vargas O, Obajemu A, Castro MAA, Tanikawa C, Vargas J, Liao S, Song C, Huang Y, Shen C, Banday AR, O’brien TR, Hu Z, Matsuda K, Robertson AG, Prokunina-olsson L. IFN-λ4 may contribute to HCV persistence by increasing ER stress and enhancing IRF1 signaling.. [DOI: 10.1101/2020.10.28.359398] [Reference Citation Analysis]
118 da Silva Prates G, Malta FM, de Toledo Gonçalves F, Monteiro MA, Fonseca LAM, R Veiga AP, M C Magri M, Duarte AJS, Casseb J, Assone T; ADEE 3002 GROUP. AIDS incidence and survival in a hospital-based cohort of HIV-positive patients from São Paulo, Brazil: The role of IFN-λ4 polymorphisms. J Med Virol 2021;93:3601-6. [PMID: 32449798 DOI: 10.1002/jmv.26054] [Reference Citation Analysis]
119 Rujescu D, Herrling M, Hartmann AM, Maul S, Giegling I, Konte B, Strupp M. High-risk Allele for Herpes Labialis Severity at the IFNL3/4 Locus is Associated With Vestibular Neuritis. Front Neurol 2020;11:570638. [PMID: 33133009 DOI: 10.3389/fneur.2020.570638] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
120 Jing JS, Wang ZQ, Jiang YK, Zhang XY, Jiang WM. Association of cytokine gene polymorphisms with chronic hepatitis C virus genotype 1b infection in Chinese Han population: An observational study. Medicine (Baltimore) 2020;99:e22362. [PMID: 32957410 DOI: 10.1097/MD.0000000000022362] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
121 Bourgeois JS, Smith CM, Ko DC. These Are the Genes You're Looking For: Finding Host Resistance Genes. Trends Microbiol 2021;29:346-62. [PMID: 33004258 DOI: 10.1016/j.tim.2020.09.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
122 Sugiyama M, Kinoshita N, Ide S, Nomoto H, Nakamoto T, Saito S, Ishikane M, Kutsuna S, Hayakawa K, Hashimoto M, Suzuki M, Izumi S, Hojo M, Tsuchiya K, Gatanaga H, Takasaki J, Usami M, Kano T, Yanai H, Nishida N, Kanto T, Sugiyama H, Ohmagari N, Mizokami M. Serum CCL17 level becomes a predictive marker to distinguish between mild/moderate and severe/critical disease in patients with COVID-19. Gene 2021;766:145145. [PMID: 32941953 DOI: 10.1016/j.gene.2020.145145] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 13.3] [Reference Citation Analysis]
123 Emmanuel B, El-Kamary SS, Magder LS, Stafford KA, Charurat ME, Chairez C, McLaughlin M, Hadigan C, Prokunina-Olsson L, O'Brien TR, Masur H, Kottilil S. Metabolic Changes in Chronic Hepatitis C Patients Who Carry IFNL4-ΔG and Achieve Sustained Virologic Response With Direct-Acting Antiviral Therapy. J Infect Dis 2020;221:102-9. [PMID: 31504644 DOI: 10.1093/infdis/jiz435] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
124 Duffy D. Understanding immune variation for improved translational medicine. Curr Opin Immunol 2020;65:83-8. [PMID: 32745736 DOI: 10.1016/j.coi.2020.06.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
125 Arai J, Ito T, Shimozuma Y, Uchikoshi M, Nakajima Y, Sakaki M, Uozumi S, Kajiwara A, Sugiura I, Otoyama Y, Nozawa H, Kurihara T, Eguchi J, Nomura N, Sakuma D, Sato M, Deguchi Y, Yoshida H. Decreased expression of interferon-stimulated genes in B cells of patients with chronic hepatitis C during interferon-free therapy potentially suggests the eradication of hepatitis C virus in the B cells: A cohort study. Health Sci Rep 2020;3:e176. [PMID: 32685701 DOI: 10.1002/hsr2.176] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
126 Martínez-Aguilar L, Pérez-Ramírez C, Maldonado-Montoro MDM, Carrasco-Campos MI, Membrive-Jiménez C, Martínez-Martínez F, García-Collado C, Calleja-Hernández MÁ, Ramírez-Tortosa MC, Jiménez-Morales A. Effect of genetic polymorphisms on therapeutic response in multiple sclerosis relapsing-remitting patients treated with interferon-beta. Mutat Res Rev Mutat Res 2020;785:108322. [PMID: 32800273 DOI: 10.1016/j.mrrev.2020.108322] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
127 Fujiwara N, Qian T, Koneru B, Hoshida Y. Omics-derived hepatocellular carcinoma risk biomarkers for precision care of chronic liver diseases. Hepatol Res 2020;50:817-30. [PMID: 32323426 DOI: 10.1111/hepr.13506] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
128 El-Fattah MA. Predictive power of Interleukin-28B gene variants for outcome of Hepatitis C Virus genotype 4 in Egyptians: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2021;45:101480. [PMID: 32622719 DOI: 10.1016/j.clinre.2020.06.006] [Reference Citation Analysis]
129 Su CI, Kao YT, Chang CC, Chang Y, Ho TS, Sun HS, Lin YL, Lai MMC, Liu YH, Yu CY. DNA-induced 2'3'-cGAMP enhances haplotype-specific human STING cleavage by dengue protease. Proc Natl Acad Sci U S A 2020;117:15947-54. [PMID: 32576686 DOI: 10.1073/pnas.1922243117] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
130 Ghanem SE, Elsabaawy M, Shebl N, Abdelsameea E, Othman W, El-Bassal FI, Elgedawy GA, Elsabaawy DM, Helal ML. Value of IFNL3 genetic polymorphism in the prediction of HCV treatment response to direct-acting antiviral drugs versus interferon therapy. Expert Rev Anti Infect Ther 2020;18:947-54. [PMID: 32419526 DOI: 10.1080/14787210.2020.1771180] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
131 Hisaka A, Yoshioka H, Hatakeyama H, Sato H, Onouchi Y, Anzai N. Global Comparison of Changes in the Number of Test-Positive Cases and Deaths by Coronavirus Infection (COVID-19) in the World. J Clin Med 2020;9:E1904. [PMID: 32570833 DOI: 10.3390/jcm9061904] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
132 Casanova JL, Abel L. The human genetic determinism of life-threatening infectious diseases: genetic heterogeneity and physiological homogeneity? Hum Genet 2020;139:681-94. [PMID: 32462426 DOI: 10.1007/s00439-020-02184-w] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 10.7] [Reference Citation Analysis]
133 Wang F, Huang S, Gao R, Zhou Y, Lai C, Li Z, Xian W, Qian X, Li Z, Huang Y, Tang Q, Liu P, Chen R, Liu R, Li X, Tong X, Zhou X, Bai Y, Duan G, Zhang T, Xu X, Wang J, Yang H, Liu S, He Q, Jin X, Liu L. Initial Whole Genome Sequencing and Analysis of the Host Genetic Contribution to COVID-19 Severity and Susceptibility.. [DOI: 10.1101/2020.06.09.20126607] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
134 Gui Y, Grzyb K, Thomas MH, Ohnmacht J, Garcia P, Buttini M, Skupin A, Sauter T, Sinkkonen L. Single nuclei chromatin profiling of ventral midbrain reveals cell identity transcription factors and cell type-specific gene regulatory variation.. [DOI: 10.1101/2020.06.10.144626] [Reference Citation Analysis]
135 Frías M, Rivero-juárez A, Machuca I, Camacho Á, Rivero A. The outlook for precision medicine for the treatment of chronic hepatitis C infection: challenges and opportunities. Expert Review of Precision Medicine and Drug Development 2020;5:253-63. [DOI: 10.1080/23808993.2020.1764346] [Reference Citation Analysis]
136 Walker A, Boyce A, Duggal P, Thio CL, Geller G. The Ethics of Precision Rationing: Human Genetics and the Need for Debate on Stratifying Access to Medication. Public Health Genomics 2020;23:149-54. [PMID: 32516789 DOI: 10.1159/000508141] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
137 Koolivand M, Allamehzadeh Z, Ahmadi A, Taheri RA, Hassanpour K, Zeini A, Farnoosh G. The Study of IFNL3 Gene Rs12979860 Polymorphism in the Hepatitis C Virus Patients and Healthy Population in Tehran Province, Iran. Jundishapur J Microbiol 2020;13. [DOI: 10.5812/jjm.95798] [Reference Citation Analysis]
138 Scaglione S, Adams W, Caines A, Devlin P, Mittal S, Singal AG, Parikh ND. Association Between Race/Ethnicity and Insurance Status with Outcomes in Patients with Hepatocellular Carcinoma. Dig Dis Sci 2020;65:1669-78. [PMID: 31643036 DOI: 10.1007/s10620-019-05890-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
139 Mukanyangezi MF, Rugwizangoga B, Manzi O, Rulisa S, Hellstrand K, Tobin G, Martner A, Bienvenu E, Giglio D. Persistence rate of cervical human papillomavirus infections and abnormal cytology in Rwanda. HIV Med 2019;20:485-95. [PMID: 31318136 DOI: 10.1111/hiv.12782] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
140 Park A, Iwasaki A. Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19. Cell Host Microbe. 2020;27:870-878. [PMID: 32464097 DOI: 10.1016/j.chom.2020.05.008] [Cited by in Crossref: 525] [Cited by in F6Publishing: 550] [Article Influence: 175.0] [Reference Citation Analysis]
141 Jalil I, Arshad M, Khan S, Dasti JI. The STAT4 and not the IFNL3 variant is associated with hepatitis B virus clearance in a population from the Khyber Pakhtunkhwa region of Pakistan. Arab J Gastroenterol 2020;21:91-4. [PMID: 32439233 DOI: 10.1016/j.ajg.2020.04.011] [Reference Citation Analysis]
142 Ozcelik F, Tanoglu A, Çıracı MZ, Ozcelik IK. Use of Immune Modulator Interferon-Gamma to Support Combating COVID-19 Pandemic. IJCV 2020;1:1-15. [DOI: 10.14302/issn.2692-1537.ijcv-20-3345] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
143 Keikha M, Eslami M, Yousefi B, Ali-Hassanzadeh M, Kamali A, Yousefi M, Karbalaei M. HCV genotypes and their determinative role in hepatitis C treatment. Virusdisease 2020;31:235-40. [PMID: 32904762 DOI: 10.1007/s13337-020-00592-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
144 Santer DM, Minty GES, Golec DP, Lu J, May J, Namdar A, Shah J, Elahi S, Proud D, Joyce M, Tyrrell DL, Houghton M. Differential expression of interferon-lambda receptor 1 splice variants determines the magnitude of the antiviral response induced by interferon-lambda 3 in human immune cells. PLoS Pathog 2020;16:e1008515. [PMID: 32353085 DOI: 10.1371/journal.ppat.1008515] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
145 Ansari MA, Marchi E, Ramamurthy N, Aschenbrenner D, Hackstein C, Lin S, Bowden R, Sharma E, Pedergnana V, Venkateswaran S, Kugathasan S, Mo A, Gibson G, Cooke G, Mclauchlan J, Barnes E, Baillie JK, Teichmann S, Mentzer A, Todd J, Knight J, Uhlig H, Klenerman P, STOP-HCV consortium, ISARIC-4C Investigators. Negative regulation of ACE2 by interferons in vivo and its genetic control.. [DOI: 10.1101/2020.04.26.20080408] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
146 Bamford CGG. mSphere of Influence: Interferon Ultra Is a Means To Fight Viral Disease. mSphere 2020;5. [DOI: 10.1128/msphere.00134-20] [Reference Citation Analysis]
147 Alberione MP, Moeller R, Kirui J, Ginkel C, Doepke M, Ströh LJ, Machtens JP, Pietschmann T, Gerold G. Single-nucleotide variants in human CD81 influence hepatitis C virus infection of hepatoma cells. Med Microbiol Immunol 2020;209:499-514. [PMID: 32322956 DOI: 10.1007/s00430-020-00675-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
148 Sherif ZA, Nouraie M, Begum R, Afsari A, Shokrani B, Lee E, Laiyemo AO, Brim H, Ashktorab H. Factors influencing treatment outcome in hepatitis C virus minority patients at an inner-city hospital: A STROBE-complaint article. Medicine (Baltimore) 2020;99:e19505. [PMID: 32243366 DOI: 10.1097/MD.0000000000019505] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
149 Freitas IT, Tinago W, Sawa H, McAndrews J, Doak B, Prior-Fuller C, Sheehan G, Lambert JS, Muldoon E, Cotter AG, Hall WW, Mallon PWG, Carr MJ. Interferon lambda rs368234815 ΔG/ΔG is associated with higher CD4+:CD8+ T-cell ratio in treated HIV-1 infection. AIDS Res Ther 2020;17:13. [PMID: 32295609 DOI: 10.1186/s12981-020-00269-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
150 Ishida Y, Kakuni M, Bang BR, Sugahara G, Lau DT, Tateno-Mukaidani C, Li M, Gale M Jr, Saito T. Hepatic IFN-Induced Protein with Tetratricopeptide Repeats Regulation of HCV Infection. J Interferon Cytokine Res 2019;39:133-46. [PMID: 30844328 DOI: 10.1089/jir.2018.0103] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
151 Negro F. Natural History of Hepatic and Extrahepatic Hepatitis C Virus Diseases and Impact of Interferon-Free HCV Therapy. Cold Spring Harb Perspect Med 2020;10:a036921. [PMID: 31636094 DOI: 10.1101/cshperspect.a036921] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
152 Mawatari S, Oda K, Kumagai K, Tabu K, Ijuin S, Fujisaki K, Inada Y, Uto H, Saisyoji A, Hiramine Y, Hori T, Taniyama O, Toyodome A, Sakae H, Hashiguchi M, Kure T, Sakurai K, Tamai T, Moriuchi A, Ido A. Viral and host factors are associated with retreatment failure in hepatitis C patients receiving all-oral direct antiviral therapy. Hepatol Res 2020;50:453-65. [PMID: 31846553 DOI: 10.1111/hepr.13474] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
153 Fenizia C, Saulle I, Clerici M, Biasin M. Genetic and epigenetic regulation of natural resistance to HIV-1 infection: new approaches to unveil the HESN secret. Expert Rev Clin Immunol 2020;16:429-45. [PMID: 32085689 DOI: 10.1080/1744666X.2020.1732820] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
154 Juárez-Vicuña Y, Pérez-Ramos J, Adalid-Peralta L, Sánchez F, Springall R, Villaseñor-Jasso J, Sixtos-Alonso MS, Ballinas-Verdugo MA, Márquez-Velasco R, Bojalil R, Amezcua-Guerra LM, Sánchez-Muñoz F. The presence of IFL3/4 rs12979860 C allele influences the in vitro IP-10 production by mononuclear cells from patients with systemic lupus erythematosus. Lupus 2020;29:482-9. [PMID: 32122227 DOI: 10.1177/0961203320909429] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
155 Bentley AR, Callier SL, Rotimi CN. Evaluating the promise of inclusion of African ancestry populations in genomics. NPJ Genom Med 2020;5:5. [PMID: 32140257 DOI: 10.1038/s41525-019-0111-x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 52] [Article Influence: 15.7] [Reference Citation Analysis]
156 Prokunina-olsson L, Morrison RD, Obajemu A, Mahamar A, Kim S, Attaher O, Florez-vargas O, Sidibe Y, Onabajo OO, Hutchinson AA, Manning M, Kwan J, Brand N, Dicko A, Fried M, Albert PS, Mbulaiteye SM, Duffy PE. IFN-λ4 is associated with increased risk and earlier occurrence of gastrointestinal, respiratory and malarial infections in Malian children.. [DOI: 10.1101/2020.02.24.962688] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
157 Nahon P, Cobat A. Human genetics of HCV infection phenotypes in the era of direct-acting antivirals. Hum Genet 2020;139:855-63. [PMID: 32100095 DOI: 10.1007/s00439-020-02136-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
158 Duncan JD, Urbanowicz RA, Tarr AW, Ball JK. Hepatitis C Virus Vaccine: Challenges and Prospects. Vaccines (Basel) 2020;8:E90. [PMID: 32079254 DOI: 10.3390/vaccines8010090] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 11.3] [Reference Citation Analysis]
159 da Silva Cezar RD, da Silva Castanha PM, Matos Freire N, Mola C, Feliciano do Carmo R, Tenório Cordeiro M, Baptista P, Silva Vasconcelos LR, Moura P, da Silva Teixeira VG. Association between interferon lambda 3 rs12979860 polymorphism and clinical outcome in dengue virus-infected children. Int J Immunogenet 2020;47:351-8. [PMID: 32065450 DOI: 10.1111/iji.12477] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
160 Zhou H, Møhlenberg M, Terczyńska-Dyla E, Winther KG, Hansen NH, Vad-Nielsen J, Laloli L, Dijkman R, Nielsen AL, Gad HH, Hartmann R. The IFNL4 Gene Is a Noncanonical Interferon Gene with a Unique but Evolutionarily Conserved Regulation. J Virol 2020;94:e01535-19. [PMID: 31776283 DOI: 10.1128/JVI.01535-19] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
161 Ferrari C, Barili V, Varchetta S, Mondelli MU. Immune Mechanisms of Viral Clearance and Disease Pathogenesis During Viral Hepatitis. The Liver 2020. [DOI: 10.1002/9781119436812.ch63] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
162 El-garawani I, Hassab El-nabi S, Gadallah M, Abdelsameea E. Association between IFN-λ 3 Gene Polymorphisms and Outcome of Treatment with Direct Acting Antivirals in Chronic HCV-Infected Egyptian Patients. Immunological Investigations 2021;50:12-22. [DOI: 10.1080/08820139.2020.1722158] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
163 Chen H, Sun J, Zhou B, Peng J, Xie Q, Liang X, Fan R, Conran C, Xu J, Ji Y, Zhang X, Sun L, Jia J, Wang G, Hou J, Jiang DK. A missense variant in complement factor B (CFB) is a potential predictor of 24-week off-treatment response to PegIFNα therapy in Chinese HBeAg-positive chronic hepatitis B patients. Aliment Pharmacol Ther 2020;51:469-78. [PMID: 31943297 DOI: 10.1111/apt.15624] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
164 Alkharsah KR, Alzahrani AJ, Obeid OE, Aljindan RY, Guella A, Al-Ali AK, Al-Turaifi HR, Sallam TA. Association between Hepatitis C Virus Viremia and the rs12979860, rs2228145 and rs1800795 SNP (CT/AC/GG) Genotype in Saudi Kidney Transplant Recipients. Saudi J Med Med Sci 2020;8:46-52. [PMID: 31929778 DOI: 10.4103/sjmms.sjmms_175_18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
165 Kanto T, Yoshio S. Hepatitis C. Liver Immunology 2020. [DOI: 10.1007/978-3-030-51709-0_17] [Reference Citation Analysis]
166 El-kamary SS, Kottilil S. Viral Hepatitis. Hunter's Tropical Medicine and Emerging Infectious Diseases 2020. [DOI: 10.1016/b978-0-323-55512-8.00035-1] [Reference Citation Analysis]
167 Padmanabhan P, Raja R, Dixit NM. Bistability in virus–host interaction networks underlies the success of hepatitis C treatments. Phenotypic Switching 2020. [DOI: 10.1016/b978-0-12-817996-3.00024-4] [Reference Citation Analysis]
168 Meng X, Zhang Q, Dong P. Pharmacogenomics of Anti-Infective Agents. Pharmacogenomics in Precision Medicine 2020. [DOI: 10.1007/978-981-15-3895-7_7] [Reference Citation Analysis]
169 Zakaria ZA, Knapp S, Hashem M, Zaghla H, Thursz M, Waked I, Abdelwahab S. Interleukin 28A.rs12980602 and interleukin 28B.rs8103142 genotypes could be protective against HCV infection among Egyptians. Immunol Res 2019;67:123-33. [PMID: 30402710 DOI: 10.1007/s12026-018-9035-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
170 Sandler YG, Vinnitskaya EV, Saliev KG, Khomeriki SG, Кhaimenova TY. Drugs-induced liver injury associated with non-steroidal anti-inflammatory drugs: a case report and clinical insights. Alʹm klin med 2019;47:579-591. [DOI: 10.18786/2072-0505-2019-47-060] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
171 Baker JL, Shriner D, Bentley AR, Rotimi CN. Pharmacogenomics and Infectious Diseases in Africa. The Genetics of African Populations in Health and Disease 2019. [DOI: 10.1017/9781139680295.006] [Reference Citation Analysis]
172 Fang MZ, Jackson SS, O'Brien TR. IFNL4: Notable variants and associated phenotypes. Gene 2020;730:144289. [PMID: 31846709 DOI: 10.1016/j.gene.2019.144289] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
173 Tam V, Patel N, Turcotte M, Bossé Y, Paré G, Meyre D. Benefits and limitations of genome-wide association studies. Nat Rev Genet 2019;20:467-84. [DOI: 10.1038/s41576-019-0127-1] [Cited by in Crossref: 681] [Cited by in F6Publishing: 720] [Article Influence: 170.3] [Reference Citation Analysis]
174 Tierney AR, Huepfel W, Shaukat AP, Lake JR, Boldt M, Wang Q, Hassan MA. Direct-Acting Antiviral Therapy for Hepatitis C Infection in a Large Immigrant Community. J Immigr Minor Health 2019;21:549-54. [PMID: 29802526 DOI: 10.1007/s10903-018-0758-x] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
175 Youssef SS, Abbas EAER, Youness RA, Elemeery MN, Nasr AS, Seif S. PNPLA3 and IL 28B signature for predicting susceptibility to chronic hepatitis C infection and fibrosis progression. Arch Physiol Biochem 2019;:1-7. [PMID: 31793339 DOI: 10.1080/13813455.2019.1694039] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
176 Fellay J, Pedergnana V. Exploring the interactions between the human and viral genomes. Hum Genet 2020;139:777-81. [PMID: 31729546 DOI: 10.1007/s00439-019-02089-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
177 Jiang JJ, Fang MZ, Jackson SS, O'Brien TR. CCR5-Δ32 and IFNL4-ΔG/TT. Clin Ther 2019;41:2658-9. [PMID: 31711627 DOI: 10.1016/j.clinthera.2019.10.004] [Reference Citation Analysis]
178 Hou W, Qiao K, Huo Z, Du Y, Wang C, Syn WK. Association of IFNL3 rs12979860 polymorphism with HCV-related hepatocellular carcinoma susceptibility in a Chinese population. Clin Exp Gastroenterol 2019;12:433-9. [PMID: 31807049 DOI: 10.2147/CEG.S206194] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
179 Gawrieh S, Guo X, Tan J, Lauzon M, Taylor KD, Loomba R, Cummings OW, Pillai S, Bhatnagar P, Kowdley KV, Yates K, Wilson LA, Chen YI, Rotter JI, Chalasani N; NASH Clinical Research Network. A Pilot Genome-Wide Analysis Study Identifies Loci Associated With Response to Obeticholic Acid in Patients With NASH. Hepatol Commun 2019;3:1571-84. [PMID: 31832568 DOI: 10.1002/hep4.1439] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
180 Morihara D, Ko YL, Shibata K, Yamauchi R, Fukuda H, Tsuchiya N, Fukunaga A, Kunimoto H, Iwashita H, Takata K, Tanaka T, Sakurai K, Inomata S, Yokoyama K, Nishizawa S, Takeyama Y, Irie M, Shakado S, Sohda T, Sakisaka S. IL28B gene polymorphism is correlated with changes in low-density lipoprotein cholesterol levels after clearance of hepatitis C virus using direct-acting antiviral treatment. J Gastroenterol Hepatol 2019;34:2019-27. [PMID: 31144350 DOI: 10.1111/jgh.14741] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
181 Serdari D, Kostaki EG, Paraskevis D, Stamatakis A, Kapli P. Automated, phylogeny-based genotype delimitation of the Hepatitis Viruses HBV and HCV. PeerJ 2019;7:e7754. [PMID: 31667012 DOI: 10.7717/peerj.7754] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
182 McPhee F. Developments in the treatment of HCV genotype 3 infection. Expert Rev Anti Infect Ther 2019;17:775-85. [PMID: 31584833 DOI: 10.1080/14787210.2019.1676730] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
183 Grzegorzewska AE. Genetic Polymorphisms within Interferon-λ Region and Interferon-λ3 in the Human Pathophysiology: Their Contribution to Outcome, Treatment, and Prevention of Infections with Hepatotropic Viruses. CMC 2019;26:4832-51. [DOI: 10.2174/0929867325666180719121142] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
184 Tian T, Huang P, Wu J, Wang C, Fan H, Zhang Y, Yu R, Wu C, Xia X, Fu Z, Li J, Yue M. CD40 polymorphisms were associated with HCV infection susceptibility among Chinese population. BMC Infect Dis 2019;19:840. [PMID: 31615434 DOI: 10.1186/s12879-019-4482-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
185 Rugwizangoga B, Andersson ME, Kabayiza JC, Nilsson MS, Ármannsdóttir B, Aurelius J, Nilsson S, Hellstrand K, Lindh M, Martner A. IFNL4 Genotypes Predict Clearance of RNA Viruses in Rwandan Children With Upper Respiratory Tract Infections. Front Cell Infect Microbiol 2019;9:340. [PMID: 31637221 DOI: 10.3389/fcimb.2019.00340] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
186 Møhlenberg M, Gad HH, Hartmann R. The Influence of the rs30461 Single Nucleotide Polymorphism on IFN-λ1 Activity and Secretion. Journal of Interferon & Cytokine Research 2019;39:661-7. [DOI: 10.1089/jir.2019.0051] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
187 Haqqi A, Munir R, Khalid M, Khurram M, Zaid M, Ali M, Shah ZH, Ahmed H, Afzal MS. Prevalence of Hepatitis C Virus Genotypes in Pakistan: Current Scenario and Review of Literature. Viral Immunol 2019;32:402-13. [PMID: 31556811 DOI: 10.1089/vim.2019.0058] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
188 Borivoje S, Svetlana S, Milan HM, Nela Đ, Olivera MĐ, Filip M, Milenko S, Srbislav P. IL28B Genetic Variations in Patients with Recurrent Herpes Simplex Keratitis. Medicina (Kaunas) 2019;55:E642. [PMID: 31561422 DOI: 10.3390/medicina55100642] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
189 Moghimi M, Tavakoli F, Doosti M, Ahmadi-Vasmehjani A, Akhondi-Meybodi M. Correlation between interleukin-28 gene polymorphism with interleukin-28 cytokine levels and viral genotypes among HCV patients in Yazd, Iran. BMC Res Notes 2019;12:626. [PMID: 31551080 DOI: 10.1186/s13104-019-4651-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
190 Chaturvedi N, Svarovskaia ES, Mo H, Osinusi AO, Brainard DM, Subramanian GM, McHutchison JG, Zeuzem S, Fellay J. Adaptation of hepatitis C virus to interferon lambda polymorphism across multiple viral genotypes. Elife 2019;8:e42542. [PMID: 31478832 DOI: 10.7554/eLife.42542] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
191 Ansari MA, Aranday-Cortes E, Ip CL, da Silva Filipe A, Lau SH, Bamford C, Bonsall D, Trebes A, Piazza P, Sreenu V, Cowton VM, Hudson E, Bowden R, Patel AH, Foster GR, Irving WL, Agarwal K, Thomson EC, Simmonds P, Klenerman P, Holmes C, Barnes E, Spencer CC, McLauchlan J, Pedergnana V; STOP-HCV Consortium. Interferon lambda 4 impacts the genetic diversity of hepatitis C virus. Elife 2019;8:e42463. [PMID: 31478835 DOI: 10.7554/eLife.42463] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
192 Roy N, Prasad C, Kumar A, Mondol K, Jain K, Yadav R, Jha JK, Nadda N, Acharya SK, Shalimar, Nayak B. IFNL4 haplotype, linkage disequilibrium and their influence on virological response to hepatitis C virus infection in Indian population. VirusDis 2019;30:344-353. [DOI: 10.1007/s13337-019-00535-4] [Reference Citation Analysis]
193 Wei L, Pavlovic V, Bansal AT, Chen X, Foster GR, He H, Kao JH, Lampertico P, Liaw YF, Motoc A, Papatheodoridis GV, Piratvisuth T, Plesniak R, Wat C. Genetic variation in FCER1A predicts peginterferon alfa-2a-induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B. J Viral Hepat 2019;26:1040-9. [PMID: 30972912 DOI: 10.1111/jvh.13107] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
194 Shridhar Gulati R, Wimalanathan T, Norheim Andersen S, Isaksen K, Lagging M, Midgard H, Moghaddam A, Dalgard O. The relationship between IFNL4 genotype and the rate of fibrosis in hepatitis C patients. Scand J Gastroenterol 2019;54:1172-5. [PMID: 31479286 DOI: 10.1080/00365521.2019.1643403] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
195 Forero A, Ozarkar S, Li H, Lee CH, Hemann EA, Nadjsombati MS, Hendricks MR, So L, Green R, Roy CN, Sarkar SN, von Moltke J, Anderson SK, Gale M Jr, Savan R. Differential Activation of the Transcription Factor IRF1 Underlies the Distinct Immune Responses Elicited by Type I and Type III Interferons. Immunity 2019;51:451-464.e6. [PMID: 31471108 DOI: 10.1016/j.immuni.2019.07.007] [Cited by in Crossref: 110] [Cited by in F6Publishing: 117] [Article Influence: 27.5] [Reference Citation Analysis]
196 Jhaveri R. "Here Today, Gone Tomorrow" or "Here Today, Stay a Long While": The Divergent Paths of Two Host Factors Important in Viral Infections. Clin Ther 2019;41:1907-11. [PMID: 31447128 DOI: 10.1016/j.clinthera.2019.07.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
197 Zhang Z, Wang C, Liu Z, Zou G, Li J, Lu M. Host Genetic Determinants of Hepatitis B Virus Infection. Front Genet. 2019;10:696. [PMID: 31475028 DOI: 10.3389/fgene.2019.00696] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 5.5] [Reference Citation Analysis]
198 Izumi T, Sakata K, Okuzaki D, Inokuchi S, Tamura T, Motooka D, Nakamura S, Ono C, Shimokawa M, Matsuura Y, Mori M, Fukuhara T, Yoshizumi T. Characterization of human pegivirus infection in liver transplantation recipients. J Med Virol 2019;91:2093-100. [PMID: 31350911 DOI: 10.1002/jmv.25555] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
199 García M, Jiménez-Sousa MA, Blanco J, Restrepo C, Pacheco YM, Brochado-Kith Ó, López-Bernaldo JC, Gutiérrez F, Portilla J, Estrada V, Górgolas M, Cabello A, Resino S, Benito JM, Rallón N; CoRIS and the Spanish HIV Biobank integrated in the Spanish AIDS Research Network Project RIS/EPICLIN 10_2015. CD4 recovery is associated with genetic variation in IFNγ and IL19 genes. Antiviral Res 2019;170:104577. [PMID: 31386862 DOI: 10.1016/j.antiviral.2019.104577] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
200 Kimble MM, Javanbakht M, Chew KW, Stafylis C, He D, Ramirez S, Baik Y, Saab S, Klausner JD. Sociodemographic and clinical characteristics of persons who experienced spontaneous hepatitis C viral clearance. BMC Infect Dis 2019;19:626. [PMID: 31307403 DOI: 10.1186/s12879-019-4223-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
201 Pol S, Lagaye S. The remarkable history of the hepatitis C virus. Microbes Infect 2019;21:263-70. [PMID: 31295571 DOI: 10.1016/j.micinf.2019.06.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
202 Bellocchi MC, Aragri M, Carioti L, Fabeni L, Pipitone RM, Brancaccio G, Sorbo MC, Barbaliscia S, Di Maio VC, Bronte F, Grimaudo S, Mazzucco W, Frigeri F, Cantone M, Pinto A, Perno CF, Craxì A, Gaeta GB, Di Marco V, Ceccherini-Silberstein F. NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients. Cells 2019;8:E666. [PMID: 31269695 DOI: 10.3390/cells8070666] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
203 Li X, Yin C, Wu Y, Zhang Z, Jiang D, Xiao D, Fang X, Zhou C. Plasmonic nanoplatform for point-of-care testing trace HCV core protein. Biosens Bioelectron 2020;147:111488. [PMID: 31350137 DOI: 10.1016/j.bios.2019.111488] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
204 Struble K, Chan-tack K, Qi K, Valappil T, Connelly S, Mishra P, Price D, Murray J, Birnkrant D. Sustained virological response rates with direct-acting antivirals in black subjects with HCV genotype 1 infection: systematic analysis of clinical trials. Journal of Virus Eradication 2019;5:138-44. [DOI: 10.1016/s2055-6640(20)30043-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
205 Pedergnana V, Irving WL, Barnes E, McLauchlan J, Spencer CCA. Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients. J Interferon Cytokine Res 2019;39:642-9. [PMID: 31260374 DOI: 10.1089/jir.2019.0013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
206 Shields LE, Jennings J, Liu Q, Lee J, Ma W, Blecha F, Miller LC, Sang Y. Cross-Species Genome-Wide Analysis Reveals Molecular and Functional Diversity of the Unconventional Interferon-ω Subtype. Front Immunol 2019;10:1431. [PMID: 31293589 DOI: 10.3389/fimmu.2019.01431] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
207 Raja R, Baral S, Dixit NM. Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon-free treatment era. Immunol Rev 2018;285:55-71. [PMID: 30129199 DOI: 10.1111/imr.12689] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
208 Song Y, Yang X, Shen Y, Wang Y, Xia X, Zhang AM. STAT3 signaling pathway plays importantly genetic and functional roles in HCV infection. Mol Genet Genomic Med 2019;7:e821. [PMID: 31219249 DOI: 10.1002/mgg3.821] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
209 Chen CW, Cheng JS, Chen TD, Le PH, Ku HP, Chang ML. The irreversible HCV-associated risk of gastric cancer following interferon-based therapy: a joint study of hospital-based cases and nationwide population-based cohorts. Therap Adv Gastroenterol 2019;12:1756284819855732. [PMID: 31244896 DOI: 10.1177/1756284819855732] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
210 Atsukawa M. Advances in Antiviral Therapy in Patients with Chronic Hepatitis C. Nihon Ika Daigaku Igakkai Zasshi 2019;15:106-114. [DOI: 10.1272/manms.15.106] [Reference Citation Analysis]
211 Wang J, Qu B, Zhang F, Zhang C, Deng W, Dao Thi VL, Xia Y. Stem Cell-Derived Hepatocyte-Like Cells as Model for Viral Hepatitis Research. Stem Cells Int 2019;2019:9605252. [PMID: 31281392 DOI: 10.1155/2019/9605252] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
212 Zhao Z, Qin Z, Zhou L, Xiang L, You J, Cao R, Wang H, Wang B, Li M. The impact of IFNL3 genotype on interferon treatment outcome in patients chronically infected with hepatitis B virus: A meta-analysis. Microb Pathog 2019;134:103598. [PMID: 31201901 DOI: 10.1016/j.micpath.2019.103598] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
213 von Felden J, Craig AJ, Villanueva A. The Impact of Translational Research in Hepatology. Clin Liver Dis (Hoboken) 2019;13:29-33. [PMID: 31168363 DOI: 10.1002/cld.805] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
214 Chmelova K, Frankova S, Jirsa M, Neroldova M, Sticova E, Merta D, Senkerikova R, Trunecka P, Spicak J, Sperl J. IL28B rs12979860 T allele protects against CMV disease in liver transplant recipients in the post-prophylaxis and late period. Transpl Infect Dis 2019;21:e13124. [PMID: 31165537 DOI: 10.1111/tid.13124] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
215 O'Brien TR, Jackson SS. What Have We Learned from Studies of IFN-λ Variants and Hepatitis C Virus Infection? J Interferon Cytokine Res 2019;39:618-26. [PMID: 31161939 DOI: 10.1089/jir.2019.0048] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
216 Han Q, Fan X, Wang X, Wang Y, Deng H, Zhang X, Zhang K, Li N, Liu Z. High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting. Virol J 2019;16:74. [PMID: 31159813 DOI: 10.1186/s12985-019-1184-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
217 Söderholm J, Yilmaz A, Svenningsson A, Büsch K, Wejstål R, Brolund A, Kövamees J, Sällberg M, Lagging M, Gisslén M. Lower risk of multiple sclerosis in patients with chronic hepatitis C: a nationwide population-based registry study. J Neurol 2019;266:2208-15. [PMID: 31152298 DOI: 10.1007/s00415-019-09397-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
218 Salum GM, Dawood RM, Abd El-Meguid M, Ibrahim NE, Abdel Aziz AO, El Awady MK. Correlation between IL28B/TLR4 genetic variants and HCC development with/without DAAs treatment in chronic HCV patients. Genes Dis 2020;7:392-400. [PMID: 32884993 DOI: 10.1016/j.gendis.2019.05.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
219 Shaala AY, Morsi MG, Harfoush RAH, Elkhouly EH, Ahmed MAR, Roshdy MN. Role of IL-28B polymorphisms in virologic response to combined pegylated interferon and ribavirin therapy in genotype 4 chronic HCV infected patients with and without cirrhosis. Alexandria Journal of Medicine 2015;51:231-9. [DOI: 10.1016/j.ajme.2014.09.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
220 Keck ZY, Pierce BG, Lau P, Lu J, Wang Y, Underwood A, Bull RA, Prentoe J, Velázquez-Moctezuma R, Walker MR, Luciani F, Guest JD, Fauvelle C, Baumert TF, Bukh J, Lloyd AR, Foung SKH. Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design. PLoS Pathog 2019;15:e1007772. [PMID: 31100098 DOI: 10.1371/journal.ppat.1007772] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 9.0] [Reference Citation Analysis]
221 Prokunina-Olsson L. Genetics of the Human Interferon Lambda Region. J Interferon Cytokine Res 2019;39:599-608. [PMID: 31070498 DOI: 10.1089/jir.2019.0043] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
222 Iakovenko NO, Zak MY, Klymenko MO, Zhuk SV, Nuzhna OK. METHODS OF TRANSMISSION AND FEATURES OF THE COURSE OF HEPATITIS C VIRUS INFECTION IN CHILDREN: MEDICAL AND SOCIAL ASPECTS. Wiad Lek 2019;72:928-932. [DOI: 10.36740/wlek201905137] [Reference Citation Analysis]
223 Smith D, Magri A, Bonsall D, Ip CLC, Trebes A, Brown A, Piazza P, Bowden R, Nguyen D, Ansari MA, Simmonds P, Barnes E; STOP-HCV Consortium. Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors. Hepatology 2019;69:1861-72. [PMID: 29425396 DOI: 10.1002/hep.29837] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 11.3] [Reference Citation Analysis]
224 Fischer L, Hay DC, O'Farrelly C. Innate immunity in stem cell-derived hepatocytes. Philos Trans R Soc Lond B Biol Sci 2018;373:20170220. [PMID: 29786555 DOI: 10.1098/rstb.2017.0220] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
225 Pol S, Lagaye S. The remarkable history of the hepatitis C virus. Genes Immun. 2019;20:436-446. [PMID: 31019253 DOI: 10.1038/s41435-019-0066-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
226 Eslam M, Ahlenstiel G, George J. Interferon Lambda and Liver Fibrosis. J Interferon Cytokine Res. 2019;39:627-635. [PMID: 31013168 DOI: 10.1089/jir.2018.0175] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
227 O'Brien TR, Young HA, Donnelly RP, Prokunina-Olsson L. Meeting Overview: Interferon Lambda-Disease Impact and Therapeutic Potential. J Interferon Cytokine Res 2019;39:586-91. [PMID: 30998425 DOI: 10.1089/jir.2019.0018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
228 Artemova MG, Abdurakhmanov DT. [Cryoglobulinemic vasculitis in chronic hepatitis C: Genetic aspects]. Ter Arkh 2017;89:110-4. [PMID: 28514410 DOI: 10.17116/terarkh2017894110-114] [Reference Citation Analysis]
229 Lapa D, Garbuglia AR, Capobianchi MR, Del Porto P. Hepatitis C Virus Genetic Variability, Human Immune Response, and Genome Polymorphisms: Which Is the Interplay? Cells 2019;8:E305. [PMID: 30987134 DOI: 10.3390/cells8040305] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
230 Vergara C, Thio CL, Johnson E, Kral AH, O'Brien TR, Goedert JJ, Mangia A, Piazzolla V, Mehta SH, Kirk GD, Kim AY, Lauer GM, Chung RT, Cox AL, Peters MG, Khakoo SI, Alric L, Cramp ME, Donfield SM, Edlin BR, Busch MP, Alexander G, Rosen HR, Murphy EL, Latanich R, Wojcik GL, Taub MA, Valencia A, Thomas DL, Duggal P. Multi-Ancestry Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus. Gastroenterology 2019;156:1496-1507.e7. [PMID: 30593799 DOI: 10.1053/j.gastro.2018.12.014] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
231 Rodrigo C, Leung P, Lloyd AR, Bull RA, Luciani F, Grebely J, Dore GJ, Applegate T, Page K, Bruneau J, Cox AL, Osburn W, Kim AY, Shoukry NH, Lauer GM, Maher L, Schinkel J, Prins M, Hellard M, Eltahla AA; InC3 Collaborative. Genomic variability of within-host hepatitis C variants in acute infection. J Viral Hepat 2019;26:476-84. [PMID: 30578702 DOI: 10.1111/jvh.13051] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
232 Rivett L, Alexander G. Is the conquest of Hepatitis C imminent? Expert Rev Mol Med 2019;21:e3. [PMID: 30909984 DOI: 10.1017/erm.2019.3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
233 Fujiwara N, Hoshida Y. Hepatocellular Carcinoma Risk Stratification by Genetic Profiling in Patients with Cirrhosis. Semin Liver Dis 2019;39:153-62. [PMID: 30912093 DOI: 10.1055/s-0039-1681031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
234 De Re V, Tornesello ML, De Zorzi M, Caggiari L, Pezzuto F, Leone P, Racanelli V, Lauletta G, Gragnani L, Buonadonna A, Vaccher E, Zignego AL, Steffan A, Buonaguro FM. Clinical Significance of Polymorphisms in Immune Response Genes in Hepatitis C-Related Hepatocellular Carcinoma. Front Microbiol 2019;10:475. [PMID: 30930876 DOI: 10.3389/fmicb.2019.00475] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
235 Behera MK, Shukla SK, Dixit VK, Nath P, Abhilash VB, Asati PK, Jain AK. Effect of vitamin D supplementation on sustained virological response in genotype 1/4 chronic hepatitis C treatment-naïve patients from India. Indian J Med Res 2018;148:200-6. [PMID: 30381543 DOI: 10.4103/ijmr.IJMR_1295_15] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
236 Noori-daloii MR, PhD of Medical Molecular Genetics, Department of Medical Genetics, School of Medicine, Tehran University of Medical Science, Tehran, Iran, Zafari N, MSc Student of Medical Genetics, Department of Medical Genetics, School of Medicine, Tehran University of Medical Science, Tehran, Iran. The personalized medicine: today and tomorrow. MEDICAL SCIENCES 2019;29:1-17. [DOI: 10.29252/iau.29.1.1] [Reference Citation Analysis]
237 Steba GS, Koekkoek SM, Tanck MWT, Vanhommerig JW, van der Meer JTM, Kwa D, Brinkman K, Prins M, Berkhout B, Pollakis G, Molenkamp R, Schinkel J, Paxton WA; MOSAIC (MSM observational Study of Acute infection with Hepatitis C) Study Group and the ACS (Amsterdam Cohort Studies). SNP rs688 within the low-density lipoprotein receptor (LDL-R) gene associates with HCV susceptibility. Liver Int 2019;39:463-9. [PMID: 30260075 DOI: 10.1111/liv.13978] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
238 Feng Z, Lemon SM. Innate Immunity to Enteric Hepatitis Viruses. Cold Spring Harb Perspect Med 2019;9:a033464. [PMID: 29686040 DOI: 10.1101/cshperspect.a033464] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
239 Angeletti A, Cantarelli C, Cravedi P. HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents. Front Med (Lausanne) 2019;6:20. [PMID: 30800660 DOI: 10.3389/fmed.2019.00020] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
240 McLauchlan J, Innes H, Dillon JF, Foster G, Holtham E, McDonald S, Wilkes B, Hutchinson SJ, Irving WL; HCV Research UK Steering Committee. Cohort Profile: The Hepatitis C Virus (HCV) Research UK Clinical Database and Biobank. Int J Epidemiol 2017;46:1391-1391h. [PMID: 28338838 DOI: 10.1093/ije/dyw362] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
241 Wang X, Wong K, Ouyang W, Rutz S. Targeting IL-10 Family Cytokines for the Treatment of Human Diseases. Cold Spring Harb Perspect Biol 2019;11:a028548. [PMID: 29038121 DOI: 10.1101/cshperspect.a028548] [Cited by in Crossref: 89] [Cited by in F6Publishing: 97] [Article Influence: 22.3] [Reference Citation Analysis]
242 Sghaier I, Brochot E, Loueslati BY, Almawi WY. Hepatitis C virus protein interaction network for HCV clearance and association of DAA to HCC occurrence via data mining approach: A systematic review and critical analysis. Rev Med Virol 2019;29:e2033. [PMID: 30614131 DOI: 10.1002/rmv.2033] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
243 Nebert DW, Zhang G. Pharmacogenomics. Emery and Rimoin's Principles and Practice of Medical Genetics and Genomics 2019. [DOI: 10.1016/b978-0-12-812537-3.00016-0] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
244 Meanwell NA, Rajamani R, Scola PM, Sun L. The Discovery and Early Clinical Evaluation of the HCV NS3/4A Protease Inhibitor Asunaprevir (BMS-650032). Topics in Medicinal Chemistry 2019. [DOI: 10.1007/7355_2018_58] [Reference Citation Analysis]
245 Wang Y, Niu J, Deng G, Zhao Y. Host Genetic Characters of Acute Exacerbation of Chronic Hepatitis B (AECHB). Acute Exacerbation of Chronic Hepatitis B 2019. [DOI: 10.1007/978-94-024-1606-0_4] [Reference Citation Analysis]
246 P. Borde J, Zajkowska J. Chapter 5: TBE in adults. Tick-borne encephalitis - The Book 2019. [DOI: 10.33442/978-981-14-0914-1_5] [Reference Citation Analysis]
247 Omae Y, Tokunaga K. Genetics of Infectious Diseases. Genome-Wide Association Studies 2019. [DOI: 10.1007/978-981-13-8177-5_6] [Reference Citation Analysis]
248 Botton MR, Campos KC, Duconge J, Scott SA. Pharmacogenomics in Latin American Populations. Pharmacogenomics 2019. [DOI: 10.1016/b978-0-12-812626-4.00012-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
249 Halim AB. Pharmacogenetics of therapeutics. Biomarkers, Diagnostics and Precision Medicine in the Drug Industry 2019. [DOI: 10.1016/b978-0-12-816121-0.00003-9] [Reference Citation Analysis]
250 Shackel NA, Patel K. Viral hepatitis. Genomic and Precision Medicine 2019. [DOI: 10.1016/b978-0-12-801496-7.00011-3] [Reference Citation Analysis]
251 Mance D, Mance D, Vitezić D. Personalized Medicine and Personalized Pricing: Degrees of Price Discrimination. Personalized Medicine in Healthcare Systems 2019. [DOI: 10.1007/978-3-030-16465-2_14] [Reference Citation Analysis]
252 Alqahtani SA, Sulkowski MS. The Role of Interferon for the Treatment of Chronic Hepatitis C Virus Infection. Topics in Medicinal Chemistry 2019. [DOI: 10.1007/7355_2018_59] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
253 Diaz VF, Olson M, Jacobson IM. The Evolution of Clinical Trials for Hepatitis C. Topics in Medicinal Chemistry 2019. [DOI: 10.1007/7355_2019_64] [Reference Citation Analysis]
254 Cohen DE. Clinical Development of Viekira Pak to Mavyret. Topics in Medicinal Chemistry 2019. [DOI: 10.1007/7355_2018_60] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
255 Iio E, Tanaka Y. Hepatitis C Virus Infection. Human Pathobiochemistry 2019. [DOI: 10.1007/978-981-13-2977-7_28] [Reference Citation Analysis]
256 Rehermann B, Thimme R. Insights From Antiviral Therapy Into Immune Responses to Hepatitis B and C Virus Infection. Gastroenterology 2019;156:369-83. [PMID: 30267712 DOI: 10.1053/j.gastro.2018.08.061] [Cited by in Crossref: 72] [Cited by in F6Publishing: 73] [Article Influence: 18.0] [Reference Citation Analysis]
257 Athuluri-divakar SK, Hoshida Y. Molecular prognosis in liver cirrhosis. Genomic and Precision Medicine 2019. [DOI: 10.1016/b978-0-12-801496-7.00021-6] [Reference Citation Analysis]
258 Matsuda K. The Association of Single Nucleotide Polymorphisms with Cancer Risk. Genome-Wide Association Studies 2019. [DOI: 10.1007/978-981-13-8177-5_5] [Reference Citation Analysis]
259 O'Brien TR, Yang HI, Groover S, Jeng WJ. Genetic Factors That Affect Spontaneous Clearance of Hepatitis C or B Virus, Response to Treatment, and Disease Progression. Gastroenterology 2019;156:400-17. [PMID: 30287169 DOI: 10.1053/j.gastro.2018.09.052] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
260 Tarokhian H, Rahimi H, Mosavat A, Shirdel A, Rafatpanah H, Akbarin MM, Bari A, Ramezani S, Rezaee SA. HTLV-1-host interactions on the development of adult T cell leukemia/lymphoma: virus and host gene expressions. BMC Cancer 2018;18:1287. [PMID: 30577817 DOI: 10.1186/s12885-018-5209-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
261 Provazzi PJS, Rossi LMG, Carneiro BM, Miura VC, Rosa PCR, de Carvalho LR, de Andrade STQ, Fachini RM, Grotto RMT, Silva GF, Valêncio CR, Neto PS, Cordeiro JA, Nogueira ML, Rahal P. Hierarchical assessment of host factors influencing the spontaneous resolution of hepatitis C infection. Braz J Microbiol 2019;50:147-55. [PMID: 30637644 DOI: 10.1007/s42770-018-0008-3] [Reference Citation Analysis]
262 Eddowes LA, Al-Hourani K, Ramamurthy N, Frankish J, Baddock HT, Sandor C, Ryan JD, Fusco DN, Arezes J, Giannoulatou E, Boninsegna S, Chevaliez S, Owens BMJ, Sun CC, Fabris P, Giordani MT, Martines D, Vukicevic S, Crowe J, Lin HY, Rehwinkel J, McHugh PJ, Binder M, Babitt JL, Chung RT, Lawless MW, Armitage AE, Webber C, Klenerman P, Drakesmith H. Antiviral activity of bone morphogenetic proteins and activins. Nat Microbiol 2019;4:339-51. [PMID: 30510168 DOI: 10.1038/s41564-018-0301-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
263 Khan AJ, Saraswat VA, Ranjan P, Parmar D, Negi TS, Mohindra S. Polymorphism in interferon λ3/interleukin-28B gene and risk to noncirrhotic chronic hepatitis C genotype 3 virus infection and its effect on the response to combined daclatasvir and sofosbuvir therapy. J Med Virol 2019;91:659-67. [PMID: 30431653 DOI: 10.1002/jmv.25359] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
264 Vasconcelos LRS, Moura P, Dutra RF. Ultrasensitive Genosensor Based on Minor Grove Binding (MGB) Probe forIL28BSingle Nucleotide Polymorphism (SNP) Detection Using SYBR Green as Electrochemical Indicator. Electroanalysis 2018;30:2847-2852. [DOI: 10.1002/elan.201800377] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
265 Chaturvedi N, Svarovskaia ES, Mo H, Osinusi AO, Brainard DM, Subramanian GM, Mchutchison JG, Zeuzem S, Fellay J. Pervasive Adaptation of Hepatitis C Virus to Interferon Lambda Polymorphism Across Multiple Genotypes.. [DOI: 10.1101/484071] [Reference Citation Analysis]
266 Bibert S, Wójtowicz A, Taffé P, Tarr PE, Bernasconi E, Furrer H, Günthard HF, Hoffmann M, Kaiser L, Osthoff M, Fellay J, Cavassini M, Bochud PY; Swiss HIV Cohort Study. Interferon lambda 3/4 polymorphisms are associated with AIDS-related Kaposi's sarcoma. AIDS 2018;32:2759-65. [PMID: 30234607 DOI: 10.1097/QAD.0000000000002004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
267 Aytekin FY, Barut HŞ, Rüstemoğlu A, Atay A, Günal Ö, Duygu F. Factors related to fatalities and clinical progression of Crimean-Congo hemorrhagic fever patients and the effects of IL 28-B gene polymorphism. Arch Virol 2019;164:547-57. [PMID: 30478788 DOI: 10.1007/s00705-018-4106-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
268 Lanford RE, Walker CM, Lemon SM. The Chimpanzee Model of Viral Hepatitis: Advances in Understanding the Immune Response and Treatment of Viral Hepatitis. ILAR J 2017;58:172-89. [PMID: 29045731 DOI: 10.1093/ilar/ilx028] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
269 Ali Q, Jamal A, Imran M, Ullah S, Kalam I, Ullah S, Waqar AB. Correlation of IL28B rs12979860 genotype and gender with spontaneous clearance of HCV infection: a Pakistani cross-section study. Per Med 2018;15:495-502. [PMID: 30398404 DOI: 10.2217/pme-2018-0016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
270 Mysore KR, Leung DH. Hepatitis B and C. Clin Liver Dis 2018;22:703-22. [PMID: 30266158 DOI: 10.1016/j.cld.2018.06.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 6.6] [Reference Citation Analysis]
271 González-Aldaco K, Torres-Reyes LA, Ojeda-Granados C, José-Ábrego A, Fierro NA, Román S. Immunometabolic Effect of Cholesterol in Hepatitis C Infection: Implications in Clinical Management and Antiviral Therapy. Ann Hepatol 2018;17:908-19. [PMID: 30600305 DOI: 10.5604/01.3001.0012.7191] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
272 Bamford CGG, Aranday-Cortes E, Filipe IC, Sukumar S, Mair D, Filipe ADS, Mendoza JL, Garcia KC, Fan S, Tishkoff SA, McLauchlan J. A polymorphic residue that attenuates the antiviral potential of interferon lambda 4 in hominid lineages. PLoS Pathog 2018;14:e1007307. [PMID: 30308076 DOI: 10.1371/journal.ppat.1007307] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
273 Peng Y, Zhu W, Feng Z, Zhu Z, Zhang Z, Chen Y, Liu S, Wu A, Wang D, Shu Y, Jiang T. Identification of genome-wide nucleotide sites associated with mammalian virulence in influenza A viruses.. [DOI: 10.1101/416586] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
274 Hasselbalch HC, Holmström MO. Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure? Semin Immunopathol 2019;41:5-19. [PMID: 30203226 DOI: 10.1007/s00281-018-0700-2] [Cited by in Crossref: 45] [Cited by in F6Publishing: 50] [Article Influence: 9.0] [Reference Citation Analysis]
275 Ramsuran V, Ewy R, Nguyen H, Kulkarni S. Variation in the Untranslated Genome and Susceptibility to Infections. Front Immunol 2018;9:2046. [PMID: 30245696 DOI: 10.3389/fimmu.2018.02046] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
276 Mylopoulou T, Papadopoulos V, Kassela K, Karakasiliotis I, Souvalidou F, Mimidis P, Veletza S, Mavromara P, Mimidis K. Relationship between antibodies to hepatitis C virus core+1 protein and treatment outcome. Ann Gastroenterol 2018;31:593-7. [PMID: 30174396 DOI: 10.20524/aog.2018.0290] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
277 Kandemir A, Ünsal B. Kronik hepatit C tedavisine yanıtı tahmin etmede IL28B gen polimorfizmi. Pamukkale Medical Journal 2018. [DOI: 10.31362/patd.428482] [Reference Citation Analysis]
278 Ramamurthy N, Marchi E, Ansari MA, Pedergnana V, Mclean A, Hudson E, Bowden R, Spencer CCA, Barnes E, Klenerman P; STOP HCV consortium. Impact of Interferon Lambda 4 Genotype on Interferon-Stimulated Gene Expression During Direct-Acting Antiviral Therapy for Hepatitis C. Hepatology 2018;68:859-71. [PMID: 29534310 DOI: 10.1002/hep.29877] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
279 Chen JY, Wang CM, Chen TD, Jan Wu YJ, Lin JC, Lu LY, Wu J. Interferon-λ3/4 genetic variants and interferon-λ3 serum levels are biomarkers of lupus nephritis and disease activity in Taiwanese. Arthritis Res Ther 2018;20:193. [PMID: 30157968 DOI: 10.1186/s13075-018-1683-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
280 Klebanov N. Genetic Predisposition to Infectious Disease. Cureus 2018;10:e3210. [PMID: 30405986 DOI: 10.7759/cureus.3210] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
281 Srinidhi BV, Fletcher GJ, Sachidanantham J, Rupali P, Ramalingam VV, Demosthenes JP, Abraham OC, Pulimood SA, Rebekah G, Kannangai R. Effect of Interleukin-28B polymorphism on Interleukin-28 expression and immunological recovery amongst HIV-1-infected individuals following antiretroviral therapy. Indian J Med Microbiol 2017;35:580-4. [PMID: 29405153 DOI: 10.4103/ijmm.IJMM_17_299] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
282 Jõgeda EL, Avi R, Pauskar M, Kallas E, Karki T, Des Jarlais D, Uusküla A, Toompere K, Lutsar I, Huik K. Association of IFNλ4 rs12979860 polymorphism with the acquisition of HCV and HIV infections among people who inject drugs. J Med Virol 2018;90:1779-83. [PMID: 29992584 DOI: 10.1002/jmv.25258] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
283 Royo JL, Real LM. Genetic Association Studies in Host-Pathogen Interaction Analysis. Methods Mol Biol 2018;1734:1-11. [PMID: 29288441 DOI: 10.1007/978-1-4939-7604-1_1] [Reference Citation Analysis]
284 Trivedi S, Murthy S, Sharma H, Hartlage AS, Kumar A, Gadi SV, Simmonds P, Chauhan LV, Scheel TKH, Billerbeck E, Burbelo PD, Rice CM, Lipkin WI, Vandegrift K, Cullen JM, Kapoor A. Viral persistence, liver disease, and host response in a hepatitis C-like virus rat model. Hepatology 2018;68:435-48. [PMID: 28859226 DOI: 10.1002/hep.29494] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 8.6] [Reference Citation Analysis]
285 Mangia A, Losappio R, Cenderello G, Potenza D, Mazzola M, De Stefano G, Terreni N, Copetti M, Minerva N, Piazzola V, Bacca D, Palmieri V, Sogari F, Santoro R. Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis. PLoS One 2018;13:e0200568. [PMID: 30063745 DOI: 10.1371/journal.pone.0200568] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
286 Scepanovic P, Alanio C, Hammer C, Hodel F, Bergstedt J, Patin E, Thorball CW, Chaturvedi N, Charbit B, Abel L, Quintana-Murci L, Duffy D, Albert ML, Fellay J; Milieu Intérieur Consortium. Human genetic variants and age are the strongest predictors of humoral immune responses to common pathogens and vaccines. Genome Med 2018;10:59. [PMID: 30053915 DOI: 10.1186/s13073-018-0568-8] [Cited by in Crossref: 82] [Cited by in F6Publishing: 82] [Article Influence: 16.4] [Reference Citation Analysis]
287 Kincaid RP, Lam VL, Chirayil RP, Randall G, Sullivan CS. RNA triphosphatase DUSP11 enables exonuclease XRN-mediated restriction of hepatitis C virus. Proc Natl Acad Sci USA. 2018;115:8197-8202. [PMID: 30038017 DOI: 10.1073/pnas.1802326115] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
288 Annibali O, Piccioni L, Tomarchio V, Circhetta E, Sarlo C, Franceschini L, Cantonetti M, Rizzo E, Angeletti S, Tirindelli MC, Scagnolari C, Statzu M, Avvisati G, Riva E. Impact of IFN lambda 3/4 single nucleotide polymorphisms on the cytomegalovirus reactivation in autologous stem cell transplant patients. PLoS One 2018;13:e0200221. [PMID: 30036376 DOI: 10.1371/journal.pone.0200221] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
289 Wei L, Wedemeyer H, Liaw YF, Chan HL, Piratvisuth T, Marcellin P, Jia J, Tan D, Chow WC, Brunetto MR, Diago M, Gurel S, Morozov V, He H, Zhu Y, Wat C, Surujbally B, Thompson AJ. No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B. PLoS One 2018;13:e0199198. [PMID: 30016335 DOI: 10.1371/journal.pone.0199198] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
290 Frias M, Rivero-Juárez A, López-López P, Rivero A. Pharmacogenetics and the treatment of HIV-/HCV-coinfected patients. Pharmacogenomics 2018;19:979-95. [PMID: 29992850 DOI: 10.2217/pgs-2018-0046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
291 Gupta V, Kumar A, Sharma P, Arora A. Newer direct-acting antivirals for hepatitis C virus infection: Perspectives for India. Indian J Med Res 2017;146:23-33. [PMID: 29168457 DOI: 10.4103/ijmr.IJMR_679_15] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
292 Parczewski M, Kordek J, Janczewska E, Pisula A, Łojewski W, Socha Ł, Wawrzynowicz-Syczewska M, Bociąga-Jasik M, Szymczak A, Cielniak I, Siwak E, Mularska E, Aksak-Wąs B, Urbańska A, Lübke N. Hepatitis C virus (HCV) genotype 1 NS5A resistance-associated variants are associated with advanced liver fibrosis independently of HCV-transmission clusters. Clin Microbiol Infect 2019;25:513.e1-6. [PMID: 29981869 DOI: 10.1016/j.cmi.2018.06.028] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
293 Sagnelli C, Uberti-Foppa C, Hasson H, Bellini G, Minichini C, Salpietro S, Messina E, Barbanotti D, Merli M, Punzo F, Coppola N, Lazzarin A, Sagnelli E, Rossi F. In vivo evidence that the cannabinoid receptor 2-63 RR variant is associated with the acquisition and/or expansion of HIV infection. HIV Med 2018;19:597-604. [PMID: 29932291 DOI: 10.1111/hiv.12638] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
294 Wrensch F, Crouchet E, Ligat G, Zeisel MB, Keck ZY, Foung SKH, Schuster C, Baumert TF. Hepatitis C Virus (HCV)-Apolipoprotein Interactions and Immune Evasion and Their Impact on HCV Vaccine Design. Front Immunol 2018;9:1436. [PMID: 29977246 DOI: 10.3389/fimmu.2018.01436] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
295 Soh BYM, Kumar R, Ekstrom VSM, Lin CYH, Thangaraju S, Tan HH, Chan KP, Choong LHL, Teo D, Chow WC. Prevalence of hepatitis C virus infection and the IL28B genotype polymorphism among blood donors and high-risk populations. Singapore Med J 2019;60:34-9. [PMID: 29926111 DOI: 10.11622/smedj.2018078] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
296 Sellers SL, Cunningham BA, Bonham VL. Physician Knowledge of Human Genetic Variation, Beliefs About Race and Genetics, and Use of Race in Clinical Decision-making. J Racial Ethn Health Disparities 2019;6:110-6. [PMID: 29926440 DOI: 10.1007/s40615-018-0505-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
297 Hitomi Y, Tokunaga K. Significance of functional disease-causal/susceptible variants identified by whole-genome analyses for the understanding of human diseases. Proc Jpn Acad Ser B Phys Biol Sci 2017;93:657-76. [PMID: 29129848 DOI: 10.2183/pjab.93.042] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
298 Dusheiko G. Hepatitis C. Sherlock's Diseases of the Liver and Biliary System 2018. [DOI: 10.1002/9781119237662.ch23] [Reference Citation Analysis]
299 Pujantell M, Franco S, Galván-Femenía I, Badia R, Castellví M, Garcia-Vidal E, Clotet B, de Cid R, Tural C, Martínez MA, Riveira-Muñoz E, Esté JA, Ballana E. ADAR1 affects HCV infection by modulating innate immune response. Antiviral Res 2018;156:116-27. [PMID: 29906476 DOI: 10.1016/j.antiviral.2018.05.012] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
300 Xie Z, Li Y, Long L, Liang H, Cai W, Shen T. Polymorphisms in the Th17 cell-related RORC gene are associated with spontaneous clearance of HCV in Chinese women. BMC Infect Dis 2018;18:254. [PMID: 29866105 DOI: 10.1186/s12879-018-3153-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
301 Shahnazarian V, Ramai D, Reddy M, Mohanty S. Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges. Ann Gastroenterol 2018;31:541-51. [PMID: 30174390 DOI: 10.20524/aog.2018.0281] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
302 Kim YM, Kim SB, Song IH, Lee SH, Kim HS, Lee TH, Kang YW, Kim SH, Lee BS, Chae HB, Song MJ, Jang JW, Ko SY, Lee JD. Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study. Clin Mol Hepatol 2018;24:311-8. [PMID: 29865774 DOI: 10.3350/cmh.2017.0070] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
303 Aisyah DN, Shallcross L, Hully AJ, O'Brien A, Hayward A. Assessing hepatitis C spontaneous clearance and understanding associated factors-A systematic review and meta-analysis. J Viral Hepat 2018;25:680-98. [PMID: 29345844 DOI: 10.1111/jvh.12866] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
304 Vasanthakumar A, Davis JW, Abunimeh M, Söderholm J, Zha J, Dumas EO, Cohen DE, Waring JF, Lagging M. Reduced ITPase activity and favorable IL28B genetic variant protect against ribavirin-induced anemia in interferon-free regimens. PLoS One 2018;13:e0198296. [PMID: 29851985 DOI: 10.1371/journal.pone.0198296] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
305 Wang X, Wang S, Liu ZH, Qi WQ, Zhang Q, Zhang YG, Sun DR, Xu Y, Wang HG, Li ZX, Cong XL, Zhao P, Zhou CY, Wang JB. Regulatory polymorphism of CXCL10 rs1439490 in seronegative occult hepatitis C virus infection. World J Gastroenterol 2018; 24(20): 2191-2202 [PMID: 29853737 DOI: 10.3748/wjg.v24.i20.2191] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
306 Alimohammadi A, Holeksa J, Thiam A, Truong D, Conway B. Real-world Efficacy of Direct-Acting Antiviral Therapy for HCV Infection Affecting People Who Inject Drugs Delivered in a Multidisciplinary Setting. Open Forum Infect Dis 2018;5:ofy120. [PMID: 29992173 DOI: 10.1093/ofid/ofy120] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
307 de Souza SL, Vidal LL, Ramos J, Cardoso CC, Coelho HSM, Villela-Nogueira CA, Perez RM, Soares MA, Santos AF. Hepatitis C Virus-Infected Responders and Relapsers to Treatment Show Similar Genetic Profiles of IL28B and IL10 Single Nucleotide Polymorphisms. Biomed Res Int 2018;2018:2931486. [PMID: 29888255 DOI: 10.1155/2018/2931486] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
308 Singh P, Dass JFP. Nearly neutral evolution in IFNL3 gene retains the immune function to detect and clear the viral infection in HCV. Prog Biophys Mol Biol 2018;140:107-16. [PMID: 29746888 DOI: 10.1016/j.pbiomolbio.2018.05.004] [Reference Citation Analysis]
309 Walker AJ, Peacock CJ, Pedergnana V, Irving WL; STOP-HCV Consortium. Host genetic factors associated with hepatocellular carcinoma in patients with hepatitis C virus infection: A systematic review. J Viral Hepat 2018;25:442-56. [PMID: 29397014 DOI: 10.1111/jvh.12871] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
310 Bhushan A, Chinnaswamy S. Identifying causal variants at the interferon lambda locus in case-control studies: Utilizing non-synonymous variant rs117648444 to probe the role of IFN-λ4. Gene 2018;664:168-80. [PMID: 29705128 DOI: 10.1016/j.gene.2018.04.076] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
311 Dustin LB. Innate and Adaptive Immune Responses in Chronic HCV Infection. Curr Drug Targets 2017;18:826-43. [PMID: 26302811 DOI: 10.2174/1389450116666150825110532] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 7.0] [Reference Citation Analysis]
312 Nosotti L, Petrelli A, Genovese D, Catone S, Argentini C, Vella S, Rossi A, Costanzo G, Fortino A, Chessa L, Miglioresi L, Mirisola C. Distribution of IL28B Polymorphism in a Cohort of Italians and Immigrants with HCV Infection: Association with Viraemia, Stage of Fibrosis and Response to Treatment. J Immigr Minor Health 2017;19:876-82. [PMID: 27271956 DOI: 10.1007/s10903-016-0444-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
313 Yudin NS, Barkhash AV, Maksimov VN, Ignatieva EV, Romaschenko AG. Human Genetic Predisposition to Diseases Caused by Viruses from Flaviviridae Family. Mol Biol 2018;52:165-81. [DOI: 10.1134/s0026893317050223] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
314 Ansari MA, Aranday-cortes E, Ip CL, Filipe ADS, Hin LS, Bamford CGG, Bonsall D, Trebes A, Piazza P, Sreenu V, Cowton VM, Hudson E, Bowden R, Patel AH, Foster GR, Irving WL, Agarwal K, Thomson EC, Simmonds P, Klenerman P, Holmes C, Barnes E, Spencer CC, Mclauchlan J, Pedergnana V, STOP-HCV Consortium. Interferon lambda 4 impacts broadly on hepatitis C virus diversity.. [DOI: 10.1101/305151] [Reference Citation Analysis]
315 Iakovenko NO, Petro Mohyla Black Sea National University 10, 68 Desantnykiv St., Mikolayiv 54003, Ukraine, Zak MY, Zhuk SV, Nuzhna OK. Features of the Course of Viral Hepatitis C in Children. Ukr ž med bìol sportu 2018;4:51-58. [DOI: 10.26693/jmbs04.02.051] [Reference Citation Analysis]
316 Bhardwaj N, Ragonnet-Cronin M, Murrell B, Chodavarapu K, Martin R, Chang S, Miller MD, Feld JJ, Sulkowski M, Mangia A, Wertheim JO, Osinusi A, McNally J, Brainard D, Mo H, Svarovskaia ES. Intrapatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir-containing regimens. J Viral Hepat 2018;25:344-53. [PMID: 29112331 DOI: 10.1111/jvh.12825] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
317 Lu MY, Huang CI, Hsieh MY, Hsieh TJ, Hsi E, Tsai PC, Tsai YS, Lin CC, Hsieh MH, Liang PC, Lin YH, Hou NJ, Yeh ML, Huang CF, Lin ZY, Chen SC, Huang JF, Chuang WL, Dai CY, Yu ML. Dynamics of PBMC gene expression in hepatitis C virus genotype 1-infected patients during combined peginterferon/ribavirin therapy. Oncotarget 2016;7:61325-35. [PMID: 27542257 DOI: 10.18632/oncotarget.11348] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
318 Egli A, Mandal J, Schumann DM, Roth M, Thomas B, Lorne Tyrrell D, Blasi F, Kostikas K, Boersma W, Milenkovic B, Lacoma A, Rentsch K, Rohde GGU, Louis R, Aerts JG, Welte T, Torres A, Tamm M, Stolz D. IFNΛ3/4 locus polymorphisms and IFNΛ3 circulating levels are associated with COPD severity and outcomes. BMC Pulm Med 2018;18:51. [PMID: 29562888 DOI: 10.1186/s12890-018-0616-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
319 Huang CI, Huang CF, Yeh ML, Lin YH, Liang PC, Liu SV, Hsieh MH, Lin ZY, Chen SC, Huang JF, Chuang WL, Dai CY, Yu ML. Role of IL-28B genetic variants in HCV-related liver disease severity in patients with different viral genotypes. Medicine (Baltimore) 2018;97:e9782. [PMID: 29517696 DOI: 10.1097/MD.0000000000009782] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
320 Kjellin M, Wesslén T, Löfblad E, Lennerstrand J, Lannergård A. The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort. Ups J Med Sci 2018;123:50-6. [PMID: 29536805 DOI: 10.1080/03009734.2018.1441928] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
321 Wilder JM, Muir A. Direct acting antivirals for the treatment of hepatitis C in ethnic minority populations. Expert Opin Pharmacother 2018;19:451-6. [PMID: 29488438 DOI: 10.1080/14656566.2018.1446945] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
322 Barnett PG, Joyce VR, Lo J, Gidwani-Marszowski R, Goldhaber-Fiebert JD, Desai M, Asch SM, Holodniy M, Owens DK. Effect of Interferon-Free Regimens on Disparities in Hepatitis C Treatment of US Veterans. Value Health 2018;21:921-30. [PMID: 30098669 DOI: 10.1016/j.jval.2017.12.025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
323 Lindgren M, Samuelsson J, Nilsson L, Knutsen H, Ghanima W, Westin J, Johansson PL, Andréasson B. Genetic variation in IL28B (IFNL3) and response to interferon-alpha treatment in myeloproliferative neoplasms. Eur J Haematol 2018;100:419-25. [PMID: 29369421 DOI: 10.1111/ejh.13034] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
324 Echeverría N, Chiodi D, López P, Sanchez Ciceron A, Angulo J, López-Lastra M, Silvera P, Canavesi A, Bianchi C, Colistro V, Cristina J, Hernandez N, Moreno P. IL28B gene polymorphism rs12979860, but not rs8099917, contributes to the occurrence of chronic HCV infection in Uruguayan patients. Virol J 2018;15:40. [PMID: 29499724 DOI: 10.1186/s12985-018-0946-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
325 Ji F, Wei B, Yeo YH, Ogawa E, Zou B, Stave CD, Li Z, Dang S, Furusyo N, Cheung RC, Nguyen MH. Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia. Aliment Pharmacol Ther 2018;47:550-62. [PMID: 29327780 DOI: 10.1111/apt.14507] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 8.4] [Reference Citation Analysis]
326 Suhail M, Sohrab SS, Qureshi A, Tarique M, Abdel-Hafiz H, Al-Ghamdi K, Qadri I. Association of HCV mutated proteins and host SNPs in the development of hepatocellular carcinoma. Infect Genet Evol 2018;60:160-72. [PMID: 29501636 DOI: 10.1016/j.meegid.2018.02.034] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
327 Schietroma I, Scheri GC, Pinacchio C, Statzu M, Petruzziello A, Vullo V. Hepatitis C Virus and Hepatocellular Carcinoma: Pathogenetic Mechanisms and Impact of Direct-Acting Antivirals. Open Virol J. 2018;12:16-25. [PMID: 29541275 DOI: 10.2174/1874357901812010016] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
328 Kleinstein SE, Shea PR, Allen AS, Koelle DM, Wald A, Goldstein DB. Genome-wide association study (GWAS) of human host factors influencing viral severity of herpes simplex virus type 2 (HSV-2). Genes Immun 2019;20:112-20. [PMID: 29535370 DOI: 10.1038/s41435-018-0013-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
329 Hashem M, Jhaveri R, Saleh DA, Sharaf SA, El-Mougy F, Abdelsalam L, Shardell MD, El-Ghazaly H, El-Kamary SS. Spontaneous Viral Load Decline and Subsequent Clearance of Chronic Hepatitis C Virus in Postpartum Women Correlates With Favorable Interleukin-28B Gene Allele. Clin Infect Dis 2017;65:999-1005. [PMID: 28903504 DOI: 10.1093/cid/cix445] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
330 Barritt AS, Jhaveri R. Treatment of Hepatitis C during Pregnancy-Weighing the Risks and Benefits in Contrast to HIV. Curr HIV/AIDS Rep 2018;15:155-61. [DOI: 10.1007/s11904-018-0386-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
331 Benhammou JN, Dong TS, May FP, Kawamoto J, Dixit R, Jackson S, Dixit V, Bhattacharya D, Han SB, Pisegna JR. Race affects SVR12 in a large and ethnically diverse hepatitis C-infected patient population following treatment with direct-acting antivirals: Analysis of a single-center Department of Veterans Affairs cohort. Pharmacol Res Perspect. 2018;6:e00379. [PMID: 29484189 DOI: 10.1002/prp2.379] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
332 Bhattacharya D, Belperio PS, Shahoumian TA, Loomis TP, Goetz MB, Mole LA, Backus LI. Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice. Clin Infect Dis 2017;64:1711-20. [PMID: 28199525 DOI: 10.1093/cid/cix111] [Cited by in Crossref: 64] [Cited by in F6Publishing: 66] [Article Influence: 12.8] [Reference Citation Analysis]
333 Valadkhan S, Fortes P. Regulation of the Interferon Response by lncRNAs in HCV Infection. Front Microbiol 2018;9:181. [DOI: 10.3389/fmicb.2018.00181] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
334 Shan Z, Huang J, Liao Q, Huang K, Wang M, Xu R, Tang X, Zhang W, Nelson K, Fu Y, Li C, Rong X. Association of killer cell immunoglobulin-like receptors with spontaneous clearance of hepatitis C virus in the Chinese population. Transfusion 2018;58:1028-35. [PMID: 29446443 DOI: 10.1111/trf.14527] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
335 Akiyama MJ, Agyemang L, Arnsten JH, Heo M, Norton BL, Schackman BR, Linas BP, Litwin AH. Rationale, design, and methodology of a trial evaluating three models of care for HCV treatment among injection drug users on opioid agonist therapy. BMC Infect Dis 2018;18:74. [PMID: 29426304 DOI: 10.1186/s12879-018-2964-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
336 Zhu DY, Deng XZ, Zhu YM, Li GT, Zhang GQ, Wang LJ, Zhang JH, Xiao W, Zhou ZX, Ding WL. Association of IL-28B, TBX21 gene polymorphisms and predictors of virological response for chronic hepatitis C. Arch Virol 2018;163:1253-62. [PMID: 29399747 DOI: 10.1007/s00705-018-3750-9] [Reference Citation Analysis]
337 De Re V, De Zorzi M, Caggiari L, Lauletta G, Tornesello ML, Fognani E, Miorin M, Racanelli V, Quartuccio L, Gragnani L, Russi S, Pavone F, Ghersetti M, Costa EG, Casarin P, Bomben R, Mazzaro C, Basaglia G, Berretta M, Vaccher E, Izzo F, Buonaguro FM, De Vita S, Zignego AL, De Paoli P, Dolcetti R. HCV-related liver and lymphoproliferative diseases: association with polymorphisms of IL28B and TLR2. Oncotarget 2016;7:37487-97. [PMID: 27183918 DOI: 10.18632/oncotarget.9303] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
338 Murata K, Asano M, Matsumoto A, Sugiyama M, Nishida N, Tanaka E, Inoue T, Sakamoto M, Enomoto N, Shirasaki T, Honda M, Kaneko S, Gatanaga H, Oka S, Kawamura YI, Dohi T, Shuno Y, Yano H, Mizokami M. Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection. Gut 2018;67:362-71. [PMID: 27789659 DOI: 10.1136/gutjnl-2016-312653] [Cited by in Crossref: 101] [Cited by in F6Publishing: 87] [Article Influence: 20.2] [Reference Citation Analysis]
339 Lee MH, Huang YH, Chen HY, Khor SS, Chang YH, Lin YJ, Jen CL, Lu SN, Yang HI, Nishida N, Sugiyama M, Mizokami M, Yuan Y, L'Italien G, Tokunaga K, Chen CJ; REVEAL-HCV Cohort Study Group. Human leukocyte antigen variants and risk of hepatocellular carcinoma modified by hepatitis C virus genotypes: A genome-wide association study. Hepatology 2018;67:651-61. [PMID: 28921602 DOI: 10.1002/hep.29531] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
340 Ahmed AM, Doheim MF, Mattar OM, Sherif NA, Truong DH, Hoa PTL, Hirayama K, Huy NT. Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis. J Med Virol 2018;90:907-18. [PMID: 28892235 DOI: 10.1002/jmv.24947] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
341 Matsuura K, Tanaka Y. Host genetic variations associated with disease progression in chronic hepatitis C virus infection. Hepatol Res 2018;48:127-33. [PMID: 29235266 DOI: 10.1111/hepr.13042] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
342 Hamdy M, Kassim SK, Khairy E, Maher M, Mansour KA, Albreedy AM. Ghrelin gene polymorphism as a genetic biomarker for prediction of therapy induced clearance in Egyptian chronic HCV patients. Gene 2018;649:74-9. [PMID: 29374597 DOI: 10.1016/j.gene.2018.01.077] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
343 Scepanovic P, Alanio C, Hammer C, Hodel F, Bergstedt J, Patin E, Thorball CW, Chaturvedi N, Charbit B, Abel L, Quintana-murci L, Duffy D, Albert ML, Fellay J, The Milieu Intérieur Consortium. Genetic factors and age are the strongest predictors of humoral immune responses to common pathogens and vaccines.. [DOI: 10.1101/254706] [Reference Citation Analysis]
344 Tang L, Meissner EG, Kottilil S. Virology and Pathogenesis of Hepatitis C. Zakim and Boyer's Hepatology 2018. [DOI: 10.1016/b978-0-323-37591-7.00028-8] [Reference Citation Analysis]
345 Lammert F. Molecular and Genetics-Based Diagnostics. Zakim and Boyer's Hepatology 2018. [DOI: 10.1016/b978-0-323-37591-7.00009-4] [Reference Citation Analysis]
346 Muir AJ. Treatment of Hepatitis C. Zakim and Boyer's Hepatology 2018. [DOI: 10.1016/b978-0-323-37591-7.00030-6] [Reference Citation Analysis]
347 Mcmillin GA, Wadelius M, Pratt VM. Pharmacogenetics. Principles and Applications of Molecular Diagnostics 2018. [DOI: 10.1016/b978-0-12-816061-9.00011-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
348 Schleiss MR, Marsh KJ. Viral Infections of the Fetus and Newborn. Avery's Diseases of the Newborn 2018. [DOI: 10.1016/b978-0-323-40139-5.00037-1] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
349 Hicks JK, Dunnenberger HM. Genetic Contributions and Personalized Medicine. Chronic Illness Care 2018. [DOI: 10.1007/978-3-319-71812-5_1] [Reference Citation Analysis]
350 Califf RM. Large Clinical Trials and Registries—Clinical Research Institutes. Principles and Practice of Clinical Research 2018. [DOI: 10.1016/b978-0-12-849905-4.00028-9] [Reference Citation Analysis]
351 Bamford CGG, Aranday-cortes E, Filipe IC, Sukumar S, Mair D, Silva Filipe AD, Mendoza JL, Garcia KC, Fan S, Tishkoff SA, Mclauchlan J. A Polymorphic Residue That Attenuates Interferon Lambda 4 Activity in Hominid Lineages. SSRN Journal. [DOI: 10.2139/ssrn.3155616] [Reference Citation Analysis]
352 Assone T, Malta FM, Bakkour S, Montalvo L, Paiva AM, Smid J, de Oliveira ACP, de Toledo Gonçalves F, do Carmo Luiz O, Fonseca LAM, Norris PJ, Casseb J. Polymorphisms in HLA-C and KIR alleles are not associated with HAM/TSP risk in HTLV-1-infected subjects. Virus Research 2018;244:71-4. [DOI: 10.1016/j.virusres.2017.11.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
353 Lin CC, Su SH, Jeng WJ, Huang CH, Teng W, Chen WT, Chen YC, Lin CY, Sheen IS. CCL4 is the only predictor for non-responder in GT-1 CHC patients with favorable IL28B genotype when treated with PegIFN/RBV. BMC Gastroenterol 2017;17:169. [PMID: 29284412 DOI: 10.1186/s12876-017-0724-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
354 Nukui A, Yanai Y, Tsuzuki T, Abe H, Arai K, Yoshida KI, Kamai T. Germline polymorphism of interferon-lambda3 is clinically associated with progression of renal cell carcinoma. Oncotarget 2018;9:4188-99. [PMID: 29423114 DOI: 10.18632/oncotarget.23683] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
355 Zang F, Yue M, Yao Y, Liu M, Fan H, Feng Y, Xia X, Huang P, Yu R. Influence of IL28B and MxA gene polymorphisms on HCV clearance in Han Chinese population. Epidemiol Infect 2018;146:379-85. [PMID: 29271328 DOI: 10.1017/S0950268817002928] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
356 Song Y, Shen Y, Xia X, Zhang AM. Association between genetic polymorphisms of the IL28B gene and leukomonocyte in Chinese hepatitis B virus-infected individuals. PeerJ 2017;5:e4149. [PMID: 29302390 DOI: 10.7717/peerj.4149] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
357 Kanda T, Nirei K, Matsumoto N, Higuchi T, Nakamura H, Yamagami H, Matsuoka S, Moriyama M. Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b. World J Gastroenterol 2017; 23(46): 8120-8127 [PMID: 29290649 DOI: 10.3748/wjg.v23.i46.8120] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
358 Cannella F, Scagnolari C, Statzu M, Sciandra I, Recine N, d'Ettorre G, Antonelli G, Pierangeli A. Interferon lambda4 polymorphism is not associated with human papillomavirus infection outcome. Virus Genes 2018;54:319-22. [PMID: 29243064 DOI: 10.1007/s11262-017-1527-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
359 Goh C, Knight JC. Enhanced understanding of the host-pathogen interaction in sepsis: new opportunities for omic approaches. Lancet Respir Med 2017;5:212-23. [PMID: 28266329 DOI: 10.1016/S2213-2600(17)30045-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.7] [Reference Citation Analysis]
360 Hemann EA, Gale M Jr, Savan R. Interferon Lambda Genetics and Biology in Regulation of Viral Control. Front Immunol. 2017;8:1707. [PMID: 29270173 DOI: 10.3389/fimmu.2017.01707] [Cited by in Crossref: 74] [Cited by in F6Publishing: 74] [Article Influence: 12.3] [Reference Citation Analysis]
361 O'Brien TR, Kottilil S, Pfeiffer RM. IFNL4 Genotype Is Associated With Virologic Relapse After 8-Week Treatment With Sofosbuvir, Velpatasvir, and Voxilaprevir. Gastroenterology 2017;153:1694-5. [PMID: 29107709 DOI: 10.1053/j.gastro.2017.06.069] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
362 Psaros Einberg A, Duberg AS, Filipovich O, Nyström J, Zhirkov A, Brenndörfer ED, Frelin L, Rukoiatkina E, Lobzin Y, Sällberg M, Fischler B, Lutckii A. Lack of Association Between Interleukin 28B Polymorphism and Vertical Transmission of Hepatitis C. J Pediatr Gastroenterol Nutr 2017;65:608-12. [PMID: 28820758 DOI: 10.1097/MPG.0000000000001711] [Reference Citation Analysis]
363 Biswas A, Gupta N, Gupta D, Datta A, Firdaus R, Chowdhury P, Bhattacharyya M, Sadhukhan PC. Association of TNF-alpha (-308 A/G) and IFN-gamma (+874 A/T) gene polymorphisms in response to spontaneous and treatment induced viral clearance in HCV infected multitransfused thalassemic patients. Cytokine 2018;106:148-53. [PMID: 29196132 DOI: 10.1016/j.cyto.2017.10.026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
364 Huang H, Duggal P, Thio CL, Latanich R, Goedert JJ, Mangia A, Cox AL, Kirk GD, Mehta S, Aneja J, Alric L, Donfield SM, Cramp ME, Khakoo SI, Tobler LH, Busch M, Alexander GJ, Rosen HR, Edlin BR, Segal FP, Lauer GM, Thomas DL, Daly MJ, Chung RT, Kim AY. Fine-mapping of genetic loci driving spontaneous clearance of hepatitis C virus infection. Sci Rep 2017;7:15843. [PMID: 29158528 DOI: 10.1038/s41598-017-16011-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
365 Robinson JR, Denny JC, Roden DM, Van Driest SL. Genome-wide and Phenome-wide Approaches to Understand Variable Drug Actions in Electronic Health Records. Clin Transl Sci 2018;11:112-22. [PMID: 29148204 DOI: 10.1111/cts.12522] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 4.5] [Reference Citation Analysis]
366 Nice TJ, Robinson BA, Van Winkle JA. The Role of Interferon in Persistent Viral Infection: Insights from Murine Norovirus. Trends Microbiol 2018;26:510-24. [PMID: 29157967 DOI: 10.1016/j.tim.2017.10.010] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
367 Parra M, Laufer N, Manrique JM, Jones LR, Quarleri J. Phylogenetic Diversity in Core Region of Hepatitis C Virus Genotype 1a as a Factor Associated with Fibrosis Severity in HIV-1-Coinfected Patients. Biomed Res Int 2017;2017:1728456. [PMID: 29259976 DOI: 10.1155/2017/1728456] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
368 Bamford CGG, Aranday-cortes E, Filipe IC, Sukumar S, Mair D, da Silva Filipe A, Mendoza JL, Christopher Garcia K, Fan S, Tishkoff SA, Mclauchlan J. A Polymorphic Residue That Attenuates the Antiviral Potential of Interferon Lambda 4 in Hominid Lineages.. [DOI: 10.1101/214825] [Reference Citation Analysis]
369 Clouston SA, Rubin MS, Phelan JC, Link BG. A Social History of Disease: Contextualizing the Rise and Fall of Social Inequalities in Cause-Specific Mortality. Demography 2016;53:1631-56. [PMID: 27531503 DOI: 10.1007/s13524-016-0495-5] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 9.0] [Reference Citation Analysis]
370 Falade-Nwulia O, Sutcliffe C, Moon J, Chander G, Wansom T, Keruly J, Katzianer J, Nathanson A, Marks J, Mehta S, Thomas D, Moore R, Sulkowski M. High hepatitis C cure rates among black and nonblack human immunodeficiency virus-infected adults in an urban center. Hepatology 2017;66:1402-12. [PMID: 28608973 DOI: 10.1002/hep.29308] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 5.5] [Reference Citation Analysis]
371 Grzegorzewska AE, Świderska MK, Mostowska A, Jagodziński PP. Circulating Interferon-λ3, Responsiveness to HBV Vaccination, and HBV/HCV Infections in Haemodialysis Patients. Biomed Res Int 2017;2017:3713025. [PMID: 29226133 DOI: 10.1155/2017/3713025] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
372 Zaidane I, Wakrim L, Oulad Lahsen A, Bensghir R, Chihab H, Jadid FZ, El Fihry R, Lamdini H, Fayssel N, Marhoum El Filali K, Oudghiri M, Benjelloun S, Ezzikouri S. Interleukin 28B rs12979860 genotype and Human Immunodeficiency Virus type 1: Susceptibility, AIDS development and therapeutic outcome. Hum Immunol 2018;79:70-5. [PMID: 29080719 DOI: 10.1016/j.humimm.2017.10.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
373 Wieczorek-Godlewska R, Płoski R, Perkowska-Ptasińska A, Tronina O, Sadowska A, Pacholczyk M, Lisik W, Durlik M. The impact of the recipient and donor interferon lambda-3 polymorphism on the course of HCV infection following liver transplantation. Clin Exp Hepatol 2017;3:152-8. [PMID: 29062905 DOI: 10.5114/ceh.2017.68401] [Reference Citation Analysis]
374 Moosavy SH, Davoodian P, Nazarnezhad MA, Nejatizaheh A, Eftekhar E, Mahboobi H. Epidemiology, transmission, diagnosis, and outcome of Hepatitis C virus infection. Electron Physician 2017;9:5646-56. [PMID: 29238510 DOI: 10.19082/5646] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.8] [Reference Citation Analysis]
375 Obajemu AA, Rao N, Dilley KA, Vargas JM, Sheikh F, Donnelly RP, Shabman RS, Meissner EG, Prokunina-Olsson L, Onabajo OO. IFN-λ4 Attenuates Antiviral Responses by Enhancing Negative Regulation of IFN Signaling. J Immunol 2017;199:3808-20. [PMID: 29070670 DOI: 10.4049/jimmunol.1700807] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 7.8] [Reference Citation Analysis]
376 Fried MW, Darling JM, Lemon SM. Hepatitis C. Schiff's Diseases of the Liver 2017. [DOI: 10.1002/9781119251316.ch25] [Reference Citation Analysis]
377 Uemura H, Tsukada K, Mizushima D, Aoki T, Watanabe K, Kinai E, Teruya K, Gatanaga H, Kikuchi Y, Sugiyama M, Mizokami M, Oka S. Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disorders. PLoS One 2017;12:e0186255. [PMID: 29045448 DOI: 10.1371/journal.pone.0186255] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
378 Nguyen LT, Van Nguyen D, Carr MJ, Hall WW, Nguyen LA. Association of interferon lambda polymorphisms with elevated baseline viral loads in chronic hepatitis C virus genotype 6 infection. Arch Virol 2018;163:115-24. [PMID: 29022122 DOI: 10.1007/s00705-017-3583-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
379 Costa AS, Agostini S, Guerini FR, Mancuso R, Zanzottera M, Ripamonti E, Racca V, Nemni R, Clerici M, Arosio B. Modulation of Immune Responses to Herpes Simplex Virus Type 1 by IFNL3 and IRF7 Polymorphisms: A Study in Alzheimer’s Disease. JAD 2017;60:1055-63. [DOI: 10.3233/jad-170520] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
380 Cvitanović T, Reichert MC, Moškon M, Mraz M, Lammert F, Rozman D. Large-scale computational models of liver metabolism: How far from the clinics? Hepatology 2017;66:1323-34. [PMID: 28520105 DOI: 10.1002/hep.29268] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
381 Fischer J, Weber ANR, Böhm S, Dickhöfer S, El Maadidi S, Deichsel D, Knop V, Klinker H, Möller B, Rasenack J, Wang L, Sharma M, Hinrichsen H, Spengler U, Buggisch P, Sarrazin C, Pawlita M, Waterboer T, Wiese M, Probst-Müller E, Malinverni R, Bochud PY, Gardiner C, O'Farrelly C, Berg T. Sex-specific effects of TLR9 promoter variants on spontaneous clearance of HCV infection. Gut 2017;66:1829-37. [PMID: 27196570 DOI: 10.1136/gutjnl-2015-310239] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
382 van Sluijs L, Pijlman GP, Kammenga JE. Why do Individuals Differ in Viral Susceptibility? A Story Told by Model Organisms. Viruses 2017;9:E284. [PMID: 28973976 DOI: 10.3390/v9100284] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
383 Barriocanal M, Fortes P. Long Non-coding RNAs in Hepatitis C Virus-Infected Cells. Front Microbiol. 2017;8:1833. [PMID: 29033906 DOI: 10.3389/fmicb.2017.01833] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
384 Cook L. Hepatitis C and the Impact of Host Genetics. J Mol Diagn 2017;19:805-8. [PMID: 28963021 DOI: 10.1016/j.jmoldx.2017.09.001] [Reference Citation Analysis]
385 Fakhriravari A. Sofosbuvir-Velpatasvir-Voxilaprevir for Chronic Hepatitis C - A Review. GHOA 2017;7. [DOI: 10.15406/ghoa.2017.07.00254] [Reference Citation Analysis]
386 Mozzi A, Pontremoli C, Sironi M. Genetic susceptibility to infectious diseases: Current status and future perspectives from genome-wide approaches. Infect Genet Evol 2018;66:286-307. [PMID: 28951201 DOI: 10.1016/j.meegid.2017.09.028] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
387 Rasmussen AL, Katze MG. Genomic Signatures of Emerging Viruses: A New Era of Systems Epidemiology. Cell Host Microbe 2016;19:611-8. [PMID: 27173929 DOI: 10.1016/j.chom.2016.04.016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
388 Hai H, Tamori A, Thuy LTT, Yoshida K, Hagihara A, Kawamura E, Uchida-Kobayashi S, Morikawa H, Enomoto M, Murakami Y, Kawada N. Polymorphisms in MICA, but not in DEPDC5, HCP5 or PNPLA3, are associated with chronic hepatitis C-related hepatocellular carcinoma. Sci Rep 2017;7:11912. [PMID: 28928439 DOI: 10.1038/s41598-017-10363-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
389 Duffy D, Mottez E, Ainsworth S, Buivan TP, Baudin A, Vray M, Reed B, Fontanet A, Rohel A, Petrov-Sanchez V, Abel L, Theodorou I, Miele G, Pol S, Albert ML. An in vitro diagnostic certified point of care single nucleotide test for IL28B polymorphisms. PLoS One 2017;12:e0183084. [PMID: 28877177 DOI: 10.1371/journal.pone.0183084] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
390 Chinnaswamy S, Wardzynska A, Pawelczyk M, Makowska J, Skaaby T, Mercader JM, Ahluwalia TS, Grarup N, Guindo-Martinez M, Bisgaard H, Torrents D, Linneberg A, Bønnelykke K, Kowalski ML. A functional IFN-λ4-generating DNA polymorphism could protect older asthmatic women from aeroallergen sensitization and associate with clinical features of asthma. Sci Rep 2017;7:10500. [PMID: 28874741 DOI: 10.1038/s41598-017-10467-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
391 Nakamoto S, Imazeki F, Kanda T, Wu S, Nakamura M, Yasui S, Tawada A, Mikata R, Chiba T, Arai M, Yokosuka O, Shirasawa H. Association of IFNL3 Genotype with Hepatic Steatosis in Chronic Hepatitis C Patients Treated with Peginterferon and Ribavirin Combination Therapy. Int J Med Sci 2017;14:1088-93. [PMID: 29104462 DOI: 10.7150/ijms.20171] [Reference Citation Analysis]
392 Ortega-Prieto AM, Dorner M. Immune Evasion Strategies during Chronic Hepatitis B and C Virus Infection. Vaccines (Basel). 2017;5:pii: E24. [PMID: 28862649 DOI: 10.3390/vaccines5030024] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 4.5] [Reference Citation Analysis]
393 Kandoussi N, Elannaz H, Melloul M, Tagajdid Mohamed R, Abi R, Elalaoui My A, Alaoui Amine S, Touil N, Elfahime E, Elkabbaj S, Zouhdi M, Mrani S. Genetic variation in interleukin 28B rs8099917 and response to antiviral therapy in Moroccan patients with chronic hepatitis C. Gene Reports 2017;8:84-87. [DOI: 10.1016/j.genrep.2017.06.003] [Reference Citation Analysis]
394 Kenney AD, Dowdle JA, Bozzacco L, McMichael TM, St Gelais C, Panfil AR, Sun Y, Schlesinger LS, Anderson MZ, Green PL, López CB, Rosenberg BR, Wu L, Yount JS. Human Genetic Determinants of Viral Diseases. Annu Rev Genet 2017;51:241-63. [PMID: 28853921 DOI: 10.1146/annurev-genet-120116-023425] [Cited by in Crossref: 80] [Cited by in F6Publishing: 97] [Article Influence: 13.3] [Reference Citation Analysis]
395 Wang YZ, Li JL, Wang X, Zhang T, Ho WZ. (-)-Epigallocatechin-3-gallate enhances poly I:C-induced interferon-λ1 production and inhibits hepatitis C virus replication in hepatocytes. World J Gastroenterol 2017; 23(32): 5895-5903 [PMID: 28932081 DOI: 10.3748/wjg.v23.i32.5895] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
396 Finotti G, Tamassia N, Cassatella MA. Interferon-λs and Plasmacytoid Dendritic Cells: A Close Relationship. Front Immunol 2017;8:1015. [PMID: 28878776 DOI: 10.3389/fimmu.2017.01015] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
397 Kim HB, Myung SK, Lee YJ, Park BJ. Efficacy of vitamin D supplementation in combination with conventional antiviral therapy in patients with chronic hepatitis C infection: a meta-analysis of randomised controlled trials. J Hum Nutr Diet. 2017; Epub ahead of print. [PMID: 28833855 DOI: 10.1111/jhn.12503] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
398 Douam F, Soto Albrecht YE, Hrebikova G, Sadimin E, Davidson C, Kotenko SV, Ploss A. Type III Interferon-Mediated Signaling Is Critical for Controlling Live Attenuated Yellow Fever Virus Infection In Vivo. mBio 2017;8:e00819-17. [PMID: 28811340 DOI: 10.1128/mBio.00819-17] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 6.5] [Reference Citation Analysis]
399 Leiva-Torres GA, Nebesio N, Vidal SM. Discovery of Variants Underlying Host Susceptibility to Virus Infection Using Whole-Exome Sequencing. Methods Mol Biol 2017;1656:209-27. [PMID: 28808973 DOI: 10.1007/978-1-4939-7237-1_14] [Reference Citation Analysis]
400 Ellwanger JH, Kaminski VL, Valverde-Villegas JM, Simon D, Lunge VR, Chies JAB. Immunogenetic studies of the hepatitis C virus infection in an era of pan-genotype antiviral therapies - Effective treatment is coming. Infect Genet Evol 2018;66:376-91. [PMID: 28811194 DOI: 10.1016/j.meegid.2017.08.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
401 Oh IS, Won JW, Kim HJ, Lee HW. Clinical implication of serum uric acid level in pegylated interferon and ribavirin combination therapy for chronic hepatitis C infection. Korean J Intern Med 2017;32:1010-7. [PMID: 28797159 DOI: 10.3904/kjim.2016.405] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
402 Huang CM, Chang KC, Hung CH, Chiu KW, Lu SN, Wang JH, Chen CH, Kee KM, Kuo YH, Tsai MC, Tseng PL, Lin MT, Wu CK, Hu TH, Cho CL, Yen YH. Impact of PNPLA3 and IFNL3 polymorphisms on hepatic steatosis in Asian patients with chronic hepatitis C. PLoS One 2017;12:e0182204. [PMID: 28797039 DOI: 10.1371/journal.pone.0182204] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
403 Klepper A, Eng FJ, Doyle EH, El-Shamy A, Rahman AH, Fiel MI, Avino GC, Lee M, Ye F, Roayaie S, Bansal MB, MacDonald MR, Schiano TD, Branch AD. Hepatitis C virus double-stranded RNA is the predominant form in human liver and in interferon-treated cells. Hepatology 2017;66:357-70. [PMID: 27642141 DOI: 10.1002/hep.28846] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
404 Yu ML. Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens. J Gastroenterol Hepatol 2017;32:1436-42. [PMID: 28124463 DOI: 10.1111/jgh.13747] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
405 Zeng QL, Li B, Zhang XX, Chen Y, Fu YL, Lv J, Liu YM, Yu ZJ. Clinical Model for Predicting Hepatocellular Carcinomas in Patients with Post-Sustained Virologic Responses of Chronic Hepatitis C: A Case Control Study. Gut Liver 2016;10:955-61. [PMID: 27257023 DOI: 10.5009/gnl15321] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
406 Westhaus S, Deest M, Nguyen ATX, Stanke F, Heckl D, Costa R, Schambach A, Manns MP, Berg T, Vondran FWR, Sarrazin C, Ciesek S, von Hahn T. Scavenger receptor class B member 1 (SCARB1) variants modulate hepatitis C virus replication cycle and viral load. J Hepatol 2017;67:237-45. [PMID: 28363797 DOI: 10.1016/j.jhep.2017.03.020] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
407 Sagnelli C, Uberti-Foppa C, Hasson H, Bellini G, Minichini C, Salpietro S, Messina E, Barbanotti D, Merli M, Punzo F, Coppola N, Lazzarin A, Sagnelli E, Rossi F. Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfected patients. PLoS One 2017;12:e0181890. [PMID: 28759568 DOI: 10.1371/journal.pone.0181890] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
408 Jung CH, Um SH, Kim TH, Yim SY, Suh SJ, Yim HJ, Seo YS, Choi HS, Chun HJ. Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C. Gut Liver 2016;10:808-17. [PMID: 27114417 DOI: 10.5009/gnl15360] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
409 Dvir R, Paloschi V, Canducci F, Dell'Antonio G, Racca S, Caldara R, Pantaleo G, Clementi M, Secchi A. IL28B rs12979860 genotype as a predictor marker of progression to BKVirus Associated nephropathy, after kidney transplantation. Sci Rep 2017;7:6746. [PMID: 28751760 DOI: 10.1038/s41598-017-06915-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
410 Elsemman IE, Mardinoglu A, Shoaie S, Soliman TH, Nielsen J. Systems biology analysis of hepatitis C virus infection reveals the role of copy number increases in regions of chromosome 1q in hepatocellular carcinoma metabolism. Mol Biosyst. 2016;12:1496-1506. [PMID: 27040643 DOI: 10.1039/c5mb00827a] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
411 Bhushan A, Ghosh S, Bhattacharjee S, Chinnaswamy S. Confounding by Single Nucleotide Polymorphism rs117648444 (P70S) Affects the Association of Interferon Lambda Locus Variants with Response to Interferon-α-Ribavirin Therapy in Patients with Chronic Genotype 3 Hepatitis C Virus Infection. J Interferon Cytokine Res 2017;37:369-82. [PMID: 28727946 DOI: 10.1089/jir.2017.0002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
412 Asnavandi M, Zargar M, Vaziri F, Jamnani FR, Gharibzadeh S, Fateh A, Siadat SD. EGFR rs11506105 and IFNL3 SNPs but not rs8099917 are strongly associated with treatment responses in Iranian patients with chronic hepatitis C. Genes Immun 2017;18:144-51. [DOI: 10.1038/gene.2017.12] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
413 López-Rodríguez R, Hernández-Bartolomé Á, Borque MJ, Rodríguez-Muñoz Y, Martín-Vílchez S, García-Buey L, González-Moreno L, Real-Martínez Y, Muñoz de Rueda P, Salmerón J, Vidal-Castiñeira JR, López-Larrea C, Rodrigo L, Moreno-Otero R, Sanz-Cameno P. Interferon-related genetic markers of necroinflammatory activity in chronic hepatitis C. PLoS One 2017;12:e0180927. [PMID: 28704535 DOI: 10.1371/journal.pone.0180927] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
414 Payami H. The emerging science of precision medicine and pharmacogenomics for Parkinson's disease. Mov Disord 2017;32:1139-46. [PMID: 28686320 DOI: 10.1002/mds.27099] [Cited by in Crossref: 16] [Cited by in F6Publishing: 37] [Article Influence: 2.7] [Reference Citation Analysis]
415 Wooller SK, Benstead-Hume G, Chen X, Ali Y, Pearl FMG. Bioinformatics in translational drug discovery. Biosci Rep 2017;37:BSR20160180. [PMID: 28487472 DOI: 10.1042/BSR20160180] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
416 Kunwar S, Devkota AR, Ghimire DKC, Adhikari P. A fixed-dose combination of ledipasvir and sofosbuvir ± ribavirin for treatment of hepatitis C infection: a systematic review and meta-analysis. Drugs Ther Perspect 2017;33:348-360. [DOI: 10.1007/s40267-017-0401-2] [Reference Citation Analysis]
417 Khubaib B, Idrees M, Fatima Z, Akram M, Afzal S, Amin I, Shahid M, Wasim M. Evaluation of three techniques for detection of IL28B SNP: A prognostic tool for HCV treatment outcome. J Dig Dis 2017;18:404-9. [PMID: 28608576 DOI: 10.1111/1751-2980.12497] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
418 Cheng CH, Lin CC, Chen HL, Lin IT, Wu CH, Lee YK, Wong MW, Bair MJ. High frequencies of a favorable IL-28B rs8099917 polymorphism and the clinical implications in patients with HCV in one multiracial area of Taiwan. Kaohsiung J Med Sci 2017;33:510-5. [PMID: 28962822 DOI: 10.1016/j.kjms.2017.06.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
419 Min YQ, Duan XC, Zhou YD, Kulinich A, Meng W, Cai ZP, Ma HY, Liu L, Zhang XL, Voglmeir J. Effects of microvirin monomers and oligomers on hepatitis C virus. Biosci Rep 2017;37:BSR20170015. [PMID: 28507200 DOI: 10.1042/BSR20170015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
420 Crouchet E, Baumert TF, Schuster C. Hepatitis C virus-apolipoprotein interactions: molecular mechanisms and clinical impact. Expert Rev Proteomics 2017;14:593-606. [PMID: 28625086 DOI: 10.1080/14789450.2017.1344102] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
421 Heidari Z, Moudi B, Mahmoudzadeh-Sagheb H, Moudi M. The association between interleukin-28B gene polymorphisms as a potential biomarker and the risk of chronic Periodontitis in an Iranian population. Head Face Med 2017;13:16. [PMID: 28655358 DOI: 10.1186/s13005-017-0148-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
422 Zhou Y, Wang Z, Xu Y, Zhang Z, Hua R, Liu W, Jiang C, Chen Y, Yang W, Kong W. Optimized DNA Vaccine Enhanced by Adjuvant IL28B Induces Protective Immune Responses Against Herpes Simplex Virus Type 2 in Mice. Viral Immunol 2017;30:601-14. [PMID: 28650722 DOI: 10.1089/vim.2017.0033] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
423 Zhang R, Shao C, Huo N, Li M, Xu X. Association of IL28B Genotypes and Baseline Serum Interferon-γ-Inducible- Protein-10 Levels with Treatment Response in Hepatitis C Virus Patients in China. Gut Liver 2016;10:446-55. [PMID: 26470765 DOI: 10.5009/gnl15162] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
424 Le Huu S. Relationship between Il28b Gene Polymorphisms and the Risk of Hepatocellular Carcinoma Development within Vietnamese Hepatitis B Virus Carriers. J Clin Microbiol Biochem Technol 2017. [DOI: 10.17352/jcmbt.000024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
425 Wang Y, Li T, Chen Y, Wei H, Sun R, Tian Z. Involvement of NK Cells in IL-28B-Mediated Immunity against Influenza Virus Infection. J Immunol 2017;199:1012-20. [PMID: 28637903 DOI: 10.4049/jimmunol.1601430] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
426 Lu M, Lewis CM, Traylor M. Pharmacogenetic testing through the direct-to-consumer genetic testing company 23andMe. BMC Med Genomics 2017;10:47. [PMID: 28629370 DOI: 10.1186/s12920-017-0283-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
427 Sung PS, Hong SH, Chung JH, Kim S, Park SH, Kim HM, Yoon SK, Shin EC. IFN-λ4 potently blocks IFN-α signalling by ISG15 and USP18 in hepatitis C virus infection. Sci Rep 2017;7:3821. [PMID: 28630501 DOI: 10.1038/s41598-017-04186-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
428 Lee MH, Huang CF, Lai HC, Lin CY, Dai CY, Liu CJ, Wang JH, Huang JF, Su WP, Yang HC, Kee KM, Yeh ML, Chuang PH, Hsu SJ, Huang CI, Kao JT, Chen CC, Chen SH, Jeng WJ, Yang HI, Yuan Y, Lu SN, Sheen IS, Liu CH, Peng CY, Kao JH, Yu ML, Chuang WL, Chen CJ. Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients. Sci Rep. 2017;7:3718. [PMID: 28623331 DOI: 10.1038/s41598-017-02313-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
429 Li R, Kim D, Ritchie MD. Methods to analyze big data in pharmacogenomics research. Pharmacogenomics 2017;18:807-20. [PMID: 28612644 DOI: 10.2217/pgs-2016-0152] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
430 Hussein NR, Tunjel I, Basharat Z, Taha A, Irving W. The treatment of HCV in patients with haemoglobinopathy in Kurdistan Region, Iraq: a single centre experience. Epidemiol Infect 2016;144:1634-40. [PMID: 27125573 DOI: 10.1017/S0950268815003064] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
431 Świątek-Kościelna B, Kałużna E, Strauss E, Nowak J, Bereszyńska I, Gowin E, Wysocki J, Rembowska J, Barcińska D, Mozer-Lisewska I, Januszkiewicz-Lewandowska D. Prevalence of IFNL3 rs4803217 single nucleotide polymorphism and clinical course of chronic hepatitis C. World J Gastroenterol 2017; 23(21): 3815-3824 [PMID: 28638221 DOI: 10.3748/wjg.v23.i21.3815] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
432 Gane EJ, DeJesus E, Janczewska E, George J, Diago M, Da Silva MH, Reesink H, Nikitin I, Hinrichsen H, Bourgeois S, Ferenci P, Shukla U, Kalmeijer R, Lenz O, Fevery B, Corbett C, Beumont M, Jessner W. Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study. BMC Infect Dis 2017;17:389. [PMID: 28577353 DOI: 10.1186/s12879-017-2444-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
433 Zeng QL, Xu GH, Zhang JY, Li W, Zhang DW, Li ZQ, Liang HX, Li CX, Yu ZJ. Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study. J Hepatol 2017;66:1123-9. [PMID: 28189754 DOI: 10.1016/j.jhep.2017.01.025] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 6.8] [Reference Citation Analysis]
434 Nagao Y, Nishida N, Toyo-Oka L, Kawaguchi A, Amoroso A, Carrozzo M, Sata M, Mizokami M, Tokunaga K, Tanaka Y. Genome-Wide Association Study Identifies Risk Variants for Lichen Planus in Patients With Hepatitis C Virus Infection. Clin Gastroenterol Hepatol 2017;15:937-944.e5. [PMID: 28065765 DOI: 10.1016/j.cgh.2016.12.029] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
435 Santer DM, Minty GE, Mohamed A, Baldwin L, Bhat R, Joyce M, Egli A, Tyrrell DLJ, Houghton M. A novel method for detection of IFN-lambda 3 binding to cells for quantifying IFN-lambda receptor expression. Journal of Immunological Methods 2017;445:15-22. [DOI: 10.1016/j.jim.2017.03.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
436 Lorenzo Bermejo J, Boekstegers F, González Silos R, Marcelain K, Baez Benavides P, Barahona Ponce C, Müller B, Ferreccio C, Koshiol J, Fischer C, Peil B, Sinsheimer J, Fuentes Guajardo M, Barajas O, Gonzalez-Jose R, Bedoya G, Cátira Bortolini M, Canizales-Quinteros S, Gallo C, Ruiz Linares A, Rothhammer F. Subtypes of Native American ancestry and leading causes of death: Mapuche ancestry-specific associations with gallbladder cancer risk in Chile. PLoS Genet 2017;13:e1006756. [PMID: 28542165 DOI: 10.1371/journal.pgen.1006756] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 4.8] [Reference Citation Analysis]
437 Forde KA. Ethnic Disparities in Chronic Hepatitis B Infection: African Americans and Hispanic Americans. Curr Hepatol Rep 2017;16:105-12. [PMID: 29308354 DOI: 10.1007/s11901-017-0348-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
438 Neesgaard B, Ruhwald M, Weis N. Inducible protein-10 as a predictive marker of antiviral hepatitis C treatment: A systematic review. World J Hepatol 2017; 9(14): 677-688 [PMID: 28588752 DOI: 10.4254/wjh.v9.i14.677] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
439 Read SA, O'Connor KS, Suppiah V, Ahlenstiel CLE, Obeid S, Cook KM, Cunningham A, Douglas MW, Hogg PJ, Booth D, George J, Ahlenstiel G. Zinc is a potent and specific inhibitor of IFN-λ3 signalling. Nat Commun 2017;8:15245. [PMID: 28513591 DOI: 10.1038/ncomms15245] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 6.8] [Reference Citation Analysis]
440 Pashaei Zanjani A, Esmaeilpour N, Rasoolinejad M, Moradnejad P, Hedayat Yaghoobi M. Treatment of Hepatitis C Virus Infection in the HIV- Infected Patients by Pegylated Interferon and Ribavirin in Tehran, Iran. Avicenna J Clin Microbiol Infect 2017;4:43623-43623. [DOI: 10.5812/ajcmi.43623] [Reference Citation Analysis]
441 Waring JF, Davis JW, Dumas E, Cohen D, Idler K, Abel S, Georgantas R, Podsadecki T, Dutta S. Epigenetic analysis of the IFNλ3 gene identifies a novel marker for response to therapy in HCV-infected subjects. J Viral Hepat 2017;24:397-403. [PMID: 27925355 DOI: 10.1111/jvh.12661] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
442 Matsuura K, Sawai H, Ikeo K, Ogawa S, Iio E, Isogawa M, Shimada N, Komori A, Toyoda H, Kumada T, Namisaki T, Yoshiji H, Sakamoto N, Nakagawa M, Asahina Y, Kurosaki M, Izumi N, Enomoto N, Kusakabe A, Kajiwara E, Itoh Y, Ide T, Tamori A, Matsubara M, Kawada N, Shirabe K, Tomita E, Honda M, Kaneko S, Nishina S, Suetsugu A, Hiasa Y, Watanabe H, Genda T, Sakaida I, Nishiguchi S, Takaguchi K, Tanaka E, Sugihara J, Shimada M, Kondo Y, Kawai Y, Kojima K, Nagasaki M, Tokunaga K, Tanaka Y; Japanese Genome-Wide Association Study Group for Viral Hepatitis. Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection. Gastroenterology 2017;152:1383-94. [PMID: 28163062 DOI: 10.1053/j.gastro.2017.01.041] [Cited by in Crossref: 80] [Cited by in F6Publishing: 83] [Article Influence: 13.3] [Reference Citation Analysis]
443 Ying T, Wen Y, Dimitrov DS. Precision immunomedicine. Emerg Microbes Infect 2017;6:e25. [PMID: 28442753 DOI: 10.1038/emi.2017.22] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
444 Gaudieri S, Lucas M. Innate and adaptive immunity shape circulating HCV strains. Nat Genet 2017;49:657-8. [PMID: 28442794 DOI: 10.1038/ng.3856] [Reference Citation Analysis]
445 Benito JM, García-Samaniego J, García M, Madejón A, Martín-Carbonero L, Cabello A, Álvarez B, Górgolas M, Rallón N. Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C. J Interferon Cytokine Res 2017;37:278-86. [PMID: 28440692 DOI: 10.1089/jir.2016.0078] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
446 Hajiabdolbaghi M, Shahsiah R, Motavaf M, Zavari T. The Impact of Interleukin-28B rs12979860 Polymorphism on Peginterferon-alpha and Ribavirin Combination Therapy in Iranian Patients with Hepatitis C Virus Genotype 1 Infection. J Human Gen Genom 2017;1. [DOI: 10.5812/jhgg.65255] [Reference Citation Analysis]
447 Huang H, Duggal P, Thio CL, Latanich R, Goedert JJ, Mangia A, Cox AL, Kirk GD, Mehta S, Blankson JN, Aneja J, Alric L, Donfield SM, Cramp ME, Khakoo SI, Tobler LH, Busch M, Alexander GJ, Rosen HR, Edlin BR, Lauer GM, Thomas DL, Daly MJ, Chung RT, Kim AY. Fine-mapping of genetic loci driving spontaneous clearance of hepatitis C virus infection.. [DOI: 10.1101/128975] [Reference Citation Analysis]
448 Biswas A, Firdaus R, Gupta D, Ghosh M, Saha K, Chowdhury P, Bhattacharyya M, Sadhukhan PC. Interferon λ3 gene (IL28B) is associated with spontaneous or treatment-induced viral clearance in hepatitis C virus-infected multitransfused patients with thalassemia. Transfusion 2017;57:1376-84. [PMID: 28419488 DOI: 10.1111/trf.14070] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
449 Ansari MA, Pedergnana V, L C Ip C, Magri A, Von Delft A, Bonsall D, Chaturvedi N, Bartha I, Smith D, Nicholson G, McVean G, Trebes A, Piazza P, Fellay J, Cooke G, Foster GR, Hudson E, McLauchlan J, Simmonds P, Bowden R, Klenerman P, Barnes E, Spencer CCA; STOP-HCV Consortium. Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus. Nat Genet 2017;49:666-73. [PMID: 28394351 DOI: 10.1038/ng.3835] [Cited by in Crossref: 101] [Cited by in F6Publishing: 100] [Article Influence: 16.8] [Reference Citation Analysis]
450 Eslam M, McLeod D, Kelaeng KS, Mangia A, Berg T, Thabet K, Irving WL, Dore GJ, Sheridan D, Grønbæk H, Abate ML, Hartmann R, Bugianesi E, Spengler U, Rojas A, Booth DR, Weltman M, Mollison L, Cheng W, Riordan S, Mahajan H, Fischer J, Nattermann J, Douglas MW, Liddle C, Powell E, Romero-Gomez M, George J; International Liver Disease Genetics Consortium (ILDGC). IFN-λ3, not IFN-λ4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. Nat Genet 2017;49:795-800. [PMID: 28394349 DOI: 10.1038/ng.3836] [Cited by in Crossref: 74] [Cited by in F6Publishing: 80] [Article Influence: 12.3] [Reference Citation Analysis]
451 Serti E, Park H, Keane M, O'Keefe AC, Rivera E, Liang TJ, Ghany M, Rehermann B. Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFNα. Gut 2017;66:724-35. [PMID: 26733671 DOI: 10.1136/gutjnl-2015-310033] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 7.3] [Reference Citation Analysis]
452 Sidhu SS, Malhi NS, Goyal O, Singh R, Dutta U, Grover R, Sidhu JS, Nanda V, Saluja H, Bansal A, Singh G, Sehgal A, Kishore H, Sidhu S. Treatment of chronic hepatitis C genotype 3 with Sofosbuvir-based therpy: a real-life study. Hepatol Int 2017;11:277-85. [PMID: 28361300 DOI: 10.1007/s12072-017-9794-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
453 Trinks J, Caputo M, Hulaniuk ML, Corach D, Flichman D. Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals. Pharmgenomics Pers Med 2017;10:79-91. [PMID: 28405170 DOI: 10.2147/PGPM.S125452] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
454 Lei JH, Yang X, Xiao XQ, Chen Z, Peng F. A preliminary investigation on single nucleotide polymorphism rs2287622 of bile salt export pump gene in patients with chronic hepatitis C virus infection in Hunan, China. BMC Gastroenterol 2017;17:42. [PMID: 28292275 DOI: 10.1186/s12876-017-0594-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
455 Miyaaki H, Nakao K. Significance of genetic polymorphisms in patients with nonalcoholic fatty liver disease. Clin J Gastroenterol. 2017;10:201-207. [PMID: 28290069 DOI: 10.1007/s12328-017-0732-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
456 Motawi T, Shaker OG, Hussein RM, Houssen M. Polymorphisms of α1-antitrypsin and Interleukin-6 genes and the progression of hepatic cirrhosis in patients with a hepatitis C virus infection. Balkan J Med Genet 2016;19:35-44. [PMID: 28289587 DOI: 10.1515/bjmg-2016-0034] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
457 Zulfiqar HF, Javed A, Sumbal, Afroze B, Ali Q, Akbar K, Nadeem T, Rana MA, Nazar ZA, Nasir IA, Husnain T. HIV Diagnosis and Treatment through Advanced Technologies. Front Public Health 2017;5:32. [PMID: 28326304 DOI: 10.3389/fpubh.2017.00032] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
458 Wang X, Wang H, Liu MQ, Li JL, Zhou RH, Zhou Y, Wang YZ, Zhou W, Ho WZ. IFN-λ Inhibits Drug-Resistant HIV Infection of Macrophages. Front Immunol 2017;8:210. [PMID: 28321215 DOI: 10.3389/fimmu.2017.00210] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
459 Mori N, Imamura M, Kawakami Y, Nagaoki Y, Kawaoka T, Tsuge M, Hiramatsu A, Hayes CN, Aikata H, Miki D, Ochi H, Honda Y, Takaki S, Tsuji K, Chayama K; Hiroshima Liver Study Group. IFNL4 polymorphism effects on outcome of simeprevir, peginterferon, and ribavirin therapy for older patients with genotype 1 chronic hepatitis C. Hepatol Res 2017;47:E5-E13. [PMID: 27027531 DOI: 10.1111/hepr.12715] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
460 Gonzalez-Aldaco K, Rebello Pinho JO, Panduro A, Martinez-Lopez E, Gleyzer K, Fierro N, Roman S. High Prevalence of ITPA Alleles Associated with Ribavirin-Induced Hemolytic Anemia Among Mexican Population. Ann Hepatol 2017;16:221-9. [PMID: 28233743 DOI: 10.5604/16652681.1231582] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
461 Dai C. Further refining individualized therapy with peginterferon alfa/ribavirin for chronic hepatitis C. Advances in Digestive Medicine 2017;4:1-3. [DOI: 10.1002/aid2.12001] [Reference Citation Analysis]
462 Syedbasha M, Egli A. Interferon Lambda: Modulating Immunity in Infectious Diseases. Front Immunol. 2017;8:119. [PMID: 28293236 DOI: 10.3389/fimmu.2017.00119] [Cited by in Crossref: 86] [Cited by in F6Publishing: 92] [Article Influence: 14.3] [Reference Citation Analysis]
463 Chang CY, Nguyen P, Le A, Zhao C, Ahmed A, Daugherty T, Garcia G, Lutchman G, Kumari R, Nguyen MH. Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease. Medicine (Baltimore). 2017;96:e6128. [PMID: 28178174 DOI: 10.1097/md.0000000000006128] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
464 Murakawa M, Asahina Y, Kawai-Kitahata F, Nakagawa M, Nitta S, Otani S, Nagata H, Kaneko S, Asano Y, Tsunoda T, Miyoshi M, Itsui Y, Azuma S, Kakinuma S, Tanaka Y, Iijima S, Tsuchiya K, Izumi N, Tohda S, Watanabe M. Hepatic IFNL4 expression is associated with non-response to interferon-based therapy through the regulation of basal interferon-stimulated gene expression in chronic hepatitis C patients. J Med Virol 2017;89:1241-7. [PMID: 28036111 DOI: 10.1002/jmv.24763] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
465 Ranjan P, Fletcher GJ, Radhakrishnan M, Sivakumar J, Premkumar PS, Goel A, Zachariah UG, Abraham P. Association of interleukin-28B rs12979860 and rs8099917 polymorphisms with sustained viral response in hepatitis C virus genotype 1 and 3 infected patients from the Indian subcontinent. Indian J Med Microbiol 2016;34:335-41. [PMID: 27514956 DOI: 10.4103/0255-0857.188329] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
466 Jud S, Goede JS, Senn O, Spanaus K, Manz MG, Benz R. sIL2R ratio as early marker for response in hairy cell leukemia and the prognostic relevance of IL28B genotype to interferon-α therapy. Ann Hematol 2017;96:757-63. [PMID: 28214980 DOI: 10.1007/s00277-017-2943-8] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
467 Alborzi A, Hashempour T, Moayedi J, Musavi Z, Pouladfar G, Merat S. Role of serum level and genetic variation of IL-28B in interferon responsiveness and advanced liver disease in chronic hepatitis C patients. Med Microbiol Immunol 2017;206:165-74. [PMID: 28214926 DOI: 10.1007/s00430-017-0497-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
468 Sulkowski MS, Fessel WJ, Lazzarin A, Berenguer J, Zakharova N, Cheinquer H, Côté P, Dieterich D, Gadano A, Matthews G, Molina JM, Moreno C, Pineda JA, Pulido F, Rivero A, Rockstroh J, Hernandez D, McPhee F, Eley T, Liu Z, Mendez P, Hughes E, Noviello S, Ackerman P. Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study. Hepatol Int 2017;11:188-98. [PMID: 28210927 DOI: 10.1007/s12072-017-9788-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
469 Ali M, Afzal S, Zia A, Hassan A, Khalil AT, Ovais M, Shinwari ZK, Idrees M. A systematic review of treatment response rates in Pakistani hepatitis C virus patients; current prospects and future challenges. Medicine (Baltimore) 2016;95:e5327. [PMID: 27977575 DOI: 10.1097/MD.0000000000005327] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
470 Zhang G, Nebert DW. Personalized medicine: Genetic risk prediction of drug response. Pharmacol Ther 2017;175:75-90. [PMID: 28213088 DOI: 10.1016/j.pharmthera.2017.02.036] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
471 Mao R, Yang R, Chen X, Harhaj EW, Wang X, Fan Y. Regnase-1, a rapid response ribonuclease regulating inflammation and stress responses. Cell Mol Immunol 2017;14:412-22. [PMID: 28194024 DOI: 10.1038/cmi.2016.70] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 6.2] [Reference Citation Analysis]
472 Wansom T, Falade-Nwulia O, Sutcliffe CG, Mehta SH, Moore RD, Thomas DL, Sulkowski MS. Barriers to Hepatitis C Virus (HCV) Treatment Initiation in Patients With Human Immunodeficiency Virus/HCV Coinfection: Lessons From the Interferon Era. Open Forum Infect Dis 2017;4:ofx024. [PMID: 28480293 DOI: 10.1093/ofid/ofx024] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
473 Yang CHT, Yoo ER, Ahmed A. The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C. J Clin Transl Hepatol. 2017;5:59-66. [PMID: 28507928 DOI: 10.14218/jcth.2016.00053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
474 Vutien P, Hoang J, Brooks L Jr, Nguyen NH, Nguyen MH. Racial Disparities in Treatment Rates for Chronic Hepatitis C: Analysis of a Population-Based Cohort of 73,665 Patients in the United States. Medicine (Baltimore) 2016;95:e3719. [PMID: 27258498 DOI: 10.1097/MD.0000000000003719] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
475 Novotny D, Roubalova L, Aiglova K, Bednarikova J, Bartkova M. IL28B genotyping and treatment of HCV infected subjects. Asian Biomedicine 2014;8:445-52. [DOI: 10.5372/1905-7415.0804.313] [Reference Citation Analysis]
476 Weber SN, Lammert F. Genetics in liver diseases: From diagnostics to precise therapy. Clin Liver Dis (Hoboken) 2017;9:1-4. [PMID: 30992947 DOI: 10.1002/cld.605] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
477 Bruening J, Weigel B, Gerold G. The Role of Type III Interferons in Hepatitis C Virus Infection and Therapy. J Immunol Res 2017;2017:7232361. [PMID: 28255563 DOI: 10.1155/2017/7232361] [Cited by in Crossref: 17] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
478 Herta T, Fischer J, Berg T. Genetik metabolischer und viraler Lebererkrankungen. Gastroenterologe 2017;12:16-31. [DOI: 10.1007/s11377-016-0128-y] [Reference Citation Analysis]
479 Su F, Green PK, Berry K, Ioannou GN. The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection. Hepatology 2017;65:426-38. [PMID: 27775854 DOI: 10.1002/hep.28901] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 9.5] [Reference Citation Analysis]
480 Zupin L, Polesello V, Alberi G, Moratelli G, Crocè SL, Masutti F, Pozzato G, Crovella S, Segat L. MBL2 Genetic Variants in HCV Infection Susceptibility, Spontaneous Viral Clearance and Pegylated Interferon Plus Ribavirin Treatment Response. Scand J Immunol 2016;84:61-9. [PMID: 27136459 DOI: 10.1111/sji.12444] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
481 Danilau D, Litvinchuk D, Solovey N, Krasko O, Karpov I. Association of TNF-α and CCL5 with response to interferon-based therapy in patients with HCV 1 genotype. Clin Exp Hepatol 2017;3:16-22. [PMID: 28856285 DOI: 10.5114/ceh.2017.65279] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
482 Lu M, Lewis CM, Traylor M. Pharmacogenetic testing through the direct-to-consumer genetic testing company 23andMe.. [DOI: 10.1101/098541] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
483 Pouryasin M, Sharafi H, Behnava B, Alavian SM, Keshvari M, Pouryasin A. A Simple PCR-RFLP Method for Genotyping of IFNL4 rs368234815 Polymorphism in Patients With Chronic Hepatitis C. Lab Med 2017;48:51-6. [PMID: 28057801 DOI: 10.1093/labmed/lmw060] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
484 Degrave W, Mendonça-lima L. Interferons. Current Developments in Biotechnology and Bioengineering 2017. [DOI: 10.1016/b978-0-444-63660-7.00003-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
485 Hicks JK, Mcleod HL. Pharmacogenetics and Pharmacogenomics. Genomic and Precision Medicine 2017. [DOI: 10.1016/b978-0-12-800685-6.00004-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
486 Echeverría N, Moreno P, Cristina J. Molecular Evolution of Hepatitis C Virus: From Epidemiology to Antiviral Therapy (Current Research in Latin America). Human Virology in Latin America 2017. [DOI: 10.1007/978-3-319-54567-7_17] [Reference Citation Analysis]
487 Perales C, Ortega-prieto AM, Beach NM, Sheldon J, Menéndez-arias L, Domingo E. Quasispecies and Drug Resistance. Handbook of Antimicrobial Resistance 2017. [DOI: 10.1007/978-1-4939-0694-9_1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
488 Jain KK. Biomarkers of Infectious Diseases. The Handbook of Biomarkers 2017. [DOI: 10.1007/978-1-4939-7431-3_9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
489 Tu T, Patel K, Shackel NA. Viral Hepatitis. Genomic and Precision Medicine 2017. [DOI: 10.1016/b978-0-12-800685-6.00017-5] [Reference Citation Analysis]
490 Rao HY, Li H, Chen H, Shang J, Xie Q, Gao ZL, Li J, Sun Y, Jiang J, Wang L, Zhao L, Zhang L, Yang W, Niu J, Gong Z, Gong G, Yang R, Lee MH, Wei L. Real-world treatment patterns and clinical outcomes of HCV treatment-naive patients in China: an interim analysis from the CCgenos study. J Gastroenterol Hepatol 2017;32:244-52. [PMID: 27289083 DOI: 10.1111/jgh.13467] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
491 Heinrich B, Bilello JP. HCV Drug Resistance. Antimicrobial Drug Resistance 2017. [DOI: 10.1007/978-3-319-46718-4_39] [Reference Citation Analysis]
492 Parasrampuria DA. Delicate Dance in Treating Hepatitis C Infections and Overcoming Resistance. Viral Proteases and Their Inhibitors 2017. [DOI: 10.1016/b978-0-12-809712-0.00014-9] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
493 Sofia M, Link J. Harvoni: A Combination Therapy for Curing HCV. Comprehensive Medicinal Chemistry III 2017. [DOI: 10.1016/b978-0-12-409547-2.12451-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
494 Bunchorntavakul C, Reddy KR. Viral Hepatitis: Hepatitis C. Liver Disorders 2017. [DOI: 10.1007/978-3-319-30103-7_11] [Reference Citation Analysis]
495 Boisvert M, Shoukry NH. Type III Interferons in Hepatitis C Virus Infection. Front Immunol 2016;7:628. [PMID: 28066437 DOI: 10.3389/fimmu.2016.00628] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
496 Bokharaei-salim F, Salehi-vaziri M, Sadeghi F, Khanaliha K, Esghaei M, Monavari SH, Alavian SM, Fakhim S, Keyvani H. Genetic Variation in Interleukin-28B and Response to Peg-IFNα-2a/RBV Combination Therapy in Patients with Hepatitis C Virus Infection. Jundishapur J Microbiol 2016;10. [DOI: 10.5812/jjm.39178] [Reference Citation Analysis]
497 Li Y, Zhu C, Wang F, Zhu T, Li J, Liu S, Xiao F. Expression of Interferon Effector Gene SART1 Correlates with Interferon Treatment Response against Hepatitis B Infection. Mediators Inflamm 2016;2016:3894816. [PMID: 28077916 DOI: 10.1155/2016/3894816] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
498 Palenzuela Gardón D, Guillen IA, Fernández JR, Camacho H, Estevez ZC, Dueñas S, Alvares-Lajonchere L, Amador Y, Martinez-Donato G, Han J, Zhang Z, Zhang X, Gao Y, Campaña JR, Novoa LI. Assessment of IL-28: rs12979860 and rs8099917 Polymorphisms in a Cohort of Cuban Chronic HCV Genotype 1b Patients. J Biomol Tech 2017;28:80-6. [PMID: 28058039 DOI: 10.7171/jbt.17-2801-001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
499 Boesecke C, Ingiliz P, Reiberger T, Stellbrink HJ, Bhagani S, Page E, Mauss S, Lutz T, Voigt E, Guiguet M, Valantin MA, Baumgarten A, Nelson M, Vogel M, Rockstroh JK; NEAT Study Group. Dual treatment of acute HCV infection in HIV co-infection: influence of HCV genotype upon treatment outcome. Infection 2016;44:93-101. [PMID: 26481253 DOI: 10.1007/s15010-015-0856-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
500 Sofia MJ. Sofosbuvir: The Discovery of a Curative Therapy for the Treatment of Hepatitis C Virus. Successful Drug Discovery 2016. [DOI: 10.1002/9783527800315.ch8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
501 Ibrahim MK, Salama H, Abd El Rahman M, Dawood RM, Bader El Din NG, Salem HF, Abdelrahim ME, Omran D, Omran MH, El-wakeel KH, Abdelhafez TH, Khedr A, El Awady MK. Three Gene Signature for Predicting the Development of Hepatocellular Carcinoma in Chronically Infected Hepatitis C Virus Patients. Journal of Interferon & Cytokine Research 2016;36:698-705. [DOI: 10.1089/jir.2016.0042] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
502 Indolfi G, Nebbia G, Cananzi M, Maccabruni A, Zaramella M, D’antiga L, Grisotto L, Azzari C, Resti M. Kinetic of Virologic Response to Pegylated Interferon and Ribavirin in Children With Chronic Hepatitis C Predicts the Effect of Treatment. Pediatric Infectious Disease Journal 2016;35:1300-3. [DOI: 10.1097/inf.0000000000001325] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
503 Aiken T, Garber A, Thomas D, Hamon N, Lopez R, Konjeti R, McCullough A, Zein N, Fung J, Askar M, John BV. Donor IFNL4 Genotype Is Associated with Early Post-Transplant Fibrosis in Recipients with Hepatitis C. PLoS One 2016;11:e0166998. [PMID: 27875564 DOI: 10.1371/journal.pone.0166998] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
504 Mangia A, De Ledinghen V, Bailly F, Brahm J, Keiss J, Valantinas J, Rasmann N, Messinger D, Tatsch F, Bakalos G, Foster GR; Gen-C study group. IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C study. Springerplus. 2016;5:1990. [PMID: 27917361 DOI: 10.1186/s40064-016-3663-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
505 Jarret A, McFarland AP, Horner SM, Kell A, Schwerk J, Hong M, Badil S, Joslyn RC, Baker DP, Carrington M, Hagedorn CH, Gale M Jr, Savan R. Hepatitis-C-virus-induced microRNAs dampen interferon-mediated antiviral signaling. Nat Med 2016;22:1475-81. [PMID: 27841874 DOI: 10.1038/nm.4211] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
506 Mozhgani S, Jaberi N, Rezaee SA, Bustani R, Jazayeri SM, Akbarin MM, Milani S, Tarokhian H, Norouzi M. Evaluation of HTLV-1 HBZ and proviral load, together with host IFN λ3 , in pathogenesis of HAM/TSP: HTLV-1 Associated Myelopathy and IFN-Lambda 3. J Med Virol 2017;89:1102-7. [DOI: 10.1002/jmv.24721] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
507 Hayes CN, Chayama K. Interferon stimulated genes and innate immune activation following infection with hepatitis B and C viruses: ISGs in HCV and HBV Infection. J Med Virol 2017;89:388-96. [DOI: 10.1002/jmv.24659] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
508 Domagalski K, Pawłowska M, Zaleśna A, Pilarczyk M, Rajewski P, Halota W, Tretyn A. Impact of IL28B and OAS gene family polymorphisms on interferon treatment response in Caucasian children chronically infected with hepatitis B virus. World J Gastroenterol 2016; 22(41): 9186-9195 [PMID: 27895405 DOI: 10.3748/wjg.v22.i41.9186] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
509 Ulveling D, Le Clerc S, Cobat A, Labib T, Noirel J, Laville V, Coulonges C, Carpentier W, Nalpas B, Heim MH, Poynard T, Cerny A, Pol S, Bochud PY, Dabis F, Theodorou I, Lévy Y, Salmon D, Abel L, Dominguez S, Zagury JF; HEPAVIH ANRS CO13 Cohort Study Group, Swiss Hepatitis C Cohort Study Group, French ANRS HC EP 26 Genoscan Study Group. A new 3p25 locus is associated with liver fibrosis progression in human immunodeficiency virus/hepatitis C virus-coinfected patients. Hepatology 2016;64:1462-72. [PMID: 27339598 DOI: 10.1002/hep.28695] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
510 Shah SR, Rao PN, Sarin SK, Chowdhury A, Bhatia S, Dharamsi R, Goswami BD, Kapoor D, Luaia R, Mehta R, Mukewar S, Prasad VG, Rai RR, Saigal S, Singh D, Trehanpati N, Chen S, Gaggar A, Knox SJ, Subramanian GM, Singh SP, Sood A, Varghese J, Venugopal RV. Chronic hepatitis C virus infection in India: Regional demographics and distribution of viral genotypes. Indian J Gastroenterol 2016;35:469-77. [PMID: 27844277 DOI: 10.1007/s12664-016-0709-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
511 Mah Y, Liu C, Chen C, Tseng T, Liu C, Chen P, Chen D, Kao J. Prevalence and clinical implications of IL28B genotypes in Taiwanese patients with chronic hepatitis C. Journal of the Formosan Medical Association 2016;115:953-60. [DOI: 10.1016/j.jfma.2016.07.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
512 Mancebo M, Real LM, Mira JA, Recio E, Pérez E, Monje-Agudo P, Merchante N, Macías J, Neukam K, Pineda JA. Changes in the response to treatment against chronic hepatitis C between 1999 and 2015: data from a prospective cohort. Eur J Gastroenterol Hepatol 2016;28:1253-7. [PMID: 27415157 DOI: 10.1097/MEG.0000000000000705] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
513 Hong M, Schwerk J, Lim C, Kell A, Jarret A, Pangallo J, Loo YM, Liu S, Hagedorn CH, Gale M Jr, Savan R. Interferon lambda 4 expression is suppressed by the host during viral infection. J Exp Med 2016;213:2539-52. [PMID: 27799623 DOI: 10.1084/jem.20160437] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 6.6] [Reference Citation Analysis]
514 Zhong YW, Zhang HF, Shi YM, Li YL, Chu F, Xu ZQ, Chen DW, Gan Y, Wang FC, Gu ML, Dong Y, Zhu SS, Shi C, Fan HH, Zhang XC, Zhang M. IL28B SNP rs12979860 is the Critical Predictor for Sustained Viral Response in Chinese Children Aged 1 to 6 Years with Chronic Hepatitis C. Int J Biol Sci 2016;12:1357-62. [PMID: 27877087 DOI: 10.7150/ijbs.16220] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
515 Baker JL, Shriner D, Bentley AR, Rotimi CN. Pharmacogenomic implications of the evolutionary history of infectious diseases in Africa. Pharmacogenomics J 2017;17:112-20. [PMID: 27779243 DOI: 10.1038/tpj.2016.78] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
516 Bogdanović Z, Marinović-Terzić I, Kuret S, Jerončić A, Bradarić N, Forempoher G, Polašek O, Anđelinović Š, Terzić J. The impact of IL-6 and IL-28B gene polymorphisms on treatment outcome of chronic hepatitis C infection among intravenous drug users in Croatia. PeerJ 2016;4:e2576. [PMID: 27812403 DOI: 10.7717/peerj.2576] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
517 Rizzo SR, Gazito D, Pott-Junior H, Latini FR, Castelo A. Prevalence of IFNL3 gene polymorphism among blood donors and its relation to genomic profile of ancestry in Brazil. Braz J Infect Dis 2016;20:619-22. [PMID: 27789282 DOI: 10.1016/j.bjid.2016.10.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
518 Ekstrom V, Kumar R, Zhao Y, Yee ML, Sung C, Toh D, Loh PY, Tan J, Teo EK, Chow WC. Real world experience with pegylated interferon and ribavirin in hepatitis C genotype 1 population with favourable IL28B polymorphism. Gastroenterol Rep (Oxf) 2017;5:208-12. [PMID: 28852525 DOI: 10.1093/gastro/gow033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
519 Wilson EM, Rosenthal ES, Kattakuzhy S, Tang L, Kottilil S. Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C. Clin Microbiol Rev 2017;30:23-42. [PMID: 27795306 DOI: 10.1128/CMR.00037-16] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
520 Almasio PL, Licata A, Maida M, Macaluso FS, Costantino A, Alessi N, Grimaudo S, Accardi G, Caruso C, Craxi A. Clinical Course and Genetic Susceptibility of Primary Biliary Cirrhosis: Analysis of a Prospective Cohort. Hepat Mon 2016;16:e31681. [PMID: 28070198 DOI: 10.5812/hepatmon.31681] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
521 Keshvari M, Alavian SM, Behnava B, Pouryasin A, Craig JC, Sharafi H. Impact of IFNL4 rs12979860 and rs8099917 polymorphisms on response to Peg-Interferon-α and Ribavirin in patients with congenital bleeding disorder and chronic hepatitis C. J Clin Lab Anal 2017;31. [PMID: 27735085 DOI: 10.1002/jcla.22063] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
522 Eslam M, George J. Targeting IFN-λ: therapeutic implications. Expert Opinion on Therapeutic Targets 2016;20:1425-32. [DOI: 10.1080/14728222.2016.1241242] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
523 Fuchs S, Kaiser-labusch P, Bank J, Ammann S, Kolb-kokocinski A, Edelbusch C, Omran H, Ehl S. Tyrosine kinase 2 is not limiting human antiviral type III interferon responses. Eur J Immunol 2016;46:2639-49. [DOI: 10.1002/eji.201646519] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 5.7] [Reference Citation Analysis]
524 Moudi B, Heidari Z, Mahmoudzadeh-sagheb H. Impact of host gene polymorphisms on susceptibility to chronic hepatitis B virus infection. Infection, Genetics and Evolution 2016;44:94-105. [DOI: 10.1016/j.meegid.2016.06.043] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
525 Asselah T, Esmat G, Sanai FM, Goulis I, Messinger D, Bakalos G, Waked I. Simple Predictive Model for Identifying Patients with Chronic Hepatitis C and Hepatitis C Virus Genotype 4 Infection with a High Probability of Sustained Virologic Response with Peginterferon Alfa-2a/Ribavirin: Pooled Analysis of Data from Two Large, International Cohort Studies. Adv Ther 2016;33:1797-813. [PMID: 27517563 DOI: 10.1007/s12325-016-0396-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
526 Andrighetto LV, Dos Santos JS, Nicoletti G, Bock PM. INFLUÊNCIA DA VITAMINA D ASSOCIADA AO INTERFERON ALFA PEGUILADO E RIBAVIRINA NA RESPOSTA VIROLOGICA SUSTENTADA NA HEPATITE C CRÔNICA. Infarma 2016;28:140-148. [DOI: 10.14450/2318-9312.v28.e3.a2016.pp140-148] [Reference Citation Analysis]
527 Asadi-Saghandi A, Shams A, Eslami G, Mirghanizadeh SA, Eskandari-Nasab E. Peginterferon Alfa-2a/Ribavirin treatment efficacy in chronic hepatitis C patients is related to natural killer group 2D gene rs1049174 GC polymorphism. Virusdisease 2016;27:369-74. [PMID: 28004016 DOI: 10.1007/s13337-016-0349-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
528 Rehman SU, Rauf M, Abbas Z, Hamed MH, Qadri I. Role of Some Predominant Host Immunomodulators' Single Nucleotide Polymorphisms in Severity of Hepatitis B Virus and Hepatitis C Virus Infection. Viral Immunol 2016;29:536-45. [PMID: 27676210 DOI: 10.1089/vim.2016.0062] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
529 Morán-Auth Y, Penna-Martinez M, Perner D, Susser S, Wicker S, Zeuzem S, Sarrazin C, Badenhoop K. IL28B gene variants and glucose metabolism in Type 2 Diabetes. Hum Immunol 2016;77:1280-3. [PMID: 27664841 DOI: 10.1016/j.humimm.2016.09.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
530 Afzal MS. Predictive potential of IL-28B genetic testing for interferon based hepatitis C virus therapy in Pakistan: Current scenario and future perspective. World J Hepatol 2016; 8(26): 1116-1118 [PMID: 27660680 DOI: 10.4254/wjh.v8.i26.1116] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
531 Mizzi C, Dalabira E, Kumuthini J, Dzimiri N, Balogh I, Başak N, Böhm R, Borg J, Borgiani P, Bozina N, Bruckmueller H, Burzynska B, Carracedo A, Cascorbi I, Deltas C, Dolzan V, Fenech A, Grech G, Kasiulevicius V, Kádaši Ľ, Kučinskas V, Khusnutdinova E, Loukas YL, Macek M Jr, Makukh H, Mathijssen R, Mitropoulos K, Mitropoulou C, Novelli G, Papantoni I, Pavlovic S, Saglio G, Setric J, Stojiljkovic M, Stubbs AP, Squassina A, Torres M, Turnovec M, van Schaik RH, Voskarides K, Wakil SM, Werk A, Del Zompo M, Zukic B, Katsila T, Lee MT, Motsinger-Rief A, Mc Leod HL, van der Spek PJ, Patrinos GP. A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics. PLoS One 2016;11:e0162866. [PMID: 27636550 DOI: 10.1371/journal.pone.0162866] [Cited by in Crossref: 76] [Cited by in F6Publishing: 80] [Article Influence: 10.9] [Reference Citation Analysis]
532 Corrales I, Solano C, Amat P, Giménez E, de la Cámara R, Nieto J, López J, García-Noblejas A, Piñana JL, Navarro D. IL28B genetic variation and cytomegalovirus-specific T-cell immunity in allogeneic stem cell transplant recipients. J Med Virol 2017;89:685-95. [PMID: 27591738 DOI: 10.1002/jmv.24676] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
533 Zare F, Hadinedoushan H, Akhondi Meybodi M, Dehghanmanshadi M, Mirghanizade Bafghi SA, Vakili M. The Effect of IL28B Gene Polymorphism on Treatment Response in Iranian Patients with Hepatitis C Virus Infection. Jundishapur J Microbiol 2016;9. [DOI: 10.5812/jjm.31501] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
534 Geller DS. New Developments in the Genetics of Hypertension: What Should Clinicians Know? Curr Cardiol Rep 2015;17:122. [PMID: 26521239 DOI: 10.1007/s11886-015-0664-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
535 Kelly A, Robinson MW, Roche G, Biron CA, O'Farrelly C, Ryan EJ. Immune Cell Profiling of IFN-λ Response Shows pDCs Express Highest Level of IFN-λR1 and Are Directly Responsive via the JAK-STAT Pathway. J Interferon Cytokine Res 2016;36:671-80. [PMID: 27617757 DOI: 10.1089/jir.2015.0169] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
536 Honegger JR, Tedesco D, Kohout JA, Prasad MR, Price AA, Lindquist T, Ohmer S, Moore-Clingenpeel M, Grakoui A, Walker CM. Influence of IFNL3 and HLA-DPB1 genotype on postpartum control of hepatitis C virus replication and T-cell recovery. Proc Natl Acad Sci U S A 2016;113:10684-9. [PMID: 27601657 DOI: 10.1073/pnas.1602337113] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
537 Price AA, Tedesco D, Prasad MR, Workowski KA, Walker CM, Suthar MS, Honegger JR, Grakoui A. Prolonged activation of innate antiviral gene signature after childbirth is determined by IFNL3 genotype. Proc Natl Acad Sci U S A 2016;113:10678-83. [PMID: 27601663 DOI: 10.1073/pnas.1602319113] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
538 Zhao YJ, Khoo AL, Lin L, Teng M, Koh CJ, Lim SG, Lim BP, Dan YY. Cost-effectiveness of strategy-based approach to treatment of genotype 1 chronic hepatitis C. J Gastroenterol Hepatol 2016;31:1628-37. [PMID: 26990023 DOI: 10.1111/jgh.13341] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
539 Grzegorzewska AE, Świderska MK, Mostowska A, Warchoł W, Jagodziński PP. Antibodies to HBV surface antigen in relation to interferon-λ3 in hemodialysis patients. Vaccine 2016;34:4866-74. [PMID: 27595449 DOI: 10.1016/j.vaccine.2016.08.073] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
540 Jarouliya U, Keservani RK. Genomics and Proteomic Approach in the Treatment of Various Human Diseases. Advances in Medical Technologies and Clinical Practice. [DOI: 10.4018/978-1-5225-0754-3.ch004] [Reference Citation Analysis]
541 Monteleone K, Scheri GC, Statzu M, Selvaggi C, Falasca F, Giustini N, Mezzaroma I, Turriziani O, d'Ettorre G, Antonelli G, Scagnolari C. IFN-stimulated gene expression is independent of the IFNL4 genotype in chronic HIV-1 infection. Arch Virol 2016;161:3263-8. [PMID: 27558125 DOI: 10.1007/s00705-016-3016-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
542 Ampuero J, Romero-Gómez M. Pharmacogenetics of ribavirin-induced anemia in hepatitis C. Pharmacogenomics 2016;17:1587-94. [PMID: 27547881 DOI: 10.2217/pgs.16.28] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
543 Mehta M, Hetta HF, Abdel-Hameed EA, Rouster SD, Hossain M, Mekky MA, Khalil NK, Mohamed WA, El-Feky MA, Ahmed SH, Daef EA, El-Mokhtar MA, Abdelwahab SF, Medhat A, Sherman KE, Shata MT. Association between IL28B rs12979860 single nucleotide polymorphism and the frequency of colonic Treg in chronically HCV-infected patients. Arch Virol 2016;161:3161-9. [PMID: 27544760 DOI: 10.1007/s00705-016-3015-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
544 Yamagiwa Y, Asano M, Kawasaki Y, Korenaga M, Murata K, Kanto T, Mizokami M, Masaki N. Pretreatment serum levels of interferon-gamma-inducible protein-10 are associated with virologic response to telaprevir-based therapy. Cytokine 2016;88:29-36. [PMID: 27541605 DOI: 10.1016/j.cyto.2016.07.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
545 Dondeti MF, El-Maadawy EA, Talaat RM. Hepatitis-related hepatocellular carcinoma: Insights into cytokine gene polymorphisms. World J Gastroenterol 2016; 22(30): 6800-6816 [PMID: 27570418 DOI: 10.3748/wjg.v22.i30.6800] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
546 Budzko L, Marcinkowska-Swojak M, Jackowiak P, Kozlowski P, Figlerowicz M. Copy number variation of genes involved in the hepatitis C virus-human interactome. Sci Rep 2016;6:31340. [PMID: 27510840 DOI: 10.1038/srep31340] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
547 Huang J, Huang K, Xu R, Wang M, Liao Q, Xiong H, Li C, Tang X, Shan Z, Zhang M, Rong X, Nelson K, Fu Y. The Associations of HLA-A*02:01 and DRB1*11:01 with Hepatitis C Virus Spontaneous Clearance Are Independent of IL28B in the Chinese Population. Sci Rep 2016;6:31485. [PMID: 27511600 DOI: 10.1038/srep31485] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
548 Toyota J, Karino Y, Suzuki F, Ikeda F, Ido A, Tanaka K, Takaguchi K, Naganuma A, Tomita E, Chayama K, Fujiyama S, Inada Y, Yoshiji H, Watanabe H, Ishikawa H, Hu W, McPhee F, Linaberry M, Yin PD, Swenson ES, Kumada H. Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection. J Gastroenterol 2017;52:385-95. [PMID: 27502287 DOI: 10.1007/s00535-016-1245-6] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 5.9] [Reference Citation Analysis]
549 Shirvani-Dastgerdi E, Schwartz RE, Ploss A. Hepatocarcinogenesis associated with hepatitis B, delta and C viruses. Curr Opin Virol 2016;20:1-10. [PMID: 27504999 DOI: 10.1016/j.coviro.2016.07.009] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
550 Malov IV, Malov SI, Savilov ED, Gantulga D, Stepanenko LA, Ogarkov OB, Nyamkhuu D, Aitov KA, Nyamdawa P, Kolesnikov SI. Population Polymorphism of IFNL3 and IFNL4 Genes of Type 3 Interferon Associated with Spontaneous Clearance of Hepatitis C Virus in Representatives of Caucasian and Mongoloid Races. Bull Exp Biol Med 2016;161:404-7. [PMID: 27492404 DOI: 10.1007/s10517-016-3425-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
551 Mansoor S, Riaz S, Kausar S, Muhammad Din S, Javed A, Sultan A, Mansoor A. Can IFNL3 polymorphisms predict response to interferon/ribavirin treatment in hepatitis C patients with genotype 3? J Gen Virol 2016;97:2592-8. [PMID: 27498543 DOI: 10.1099/jgv.0.000572] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
552 Kao JH, Chien RN, Chang TT, Peng CY, Hu TH, Lo GH, Wang HY, Chen JJ, Yang JC, Knox SJ, Han L, Mo H, Mathias A, Brainard DM, Sheen IS, Hsu YC, Chu CJ, Chuang WL. A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection. Liver Int 2016;36:1101-7. [PMID: 26835876 DOI: 10.1111/liv.13082] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
553 Trépo E, Romeo S, Zucman-Rossi J, Nahon P. PNPLA3 gene in liver diseases. J Hepatol 2016;65:399-412. [PMID: 27038645 DOI: 10.1016/j.jhep.2016.03.011] [Cited by in Crossref: 168] [Cited by in F6Publishing: 163] [Article Influence: 24.0] [Reference Citation Analysis]
554 Chang ML, Liang KH, Ku CL, Lo CC, Cheng YT, Hsu CM, Yeh CT, Chiu CT. Resistin reinforces interferon λ-3 to eliminate hepatitis C virus with fine-tuning from RETN single-nucleotide polymorphisms. Sci Rep 2016;6:30799. [PMID: 27477870 DOI: 10.1038/srep30799] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
555 Lunemann S, Martrus G, Hölzemer A, Chapel A, Ziegler M, Körner C, Garcia Beltran W, Carrington M, Wedemeyer H, Altfeld M. Sequence variations in HCV core-derived epitopes alter binding of KIR2DL3 to HLA-C∗03:04 and modulate NK cell function. J Hepatol 2016;65:252-8. [PMID: 27057987 DOI: 10.1016/j.jhep.2016.03.016] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 4.9] [Reference Citation Analysis]
556 Mei R, Chi X, Wu R, Xu H, Wang X, Gao X, Sun H, Lv J, Yu G, Kong F, Jiang J, Sun B, Zhong J, Pan Y, Niu J. Sustained viral response and treatment-induced cytopenia correlate with SLCs and KLF12 genotypes in interferon/ribavirin-treated Chinese chronic hepatitis C patients. J Gastroenterol Hepatol 2016;31:1489-97. [PMID: 26750805 DOI: 10.1111/jgh.13290] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
557 Turnpenny PD. Digesting GWAS. Cell Mol Gastroenterol Hepatol 2016;2:542-3. [PMID: 28174734 DOI: 10.1016/j.jcmgh.2016.07.003] [Reference Citation Analysis]
558 Alves CF, Grott CS, Lunge VR, Béria JU, Tietzmann DC, Stein AT, Simon D. Interferon lambda 4 (IFNL4) gene polymorphism is associated with spontaneous clearance of HCV in HIV-1 positive patients. Genet Mol Biol 2016;39:374-9. [PMID: 27560987 DOI: 10.1590/1678-4685-GMB-2015-0106] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
559 Pittman KJ, Glover LC, Wang L, Ko DC. The Legacy of Past Pandemics: Common Human Mutations That Protect against Infectious Disease. PLoS Pathog 2016;12:e1005680. [PMID: 27442518 DOI: 10.1371/journal.ppat.1005680] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
560 Daneshvar M, Nikbin M, Talebi S, Javadi F, Aghasadeghi MR, Mahmazi S, Sadat SM. Role of IL28-B Polymorphism (rs12979860) on Sustained Virological Response to Pegylated Interferon/Ribavirin in Iranian Patients With Chronic Hepatitis C. Iran Red Crescent Med J 2016;18:e28566. [PMID: 28144454 DOI: 10.5812/ircmj.28566] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
561 Kuntzen T, Kuhn S, Kuntzen D, Seifert B, Müllhaupt B, Geier A. Influence of Ribavirin Serum Levels on Outcome of Antiviral Treatment and Anemia in Hepatitis C Virus Infection. PLoS One 2016;11:e0158512. [PMID: 27388623 DOI: 10.1371/journal.pone.0158512] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
562 Belle A, Gizard E, Conroy G, Lopez A, Bouvier-Alias M, Rouanet S, Peyrin-Biroulet L, Pawlotsky JM, Bronowicki JP. 25-OH vitamin D level has no impact on the efficacy of antiviral therapy in naïve genotype 1 HCV-infected patients. United European Gastroenterol J 2017;5:69-75. [PMID: 28405324 DOI: 10.1177/2050640616640157] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
563 Shin EC, Sung PS, Park SH. Immune responses and immunopathology in acute and chronic viral hepatitis. Nat Rev Immunol. 2016;16:509-523. [PMID: 27374637 DOI: 10.1038/nri.2016.69] [Cited by in Crossref: 187] [Cited by in F6Publishing: 193] [Article Influence: 26.7] [Reference Citation Analysis]
564 Petersen T, Lee YJ, Osinusi A, Amorosa VK, Wang C, Kang M, Matining R, Zhang X, Dou D, Umbleja T, Kottilil S, Peters MG. Interferon Stimulated Gene Expression in HIV/HCV Coinfected Patients Treated with Nitazoxanide/Peginterferon-Alfa-2a and Ribavirin. AIDS Res Hum Retroviruses 2016;32:660-7. [PMID: 26974581 DOI: 10.1089/aid.2015.0236] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
565 Langman LJ, Nesher L, Shah DP, Azzi JM, Shpall EJ, Rezvani K, Black JL 3rd, Chemaly RF. Challenges in Determining Genotypes for Pharmacogenetics in Allogeneic Hematopoietic Cell Transplant Recipients. J Mol Diagn 2016;18:638-42. [PMID: 27371869 DOI: 10.1016/j.jmoldx.2016.03.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
566 El-Guindi MA. Hepatitis C Viral Infection in Children: Updated Review. Pediatr Gastroenterol Hepatol Nutr 2016;19:83-95. [PMID: 27437184 DOI: 10.5223/pghn.2016.19.2.83] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
567 FakhriRavari A, Malakouti M, Brady R. Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 Infection. J Clin Transl Hepatol 2016;4:97-112. [PMID: 27350940 DOI: 10.14218/JCTH.2016.00007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
568 O'Connor KS, Read SA, Wang M, Schibeci S, Eslam M, Ong A, Weltman MD, Douglas MW, Mazzola A, Craxì A, Petta S, Stewart GJ, Liddle C, George J, Ahlenstiel G, Booth DR. IFNL3/4 genotype is associated with altered immune cell populations in peripheral blood in chronic hepatitis C infection. Genes Immun 2016;17:328-34. [PMID: 27307212 DOI: 10.1038/gene.2016.27] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
569 Huik K, Avi R, Pauskar M, Kallas E, Jõgeda EL, Karki T, Rüütel K, Talu A, Abel-Ollo K, Uusküla A, Carrillo A, Ahuja SK, He W, Lutsar I. A CCL5 Haplotype Is Associated with Low Seropositivity Rate of HCV Infection in People Who Inject Drugs. PLoS One 2016;11:e0156850. [PMID: 27304910 DOI: 10.1371/journal.pone.0156850] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
570 Hydes TJ, Moesker B, Traherne JA, Ashraf S, Alexander GJ, Dimitrov BD, Woelk CH, Trowsdale J, Khakoo SI. The interaction of genetic determinants in the outcome of HCV infection: evidence for discrete immunological pathways. Tissue Antigens 2015;86:267-75. [PMID: 26381047 DOI: 10.1111/tan.12650] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
571 Fan W, Xie S, Zhao X, Li N, Chang C, Li L, Yu G, Chi X, Pan Y, Niu J, Zhong J, Sun B. IFN-λ4 desensitizes the response to IFN-α treatment in chronic hepatitis C through long-term induction of USP18. J Gen Virol 2016;97:2210-20. [PMID: 27302182 DOI: 10.1099/jgv.0.000522] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
572 Chinnaswamy S. Gene-disease association with human IFNL locus polymorphisms extends beyond hepatitis C virus infections. Genes Immun 2016;17:265-75. [PMID: 27278127 DOI: 10.1038/gene.2016.24] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
573 Romagnoli R, Martini S, Tandoi F, Dell Olio D, Magistroni P, Bertinetto FE, Dametto E, Rizzetto M, Salizzoni M, Amoroso A. Early reduced liver graft survival in hepatitis C recipients identified by two combined genetic markers. Transpl Int 2016;29:1070-84. [DOI: 10.1111/tri.12795] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
574 Waldron PR, Belitskaya-Lévy I, Chary A, Won J, Winters M, Monto A, Ryan J, Lazzeroni LC, Holodniy M. Genetic Variation in the IL-6 and HLA-DQB1 Genes Is Associated with Spontaneous Clearance of Hepatitis C Virus Infection. J Immunol Res 2016;2016:6530436. [PMID: 27340680 DOI: 10.1155/2016/6530436] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
575 Di Marco V, D'Ambrosio R, Bronte F, Saracco G, Lanza AG, Forni G, Poggiali E, Calvaruso V; on behalf ITHACA (Italy for THAalassemia, hepatitis C Advances) Group. Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication? Dig Liver Dis 2016;48:650-5. [PMID: 27012446 DOI: 10.1016/j.dld.2016.02.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
576 D'Avolio A, Cusato J, De Nicolò A, Allegra S, Di Perri G. Pharmacogenetics of ribavirin-induced anemia in HCV patients. Pharmacogenomics 2016;17:925-41. [PMID: 27248282 DOI: 10.2217/pgs.16.22] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
577 Tangkijvanich P, Chittmittraprap S, Poovorawan K, Limothai U, Khlaiphuengsin A, Chuaypen N, Wisedopas N, Poovorawan Y. A randomized clinical trial of peginterferon alpha-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B: Role of host and viral factors associated with treatment response. J Viral Hepat 2016;23:427-38. [PMID: 26387494 DOI: 10.1111/jvh.12467] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
578 Minakari M, Golshani M, Yaran M, Ataei B. Prevalence of interleukin-28B single nucleotide polymorphism genotypes in patients with hepatitis C infection in Isfahan, Iran. Adv Biomed Res 2016;5:90. [PMID: 27308262 DOI: 10.4103/2277-9175.183138] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
579 Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, Lesmana CR, Sollano J, Kumar M, Jindal A. APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. Hepatol Int. 2016;10:681-701. [PMID: 27229718 DOI: 10.1007/s12072-016-9736-3] [Cited by in Crossref: 58] [Cited by in F6Publishing: 66] [Article Influence: 8.3] [Reference Citation Analysis]
580 Grandi T, Silva CM, Amaral KM, Picon PD, Costi C, Fré NN, Fiegenbaum M, Gregianini TS, Niel C, Rossetti ML. Tumour necrosis factor -308 and -238 promoter polymorphisms are predictors of a null virological response in the treatment of Brazilian hepatitis C patients. Mem Inst Oswaldo Cruz 2014;109:345-51. [PMID: 24789557 DOI: 10.1590/0074-0276130372] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
581 Domingues P, Bamford CGG, Boutell C, McLauchlan J. Inhibition of hepatitis C virus RNA replication by ISG15 does not require its conjugation to protein substrates by the HERC5 E3 ligase. J Gen Virol 2015;96:3236-42. [PMID: 26361997 DOI: 10.1099/jgv.0.000283] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
582 Abdelwahab SF. Cellular immune response to hepatitis-C-virus in subjects without viremia or seroconversion: is it important? Infect Agent Cancer 2016;11:23. [PMID: 27186234 DOI: 10.1186/s13027-016-0070-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
583 Bang BR, Elmasry S, Saito T. Organ system view of the hepatic innate immunity in HCV infection. J Med Virol 2016;88:2025-37. [PMID: 27153233 DOI: 10.1002/jmv.24569] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
584 Waldenström J, Westin J, Nyström K, Christensen P, Dalgard O, Färkkilä M, Lindahl K, Nilsson S, Norkrans G, Krarup H, Norrgren H, Rauning Buhl M, Stenmark S, Lagging M. Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection. PLoS One 2016;11:e0155142. [PMID: 27167219 DOI: 10.1371/journal.pone.0155142] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
585 Manolakopoulos S, Zacharakis G, Zissis M, Giannakopoulos V. Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis C. Ann Gastroenterol 2016;29:282-96. [PMID: 27366028 DOI: 10.20524/aog.2016.0041] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
586 Kondo C, Atsukawa M, Tsubota A, Shimada N, Abe H, Aizawa Y. Evaluation of factors associated with relapse in telaprevir-based triple therapy for chronic hepatitis C. J Postgrad Med 2016;62:20-5. [PMID: 26732192 DOI: 10.4103/0022-3859.173191] [Reference Citation Analysis]
587 Kadjbaf D, Keshvari M, Alavian SM, Pouryasin A, Behnava B, Salimi S, Mehrnoush L, Karimi Elizee P, Sharafi H. The Prevalence of Hepatitis C Virus Core Amino Acid 70 Substitution and Genotypes of Polymorphisms Near the IFNL3 Gene in Iranian Patients With Chronic Hepatitis C. Hepat Mon 2016;16:e37011. [PMID: 27630727 DOI: 10.5812/hepatmon.37011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
588 Duarte-Rojo A, Fischer SE, Adeyi O, Zita D, Deneke MG, Selzner N, Chen L, Malespin M, Cotler SJ, McGilvray ID, Feld JJ. Protease inhibitors partially overcome the interferon nonresponse phenotype in patients with chronic hepatitis C. J Viral Hepat 2016;23:340-7. [PMID: 26710754 DOI: 10.1111/jvh.12494] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
589 Kanwal F, Kramer JR, El-Serag HB, Frayne S, Clark J, Cao Y, Taylor T, Smith D, White D, Asch SM. Race and Gender Differences in the Use of Direct Acting Antiviral Agents for Hepatitis C Virus. Clin Infect Dis 2016;63:291-9. [PMID: 27131869 DOI: 10.1093/cid/ciw249] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 6.4] [Reference Citation Analysis]
590 Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, Lesmana CR, Sollano J, Kumar M, Jindal A, Sharma BC, Hamid SS, Dokmeci AK, Mamun-Al-Mahtab, McCaughan GW, Wasim J, Crawford DH, Kao JH, Yokosuka O, Lau GK, Sarin SK. APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int. 2016;10:702-726. [PMID: 27130427 DOI: 10.1007/s12072-016-9717-6] [Cited by in Crossref: 157] [Cited by in F6Publishing: 153] [Article Influence: 22.4] [Reference Citation Analysis]
591 Wang LS, D'Souza LS, Jacobson IM. Hepatitis C-A clinical review. J Med Virol. 2016;88:1844-1855. [PMID: 27097298 DOI: 10.1002/jmv.24554] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
592 Wróblewska A, Bernat A, Woziwodzka A, Markiewicz J, Romanowski T, Bielawski KP, Smiatacz T, Sikorska K. Interferon lambda polymorphisms associate with body iron indices and hepatic expression of interferon-responsive long non-coding RNA in chronic hepatitis C. Clin Exp Med 2017;17:225-32. [PMID: 27125837 DOI: 10.1007/s10238-016-0423-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
593 Shuldiner SR, Gong L, Muir AJ, Altman RB, Klein TE. PharmGKB summary: peginterferon-α pathway. Pharmacogenet Genomics 2015;25:465-74. [PMID: 26111151 DOI: 10.1097/FPC.0000000000000158] [Reference Citation Analysis]
594 Shaker O, Rashad A, Abd El Aziz G, El Raziky M. Is rs8099917 polymorphism of IL-28B gene a good predictor of response to therapy of HCV than rs12979860? An Egyptian study. Cell Biochem Biophys 2015;71:307-14. [PMID: 25115611 DOI: 10.1007/s12013-014-0199-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
595 Bokharaei-Salim F, Salehi-Vaziri M, Sadeghi F, Esghaei M, Monavari SH, Alavian SM, Fakhim S, Keyvani H. The Association of Substitutions in the Hepatitis C Virus Subtype 1b Core Gene and IL28B Polymorphisms With the Response to Peg-IFNα-2a/RBV Combination Therapy in Azerbaijani Patients. Hepat Mon 2016;16:e35597. [PMID: 27313635 DOI: 10.5812/hepatmon.35597] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
596 Nunnari G, Fagone P, Condorelli F, Nicoletti F, Malaguarnera L, Di Rosa M. CD4+ T-cell gene expression of healthy donors, HIV-1 and elite controllers: Immunological chaos. Cytokine 2016;83:127-35. [PMID: 27108398 DOI: 10.1016/j.cyto.2016.04.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
597 Wei D, Li NL, Zeng Y, Liu B, Kumthip K, Wang TT, Huo D, Ingels JF, Lu L, Shang J, Li K. The Molecular Chaperone GRP78 Contributes to Toll-like Receptor 3-mediated Innate Immune Response to Hepatitis C Virus in Hepatocytes. J Biol Chem 2016;291:12294-309. [PMID: 27129228 DOI: 10.1074/jbc.M115.711598] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
598 Ogurtsov PP, Kukhareva EI. Prognostic value of the combination of blood group specificity and interleukin 28B gene polymorphism for estimation of efficiency of therapy with the use of pegylated interferon a-2 and ribavarin in patients with chronic genotype 1 hepatitis C. Klin med 2016;94:224-230. [DOI: 10.18821/0023-2149-2016-94-3-224-230] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
599 Mallory M, Hillyard D. Hepatitis C Virus. Clinical Virology Manual 2016. [DOI: 10.1128/9781555819156.ch25] [Reference Citation Analysis]
600 de la Fuente S, Citores M, Duca A, Cisneros E, Baños I, Vilches C, Cuervas-mons V. Interleukin-28B TT genotype is frequently found in patients with hepatitis C virus cirrhosis but does not influence hepatocarcinogenesis. Clin Exp Med 2017;17:217-23. [DOI: 10.1007/s10238-016-0418-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
601 Jiang DK, Wu X, Qian J, Ma XP, Yang J, Li Z, Wang R, Sun L, Liu F, Zhang P, Zhu X, Wu J, Chen K, Conran C, Zheng SL, Lu D, Yu L, Liu Y, Xu J. Genetic variation in STAT4 predicts response to interferon-α therapy for hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2016;63:1102-11. [PMID: 26704347 DOI: 10.1002/hep.28423] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
602 Tahata Y, Hiramatsu N, Oze T, Urabe A, Morishita N, Yamada R, Yakushijin T, Hosui A, Oshita M, Kaneko A, Hagiwara H, Mita E, Ito T, Yamada Y, Inada M, Katayama K, Tamura S, Imai Y, Hikita H, Sakamori R, Yoshida Y, Tatsumi T, Hayashi N, Takehara T. Impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin combination therapy. J Med Virol 2016;88:1776-84. [PMID: 26991414 DOI: 10.1002/jmv.24528] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
603 Moreira JP, Malta Fde M, Diniz MA, Kikuchi L, Chagas AL, Lima Lde S, Gomes-Gouvêa MS, de Castro VF, Santana RA, Sumita NM, Paranagua Vezozzo DC, Carrilho FJ, Pinho JR. Interferon lambda and hepatitis C virus core protein polymorphisms associated with liver cancer. Virology 2016;493:136-41. [PMID: 27035616 DOI: 10.1016/j.virol.2016.03.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
604 Livingston SE, Townshend-Bulson LJ, Bruden DJ, Homan CE, Gove JE, Plotnik JN, Simons BC, Spradling PR, McMahon BJ. Results of interferon-based treatments in Alaska Native and American Indian population with chronic hepatitis C. Int J Circumpolar Health 2016;75:30696. [PMID: 27029671 DOI: 10.3402/ijch.v75.30696] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
605 Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol. 2016;22:76-139. [PMID: 27044763 DOI: 10.3350/cmh.2016.22.1.76] [Cited by in Crossref: 49] [Cited by in F6Publishing: 63] [Article Influence: 7.0] [Reference Citation Analysis]
606 Foster GR, Coppola C, Derbala M, Ferenci P, Orlandini A, Reddy KR, Tallarico L, Shiffman ML, Ahlers S, Bakalos G, Hassanein T; GUARD-C Study Group. Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort. PLoS One 2016;11:e0151703. [PMID: 27018988 DOI: 10.1371/journal.pone.0151703] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
607 Asselah T, Thompson AJ, Flisiak R, Romero-Gomez M, Messinger D, Bakalos G, Shiffman ML. A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin. PLoS One 2016;11:e0150569. [PMID: 26991780 DOI: 10.1371/journal.pone.0150569] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
608 Moqueet N, Cooper C, Gill J, Hull M, Platt RW, Klein MB; Canadian Co-infection Cohort. Responder Interferon λ Genotypes Are Associated With Higher Risk of Liver Fibrosis in HIV-Hepatitis C Virus Coinfection. J Infect Dis 2016;214:80-6. [PMID: 26984148 DOI: 10.1093/infdis/jiw088] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
609 Kumar A, Gupta V, Sharma P, Bansal N, Singla V, Arora A. Association of Overt Diabetes Mellitus with the Non-CC but not the CC Genotype of Interleukin-28B in Hepatitis C Virus Infected Patients. J Clin Transl Hepatol 2016;4:26-31. [PMID: 27047769 DOI: 10.14218/JCTH.2016.00040] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
610 Nelson MR, Johnson T, Warren L, Hughes AR, Chissoe SL, Xu CF, Waterworth DM. The genetics of drug efficacy: opportunities and challenges. Nat Rev Genet 2016;17:197-206. [PMID: 26972588 DOI: 10.1038/nrg.2016.12] [Cited by in Crossref: 75] [Cited by in F6Publishing: 76] [Article Influence: 10.7] [Reference Citation Analysis]
611 de Seixas Santos Nastri AC, de Mello Malta F, Diniz MA, Yoshino A, Abe-Sandes K, Dos Santos SE, de Castro Lyra A, Carrilho FJ, Pinho JR. Association of IFNL3 and IFNL4 polymorphisms with hepatitis C virus infection in a population from southeastern Brazil. Arch Virol 2016;161:1477-84. [PMID: 26973228 DOI: 10.1007/s00705-016-2809-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
612 Lu MY, Huang CI, Dai CY, Wang SC, Hsieh MY, Hsieh MH, Liang PC, Lin YH, Hou NJ, Yeh ML, Huang CF, Lin ZY, Chen SC, Huang JF, Chuang WL, Yu ML. Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C. Sci Rep 2016;6:22995. [PMID: 26965318 DOI: 10.1038/srep22995] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
613 Scherer ML, Sammons C, Nelson B, Hammer SM, Verna E. Anti-Hepatitis Virus Agents. Clinical Virology 2016. [DOI: 10.1128/9781555819439.ch13] [Reference Citation Analysis]
614 Streeck H, Suscovich TJ, Alter G. Immune Responses to Viral Infection. Clinical Virology 2016. [DOI: 10.1128/9781555819439.ch16] [Reference Citation Analysis]
615 Koh C, Li Q, Liang J. Hepatitis C Virus. Clinical Virology 2016. [DOI: 10.1128/9781555819439.ch54] [Reference Citation Analysis]
616 Heidari Z, Moudi B, Mahmoudzadeh-Sagheb H, Hashemi M. The Correlation Between Interferon Lambda 3 Gene Polymorphisms and Susceptibility to Hepatitis B Virus Infection. Hepat Mon 2016;16:e34266. [PMID: 27226800 DOI: 10.5812/hepatmon.34266] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
617 Cohen TS, Parker D. Microbial pathogenesis and type III interferons. Cytokine Growth Factor Rev 2016;29:45-51. [PMID: 26987613 DOI: 10.1016/j.cytogfr.2016.02.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
618 Mueller JL, King LY, Johnson KB, Gao T, Nephew LD, Kothari D, Simpson MA, Zheng H, Wei L, Corey KE, Misdraji J, Lee JH, Lin MV, Gogela NA, Fuchs BC, Tanabe KK, Gordon FD, Curry MP, Chung RT. Impact of EGF, IL28B, and PNPLA3 polymorphisms on the outcome of allograft hepatitis C: a multicenter study. Clin Transplant 2016;30:452-60. [PMID: 26854475 DOI: 10.1111/ctr.12710] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
619 Johansson S, Talloen W, Tuefferd M, Darling J, Fanning G, Fried MW, Aerssens J. High MIG (CXCL9) plasma levels favours response to peginterferon and ribavirin in HCV-infected patients regardless of DPP4 activity. Liver Int 2016;36:344-52. [PMID: 26344576 DOI: 10.1111/liv.12932] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
620 Pacella I, Timperi E, Accapezzato D, Martire C, Labbadia G, Cavallari EN, D'Ettorre G, Calvo L, Rizzo F, Severa M, Coccia EM, Vullo V, Barnaba V, Piconese S. IFN-α promotes rapid human Treg contraction and late Th1-like Treg decrease. J Leukoc Biol 2016;100:613-23. [PMID: 26921346 DOI: 10.1189/jlb.5A0415-140R] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
621 Yoshio S, Kanto T. Host-virus interactions in hepatitis B and hepatitis C infection. J Gastroenterol 2016;51:409-20. [PMID: 26894594 DOI: 10.1007/s00535-016-1183-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
622 Yoshio S, Kanto T. Host-virus interactions in hepatitis B and hepatitis C infection. J Gastroenterol. 2016;51:409-420. [PMID: 26894594 DOI: 10.1093/nar/gkh131] [Cited by in Crossref: 2191] [Cited by in F6Publishing: 2346] [Article Influence: 313.0] [Reference Citation Analysis]
623 Ferraris P, Chandra PK, Panigrahi R, Aboulnasr F, Chava S, Kurt R, Pawlotsky JM, Wilkens L, Osterlund P, Hartmann R, Balart LA, Wu T, Dash S. Cellular Mechanism for Impaired Hepatitis C Virus Clearance by Interferon Associated with IFNL3 Gene Polymorphisms Relates to Intrahepatic Interferon-λ Expression. Am J Pathol 2016;186:938-51. [PMID: 26896692 DOI: 10.1016/j.ajpath.2015.11.027] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
624 Bellanti F, Lauletta G, Villani R, Lipsi MR, Natalicchio MI, Sansonno D, Vendemiale G, Serviddio G. Combined Effects of 2 Interleukin 28B Polymorphisms on the Therapeutic Outcome of Hepatitis C Patients With Circulating Cryoglobulins. Medicine (Baltimore) 2015;94:e1409. [PMID: 26334898 DOI: 10.1097/MD.0000000000001409] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
625 Poizot-Martin I, Bellissant E, Garraffo R, Colson P, Piroth L, Solas C, Renault A, Bourlière M, Halfon P, Ghosn J, Alric L, Naqvi A, Carrieri P, Molina JM; ANRS HC27 BOCEPREVIH Study Group. Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study. HIV Clin Trials 2016;17:63-71. [PMID: 27077673 DOI: 10.1080/15284336.2015.1135553] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
626 van Vlerken LG, Lieveld FI, van Meer S, Koek GH, van Nieuwkerk KM, Friederich P, Arends JE, Siersema PD, Burger DM, van Erpecum KJ. Adherence to ribavirin in chronic hepatitis C patients on antiviral treatment: Results from a randomized controlled trial using real-time medication monitoring. Clin Res Hepatol Gastroenterol 2016;40:622-30. [PMID: 26867863 DOI: 10.1016/j.clinre.2015.12.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
627 Marotta P, Bailey R, Elkashab M, Farley J, Feinman SV, Peltekian K, Poliquin M, Witt-Sullivan H, Rampakakis E, Drolet M, Cooper C. Real-world effectiveness of peginterferon α-2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWer and RediPEN studies. Eur J Clin Microbiol Infect Dis 2016;35:597-609. [PMID: 26851949 DOI: 10.1007/s10096-016-2576-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
628 Veazey RS, Pilch-Cooper HA, Hope TJ, Alter G, Carias AM, Sips M, Wang X, Rodriguez B, Sieg SF, Reich A, Wilkinson P, Cameron MJ, Lederman MM. Prevention of SHIV transmission by topical IFN-β treatment. Mucosal Immunol 2016;9:1528-36. [PMID: 26838048 DOI: 10.1038/mi.2015.146] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 5.1] [Reference Citation Analysis]
629 Douam F, Ding Q, Ploss A. Recent advances in understanding hepatitis C. F1000Res. 2016;5:pii: F1000. [PMID: 26918166 DOI: 10.12688/f1000research.7354.1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
630 Assone T, Paiva A, Fonseca LA, Casseb J. Genetic Markers of the Host in Persons Living with HTLV-1, HIV and HCV Infections. Viruses 2016;8:E38. [PMID: 26848682 DOI: 10.3390/v8020038] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
631 Wu LS, Jimmerson LC, MacBrayne CE, Kiser JJ, D'Argenio DZ. Modeling Ribavirin-Induced Anemia in Patients with Chronic Hepatitis C Virus. CPT Pharmacometrics Syst Pharmacol 2016;5:65-73. [PMID: 26933517 DOI: 10.1002/psp4.12058] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
632 Feillant M, Jézéquel C, Lison H, Delluc A, Tanné F, Le Gruyer A, Ben Ali Z, Renard I, Latournerie M, Deugnier Y, Garioud A, Cadranel JF, Guyader D, Robaszkiewicz M, Nousbaum JB. Chronic hepatitis C: treat or wait? A prospective study on reasons for treatment or nontreatment in the era of first-generation protease inhibitors. Eur J Gastroenterol Hepatol 2016;28:164-72. [PMID: 26560750 DOI: 10.1097/MEG.0000000000000506] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
633 Yoon JC, Yang CM, Song Y, Lee JM. Natural killer cells in hepatitis C: Current progress. World J Gastroenterol 2016; 22(4): 1449-1460 [PMID: 26819513 DOI: 10.3748/wjg.v22.i4.1449] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 36] [Article Influence: 4.4] [Reference Citation Analysis]
634 Cohen A, Bont L, Engelhard D, Moore E, Fernández D, Kreisberg-Greenblatt R, Oved K, Eden E, Hays JP. A multifaceted 'omics' approach for addressing the challenge of antimicrobial resistance. Future Microbiol 2015;10:365-76. [PMID: 25812460 DOI: 10.2217/fmb.14.127] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
635 Wu R, Chi X, Wang X, Sun H, Lv J, Gao X, Yu G, Kong F, Xu H, Hua R, Jiang J, Sun B, Zhong J, Pan Y, Niu J. IFNL4 ss469415590 polymorphism contributes to treatment decisions in patients with chronic hepatitis C virus genotype 1b, but not 2a, infection. Infect Genet Evol 2016;39:132-40. [PMID: 26820907 DOI: 10.1016/j.meegid.2016.01.020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
636 Behnava B, Sharafi H, Keshvari M, Pouryasin A, Mehrnoush L, Salimi S, Karimi Elizee P, Ghazimoghaddam M, Alavian SM. The Role of Polymorphisms Near the IL28B Gene on Response to Peg-Interferon and Ribavirin in Thalassemic Patients With Hepatitis C. Hepat Mon 2016;16:e32703. [PMID: 27110259 DOI: 10.5812/hepatmon.32703] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
637 Castellaneta A, Massaro A, Rendina M, D'Errico F, Carparelli S, Rizzi SF, Thomson AW, Di Leo A. Immunomodulating effects of the anti-viral agent Silibinin in liver transplant patients with HCV recurrence. Transplant Res 2016;5:1. [PMID: 26798454 DOI: 10.1186/s13737-016-0030-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
638 Bertino G, Ardiri A, Proiti M, Rigano G, Frazzetto E, Demma S, Ruggeri MI, Scuderi L, Malaguarnera G, Bertino N, Rapisarda V, Di Carlo I, Toro A, Salomone F, Malaguarnera M, Bertino E, Malaguarnera M. Chronic hepatitis C: This and the new era of treatment. World J Hepatol 2016; 8(2): 92-106 [PMID: 26807205 DOI: 10.4254/wjh.v8.i2.92] [Cited by in Crossref: 56] [Cited by in F6Publishing: 60] [Article Influence: 8.0] [Reference Citation Analysis]
639 Lim SG. Time for Action on Viral Hepatitis. Ann Acad Med Singap 2016;45:27-30. [DOI: 10.47102/annals-acadmedsg.v45n1p27] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
640 Chen R, Kobewka M, Addison W, Lachance G, Tyrrell DL. Intrinsic Viral Factors Are the Dominant Determinants of the Hepatitis C Virus Response to Interferon Alpha Treatment in Chimeric Mice. PLoS One 2016;11:e0147007. [PMID: 26765841 DOI: 10.1371/journal.pone.0147007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
641 McLaren PJ, Raisaro JL, Aouri M, Rotger M, Ayday E, Bartha I, Delgado MB, Vallet Y, Günthard HF, Cavassini M, Furrer H, Doco-Lecompte T, Marzolini C, Schmid P, Di Benedetto C, Decosterd LA, Fellay J, Hubaux JP, Telenti A. Privacy-preserving genomic testing in the clinic: a model using HIV treatment. Genet Med 2016;18:814-22. [PMID: 26765343 DOI: 10.1038/gim.2015.167] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 4.4] [Reference Citation Analysis]
642 Mccormack PL, Lyseng-williamson KA. Daclatasvir in hepatitis C virus infection: a guide to its use in the EU. Drugs Ther Perspect 2016;32:42-9. [DOI: 10.1007/s40267-015-0272-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
643 Wu H, Li N, Jin R, Meng Q, Chen P, Zhao G, Wang R, Li L, Li W. Cytokine levels contribute to the pathogenesis of minimal hepatic encephalopathy in patients with hepatocellular carcinoma via STAT3 activation. Sci Rep 2016;6:18528. [PMID: 26757951 DOI: 10.1038/srep18528] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
644 Gonzalez-Aldaco K, Rebello Pinho JR, Roman S, Gleyzer K, Fierro NA, Oyakawa L, Ramos-Lopez O, Ferraz Santana RA, Sitnik R, Panduro A. Association with Spontaneous Hepatitis C Viral Clearance and Genetic Differentiation of IL28B/IFNL4 Haplotypes in Populations from Mexico. PLoS One. 2016;11:e0146258. [PMID: 26741362 DOI: 10.1371/journal.pone.0146258] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
645 Siest G, Visvikis-siest S. La Pharmacogénomique, meilleur exemple de médecine personnalisée. Hegel 2016;N° 1:10-21. [DOI: 10.3917/heg.061.0010] [Reference Citation Analysis]
646 Štimac D, Franjić N. Personalized Medicine in Gastroenterology. Personalized Medicine 2016. [DOI: 10.1007/978-3-319-39349-0_13] [Reference Citation Analysis]
647 Colombatto P, Bonino F, Civitano L, Oliveri F, Ricco G, Iannazzo S, Brunetto MR. Modeling HCV Dynamics in Clinical Practice to Personalize Antiviral Therapy. Hepatitis C Virus II 2016. [DOI: 10.1007/978-4-431-56101-9_12] [Reference Citation Analysis]
648 Implications of Pharmacogenetics for Antimicrobial Prescribing. Molecular Microbiology 2016. [DOI: 10.1128/9781555819071.ch43] [Reference Citation Analysis]
649 Mondal D. Pegylated Interferon Alpha-2b☆. Reference Module in Biomedical Sciences 2016. [DOI: 10.1016/b978-0-12-801238-3.99412-1] [Reference Citation Analysis]
650 Nolte FS. Hepatitis B and C Viruses. Molecular Pathology in Clinical Practice 2016. [DOI: 10.1007/978-3-319-19674-9_46] [Reference Citation Analysis]
651 Peiffer KH, Sommer L, Susser S, Vermehren J, Herrmann E, Döring M, Dietz J, Perner D, Berkowski C, Zeuzem S, Sarrazin C. Interferon lambda 4 genotypes and resistance-associated variants in patients infected with hepatitis C virus genotypes 1 and 3. Hepatology 2016;63:63-73. [PMID: 26406534 DOI: 10.1002/hep.28255] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 5.3] [Reference Citation Analysis]
652 Mousa SM, El-Ghamrawy MK, Gouda H, Khorshied M, El-Salam Ahmed DA, Shiba H. Prevalence of Hepatitis C among Egyptian Children with Sickle Cell Disease and the Role of IL28b Gene Polymorphisms in Spontaneous Viral Clearance. Mediterr J Hematol Infect Dis 2016;8:e2016007. [PMID: 26740868 DOI: 10.4084/MJHID.2016.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
653 Schwarz KB, Molleston JP, Jonas MM, Wen J, Murray KF, Rosenthal P, Gonzalez-Peralta RP, Lobritto SJ, Mogul D, Pavlovic V, Warne C, Wat C, Thompson B. Durability of Response in Children Treated With Pegylated Interferon alfa [corrected] 2a ± Ribavirin for Chronic Hepatitis C. J Pediatr Gastroenterol Nutr 2016;62:93-6. [PMID: 26284539 DOI: 10.1097/MPG.0000000000000929] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
654 Gürbüz Y, Tülek NE, Tütüncü EE, Koruk ST, Aygen B, Demirtürk N, Kınıklı S, Kaya A, Yıldırmak T, Süer K, Korkmaz F, Ural O, Akhan S, Günal Ö, Tuna N, Köse Ş, Gönen İ, Örmen B, Türker N, Saltoğlu N, Batırel A, Tuncer G, Bulut C, Sırmatel F, Ulçay A, Karagöz E, Tosun D, Şener A, Aynıoğlu A, Altunok ES. Evaluation of Dual Therapy in Real Life Setting in Treatment-Naïve Turkish Patients with HCV Infection: A Multicenter, Retrospective Study. Balkan Med J 2016;33:18-26. [PMID: 26966614 DOI: 10.5152/balkanmedj.2015.15859] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
655 Slev PR, Hillyard DR. Host Factor Pharmacogenetics for Treatment of Infectious Diseases. Molecular Pathology in Clinical Practice 2016. [DOI: 10.1007/978-3-319-19674-9_20] [Reference Citation Analysis]
656 Ghany MG, Liang TJ. Natural History of Chronic Hepatitis C. Hepatitis C Virus II 2016. [DOI: 10.1007/978-4-431-56101-9_1] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
657 Wen J, Ohmer S, Honegger J. Hepatitis C Virus Infection in Pregnancy and Childhood. Hepatitis C Virus II 2016. [DOI: 10.1007/978-4-431-56101-9_7] [Reference Citation Analysis]
658 Hertzog PJ, Bourke NM, de Weerd NA, Mangan NE. New Interferons. Encyclopedia of Immunobiology 2016. [DOI: 10.1016/b978-0-12-374279-7.10007-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
659 Tanaka Y, Mizokami M. Host Genetics and Responses to Antiviral Therapy in Chronic Hepatitis C. Hepatitis C Virus II 2016. [DOI: 10.1007/978-4-431-56101-9_8] [Reference Citation Analysis]
660 Li K. Innate Immune Recognition of Hepatitis C Virus. Hepatitis C Virus I 2016. [DOI: 10.1007/978-4-431-56098-2_13] [Reference Citation Analysis]
661 Suwanthawornkul T, Anothaisintawee T, Sobhonslidsuk A, Thakkinstian A, Teerawattananon Y. Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naïve Hepatitis C Genotype 1: A Systematic Review and Network Meta-Analysis. PLoS One 2015;10:e0145953. [PMID: 26720298 DOI: 10.1371/journal.pone.0145953] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 6.1] [Reference Citation Analysis]
662 Vidimliski P, Nikolov I, Geshkovska N, Boyanova Y, Nikolova N. Association of the Treatment Induced Clearance of Hepatitis C Virus Infection with the IL28B Gene Polymorphisms. Arch Hepat Res 2015;1:005-008. [DOI: 10.17352/ahr.000002] [Reference Citation Analysis]
663 Veillon P, Fouchard-Hubert I, Larrey D, Dao MT, D'alteroche L, Boyer-Darrigand N, Picard N, Le Guillou-Guillemette H, Saulnier P, Ducancelle A, Loustaud-Ratti V, Lunel-Fabiani F. Does Epoetin Beta Still Have a Place in Peginterferon Alpha-2a Plus Ribavirin Treatment Strategies for Chronic Hepatitis C? J Interferon Cytokine Res 2016;36:204-14. [PMID: 26700738 DOI: 10.1089/jir.2015.0131] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
664 Wiegand SB, Heidrich B, Susser S, Rogalska-Taranta M, Petersen J, Böker KH, Grigorian N, Link R, Naumann U, John C, Lueth S, Malfertheiner P, Manns MP, Wedemeyer H, Sarrazin C, Cornberg M. Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting. PLoS One 2015;10:e0145622. [PMID: 26699619 DOI: 10.1371/journal.pone.0145622] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
665 Hung CH, Hu TH, Lu SN, Chen CH, Wang JH, Lee CM. Association of vitamin D receptor gene polymorphisms with response to peginterferon plus ribavirin in Asian patients with chronic hepatitis C. J Formos Med Assoc 2016;115:278-83. [PMID: 26725771 DOI: 10.1016/j.jfma.2015.11.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
666 Hu Z, Liu Y, Qiu L, Fan Z, Nie W, Liang S, Jin R. Kinetic response of wild and mutant core codon 70 strains of HCV genotype 1b to pegylated interferon-α and ribavirin therapy. Virol J 2015;12:220. [PMID: 26684004 DOI: 10.1186/s12985-015-0451-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
667 About F, Oudot-Mellakh T, Niay J, Rabiéga P, Pedergnana V, Duffy D, Sultanik P, Cagnot C, Carrat F, Marcellin P, Zoulim F, Larrey D, Hézode C, Fontaine H, Bronowicki JP, Pol S, Albert ML, Theodorou I, Cobat A, Abel L; ANRS CO20-CUPIC study group. Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study. PLoS One 2015;10:e0145105. [PMID: 26670100 DOI: 10.1371/journal.pone.0145105] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
668 Aboulnasr F, Hazari S, Nayak S, Chandra PK, Panigrahi R, Ferraris P, Chava S, Kurt R, Song K, Dash A, Balart LA, Garry RF, Wu T, Dash S. IFN-λ Inhibits MiR-122 Transcription through a Stat3-HNF4α Inflammatory Feedback Loop in an IFN-α Resistant HCV Cell Culture System. PLoS One 2015;10:e0141655. [PMID: 26657215 DOI: 10.1371/journal.pone.0141655] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
669 Jabłońska J, Pawłowski T, Laskus T, Zalewska M, Inglot M, Osowska S, Perlejewski K, Bukowska-Ośko I, Cortes KC, Pawełczyk A, Ząbek P, Radkowski M. The correlation between pretreatment cytokine expression patterns in peripheral blood mononuclear cells with chronic hepatitis C outcome. BMC Infect Dis 2015;15:556. [PMID: 26637466 DOI: 10.1186/s12879-015-1305-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
670 Xu Y, Huang P, Yue M, Su J, Chen H, Chen M, Wang J, Li J, Peng Z, Zhang Y, Yu R. A novel polymorphism near HLA class II region is associated with spontaneous clearance of HCV and response to interferon treatment in Chinese patients. J Hum Genet 2016;61:301-5. [PMID: 26632884 DOI: 10.1038/jhg.2015.145] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
671 Teng W, Chang T, Huang C, Jeng W, Chen W, Huang C, Ho Y, Lin C, Sheen I. IL28B polymorphism and early anemia predict the rapid null response in genotype-1 chronic hepatitis C with dual therapy. Advances in Digestive Medicine 2015;2:128-134. [DOI: 10.1016/j.aidm.2015.01.005] [Reference Citation Analysis]
672 Boursier J, Ducancelle A, Vergniol J, Veillon P, Moal V, Dufour C, Bronowicki JP, Larrey D, Hézode C, Zoulim F, Fontaine H, Canva V, Poynard T, Allam S, De Lédinghen V; ANRS CO20 CUPIC Study Group. The CUPIC algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients. J Viral Hepat 2015;22:1002-10. [PMID: 26216230 DOI: 10.1111/jvh.12433] [Reference Citation Analysis]
673 Akkız H, Akgöllü E, Bekar A, Yıldırım S, Sandıkçı M, Ülger Y, Yalınbaş Kaya B, Kuran S, Üsküdar O. Relationship between IL28B gene rs8099917 polymorphism and SVR in Turkish patients with hepatitis C virus genotype 1. Clinics and Research in Hepatology and Gastroenterology 2015;39:711-7. [DOI: 10.1016/j.clinre.2015.02.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
674 Lingala S, Ghany MG. Natural History of Hepatitis C. Gastroenterol Clin North Am 2015;44:717-34. [PMID: 26600216 DOI: 10.1016/j.gtc.2015.07.003] [Cited by in Crossref: 130] [Cited by in F6Publishing: 132] [Article Influence: 16.3] [Reference Citation Analysis]
675 Doyle JS, Deterding K, Grebely J, Wedemeyer H, Sacks-Davis R, Spelman T, Matthews G, Rice TM, Morris MD, McGovern BH, Kim AY, Bruneau J, Lloyd AR, Page K, Manns MP, Hellard ME, Dore GJ; InC3 Study Group. Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort. J Viral Hepat 2015;22:1020-32. [PMID: 26098993 DOI: 10.1111/jvh.12429] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
676 Hibi T, Shinoda M, Itano O, Obara H, Kitago M, Abe Y, Yagi H, Tanaka M, Hoshino K, Fujino A, Kuroda T, Kawachi S, Tanabe M, Shimazu M, Kitagawa Y. Steroid minimization immunosuppression protocol using basiliximab in adult living donor liver transplantation for hepatitis C virus-related cirrhosis. Hepatol Res 2015;45:1178-84. [PMID: 25594837 DOI: 10.1111/hepr.12486] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
677 Kaplan DE. Immunopathogenesis of Hepatitis C Virus Infection. Gastroenterol Clin North Am 2015;44:735-60. [PMID: 26600217 DOI: 10.1016/j.gtc.2015.07.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
678 Sarkar M, Aouzierat B, Bacchetti P, Prokunina-Olsson L, French A, Seaberg E, O'Brien TR, Kuniholm MH, Minkoff H, Plankey M, Strickler HD, Peters MG; Women's Interagency HIV. Association of IFNL3 and IFNL4 polymorphisms with liver-related mortality in a multiracial cohort of HIV/HCV-coinfected women. J Viral Hepat 2015;22:1055-60. [PMID: 26115445 DOI: 10.1111/jvh.12431] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
679 Fateh A, Aghasadeghi M, Siadat SD, Vaziri F, Sadeghi F, Fateh R, Keyvani H, Tasbiti AH, Yari S, Ataei-Pirkooh A, Monavari SH. Comparison of Three Different Methods for Detection of IL28 rs12979860 Polymorphisms as a Predictor of Treatment Outcome in Patients with Hepatitis C Virus. Osong Public Health Res Perspect 2016;7:83-9. [PMID: 27169005 DOI: 10.1016/j.phrp.2015.11.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
680 Casanova JL. Human genetic basis of interindividual variability in the course of infection. Proc Natl Acad Sci U S A 2015;112:E7118-27. [PMID: 26621739 DOI: 10.1073/pnas.1521644112] [Cited by in Crossref: 120] [Cited by in F6Publishing: 125] [Article Influence: 15.0] [Reference Citation Analysis]
681 Najarro MA, Hackett JL, Smith BR, Highfill CA, King EG, Long AD, Macdonald SJ. Identifying Loci Contributing to Natural Variation in Xenobiotic Resistance in Drosophila. PLoS Genet 2015;11:e1005663. [PMID: 26619284 DOI: 10.1371/journal.pgen.1005663] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 4.8] [Reference Citation Analysis]
682 Tai AW, Chung RT. Hepatitis C Virus Infection. Yamada' s Textbook of Gastroenterology 2015. [DOI: 10.1002/9781118512074.ch96] [Reference Citation Analysis]
683 Lee MH, Yang HI, Lu SN, Lin YJ, Jen CL, Wong KH, Chan SY, Chen LC, Wang LY, L'Italien G, Yuan Y, Chen CJ. Polymorphisms near the IFNL3 Gene Associated with HCV RNA Spontaneous Clearance and Hepatocellular Carcinoma Risk. Sci Rep 2015;5:17030. [PMID: 26602024 DOI: 10.1038/srep17030] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
684 Biasiolo A, Martini A, Pontisso P. New biomarkers for clinical management of hepatitis C virus infected patients. World J Clin Infect Dis 2015; 5(4): 59-66 [DOI: 10.5495/wjcid.v5.i4.59] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
685 Amanzada A, Reinhardt L, Fey D, Zeisberg EM, Mihm S. Hepatic Interferon-λ3 (IFNL3) Gene Expression Reveals Not to Be Attenuated in Non-Favorable IFNL3 rs4803217 or IFNL4 rs368234815 Minor Allele Carriers in Chronic Hepatitis C. PLoS One 2015;10:e0143783. [PMID: 26606750 DOI: 10.1371/journal.pone.0143783] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
686 Hwang JJ, Lo CC, Lin CH, Cheng HS, Hung IW, Tsai WJ, Hung CH. Association between IPTA gene polymorphisms and hematological abnormalities in hepatitis C virus-infected patients receiving combination therapy. Gut Liver 2015;9:214-23. [PMID: 25287171 DOI: 10.5009/gnl14095] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
687 Hiramine S, Furusyo N, Ogawa E, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Koyanagi T, Kotoh K, Shimoda S, Hayashi J. Importance of virological response in the early stage of telaprevir-based triple therapy for hepatitis C. World J Hepatol 2015; 7(26): 2688-2695 [PMID: 26609346 DOI: 10.4254/wjh.v7.i26.2688] [Reference Citation Analysis]
688 Enomoto H, Nishiguchi S. Factors associated with the response to interferon-based antiviral therapies for chronic hepatitis C. World J Hepatol 2015; 7(26): 2681-2687 [PMID: 26609345 DOI: 10.4254/wjh.v7.i26.2681] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
689 Martin-santos R, Egmond E, Cavero M, Mariño Z, Subira S, Navines R, Forns X, Valdes M. Chronic hepatitis C, depression and gender: a state of art. Advances in Dual Diagnosis 2015;8:193-210. [DOI: 10.1108/add-05-2015-0009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
690 Dzekova-Vidimliski P, Nikolov IG, Matevska-Geshkovska N, Boyanova Y, Nikolova N, Romanciuc G, Dumitrascu D, Caloska-Ivanova V, Joksimovic N, Antonov K, Mateva L, Rostaing L, Dimovski A, Sikole A. Genetic predictors of the response to the treatment of hepatitis C virus infection. Bosn J Basic Med Sci 2015;15:55-9. [PMID: 26614853 DOI: 10.17305/bjbms.2015.632] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
691 Fénéant L, Ghosn J, Fouquet B, Helle F, Belouzard S, Vausselin T, Séron K, Delfraissy JF, Dubuisson J, Misrahi M. Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro. PLoS One. 2015;10:e0142539. [PMID: 26561856 DOI: 10.1371/journal.pone.0142539] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
692 Cheng CH, Chen HL, Lin IT, Wu CH, Lee YK, Wong MW, Bair MJ. The genotype distribution of hepatitis C in southeastern Taiwan: Clinical characteristics, racial difference, and therapeutic response. Kaohsiung J Med Sci 2015;31:597-602. [PMID: 26678941 DOI: 10.1016/j.kjms.2015.09.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
693 de Sá KS, Santana BB, de Souza Ferreira TC, Sousa RC, Caldas CA, Azevedo VN, Feitosa RN, Machado LF, de Oliveira Guimarães Ishak M, Ishak R, Vallinoto AC. IL28B gene polymorphisms and Th1/Th2 cytokine levels might be associated with HTLV-associated arthropathy. Cytokine 2016;77:79-87. [PMID: 26546777 DOI: 10.1016/j.cyto.2015.11.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
694 Lu YF, Mauger DM, Goldstein DB, Urban TJ, Weeks KM, Bradrick SS. IFNL3 mRNA structure is remodeled by a functional non-coding polymorphism associated with hepatitis C virus clearance. Sci Rep. 2015;5:16037. [PMID: 26531896 DOI: 10.1038/srep16037] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 5.0] [Reference Citation Analysis]
695 Fabrício-Silva GM, Poschetzky BS, de Mello Perez R, Dos Santos RC, Cavalini LT, Porto LC. Association of cytokine gene polymorphisms with hepatitis C virus infection in a population from Rio de Janeiro, Brazil. Hepat Med 2015;7:71-9. [PMID: 26586969 DOI: 10.2147/HMER.S89447] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
696 O'Brien TR, Pfeiffer RM, Paquin A, Lang Kuhs KA, Chen S, Bonkovsky HL, Edlin BR, Howell CD, Kirk GD, Kuniholm MH, Morgan TR, Strickler HD, Thomas DL, Prokunina-Olsson L. Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance. J Hepatol 2015;63:1103-10. [PMID: 26186989 DOI: 10.1016/j.jhep.2015.06.035] [Cited by in Crossref: 55] [Cited by in F6Publishing: 58] [Article Influence: 6.9] [Reference Citation Analysis]
697 Wang H, El Maadidi S, Fischer J, Grabski E, Dickhöfer S, Klimosch S, Flannery SM, Filomena A, Wolz OO, Schneiderhan-Marra N, Löffler MW, Wiese M, Pichulik T, Müllhaupt B, Semela D, Dufour JF, Bochud PY, Bowie AG, Kalinke U, Berg T, Weber AN; East-German and Swiss Hepatitis C Virus Study Groups. A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearance. Hepatology 2015;62:1375-87. [PMID: 26250868 DOI: 10.1002/hep.28105] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
698 Johansson S, Talloen W, Tuefferd M, Darling JM, Scholliers A, Fanning G, Fried MW, Aerssens J. Plasma levels of growth-related oncogene (CXCL1-3) associated with fibrosis and platelet counts in HCV-infected patients. Aliment Pharmacol Ther 2015;42:1111-21. [PMID: 26314558 DOI: 10.1111/apt.13389] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
699 Eshera N, Itana H, Zhang L, Soon G, Fadiran EO. Demographics of Clinical Trials Participants in Pivotal Clinical Trials for New Molecular Entity Drugs and Biologics Approved by FDA From 2010 to 2012. American Journal of Therapeutics 2015;22:435-55. [DOI: 10.1097/mjt.0000000000000177] [Cited by in Crossref: 50] [Cited by in F6Publishing: 55] [Article Influence: 6.3] [Reference Citation Analysis]
700 Cai Q, Zhang X, Lin C, Shao X, Guan Y, Deng H, Wei M, Huang M, Ren Z, Lu L, Mei Y, Xu M, Zhu J, Shi H, Lin G, Liu Y, Hu F, Luo Q, Lan Y, Guo F, Zhao Z, Gao Z. 24 versus 48 Weeks of Peginterferon Plus Ribavirin in Hepatitis C Virus Genotype 6 Chronically Infected Patients with a Rapid Virological Response: A Non-Inferiority Randomized Controlled Trial. PLoS One 2015;10:e0140853. [PMID: 26509605 DOI: 10.1371/journal.pone.0140853] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
701 Lazear HM, Nice TJ, Diamond MS. Interferon-λ: Immune Functions at Barrier Surfaces and Beyond. Immunity 2015;43:15-28. [PMID: 26200010 DOI: 10.1016/j.immuni.2015.07.001] [Cited by in Crossref: 302] [Cited by in F6Publishing: 261] [Article Influence: 37.8] [Reference Citation Analysis]
702 Shi X, Chi X, Pan Y, Gao Y, Li W, Yang C, Zhong J, Xu D, Zhang M, Minuk G, Jiang J, Niu J. IL28B is associated with outcomes of chronic HBV infection. Yonsei Med J 2015;56:625-33. [PMID: 25837166 DOI: 10.3349/ymj.2015.56.3.625] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
703 Macaluso FS, Maida M, Petta S. Genetic background in nonalcoholic fatty liver disease: A comprehensive review. World J Gastroenterol 2015; 21(39): 11088-11111 [PMID: 26494964 DOI: 10.3748/wjg.v21.i39.11088] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 62] [Article Influence: 7.6] [Reference Citation Analysis]
704 Zabaleta A, Riezu-Boj JI, Larrea E, Villanueva L, Lasarte JJ, Guruceaga E, Fisicaro P, Ezzikouri S, Missale G, Ferrari C. Gene expression analysis during acute hepatitis C virus infection associates dendritic cell activation with viral clearance. J Med Virol. 2016;88:843-851. [PMID: 26447929 DOI: 10.1002/jmv.24399] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
705 Akuta N, Suzuki F, Sezaki H, Hosaka T, Kobayashi M, Suzuki Y, Saitoh S, Kobayashi M, Ikeda K, Kumada H. Evolution of simeprevir-resistant variants in virological non-responders infected with HCV genotype 1b. J Med Virol 2015;87:609-18. [PMID: 25655809 DOI: 10.1002/jmv.24113] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
706 Shah FA, Fatima K, Sabir S, Ali S, Qadri I, ud Din N. Design, synthesis, structure information and biochemical activity of new floro substituted organotin(IV) carboxylates. J Photochem Photobiol B 2016;154:99-107. [PMID: 26708070 DOI: 10.1016/j.jphotobiol.2015.10.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
707 Wack A, Terczyńska-Dyla E, Hartmann R. Guarding the frontiers: the biology of type III interferons. Nat Immunol 2015;16:802-9. [PMID: 26194286 DOI: 10.1038/ni.3212] [Cited by in Crossref: 219] [Cited by in F6Publishing: 225] [Article Influence: 27.4] [Reference Citation Analysis]
708 Iolascon A, Andolfo I, Russo R. Red cells in post-genomic era: impact of personalized medicine in the treatment of anemias. Haematologica 2015;100:3-6. [PMID: 25552677 DOI: 10.3324/haematol.2014.120733] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
709 Del Campo JA, Romero-Gómez M. Modulation of host lipid metabolism by hepatitis C virus: Role of new therapies. World J Gastroenterol 2015; 21(38): 10776-10782 [PMID: 26478669 DOI: 10.3748/wjg.v21.i38.10776] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
710 Geginat J, Nizzoli G, Paroni M, Maglie S, Larghi P, Pascolo S, Abrignani S. Immunity to Pathogens Taught by Specialized Human Dendritic Cell Subsets. Front Immunol 2015;6:527. [PMID: 26528289 DOI: 10.3389/fimmu.2015.00527] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 4.4] [Reference Citation Analysis]
711 Gralinski LE, Ferris MT, Aylor DL, Whitmore AC, Green R, Frieman MB, Deming D, Menachery VD, Miller DR, Buus RJ, Bell TA, Churchill GA, Threadgill DW, Katze MG, McMillan L, Valdar W, Heise MT, Pardo-Manuel de Villena F, Baric RS. Genome Wide Identification of SARS-CoV Susceptibility Loci Using the Collaborative Cross. PLoS Genet 2015;11:e1005504. [PMID: 26452100 DOI: 10.1371/journal.pgen.1005504] [Cited by in Crossref: 116] [Cited by in F6Publishing: 118] [Article Influence: 14.5] [Reference Citation Analysis]
712 Carnero E, Fortes P. HCV infection, IFN response and the coding and non-coding host cell genome. Virus Res 2016;212:85-102. [PMID: 26454190 DOI: 10.1016/j.virusres.2015.10.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
713 Zhu SS, Zeng QL, Dong Y, Xu ZQ, Wang LM, Chen DW, Gan Y, Wang FC, Yan JG, Cao LL, Wang P, Han J, Zhang XX, Zhang Z, Zhang HF, Wang FS. Interferon-α plus ribavirin yields 98 % sustained virologic response in children aged 1-5 years with iatrogenic chronic hepatitis C. Hepatol Int 2015;9:578-85. [PMID: 26449425 DOI: 10.1007/s12072-015-9671-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
714 Maan R, van der Meer AJ, Brouwer WP, Plompen EP, Sonneveld MJ, Roomer R, van der Eijk AA, Groothuismink ZM, Hansen BE, Veldt BJ, Janssen HL, Boonstra A, de Knegt RJ. ITPA Polymorphisms Are Associated with Hematological Side Effects during Antiviral Therapy for Chronic HCV Infection. PLoS One 2015;10:e0139317. [PMID: 26441325 DOI: 10.1371/journal.pone.0139317] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
715 Lee HW, Lee SH, Lee MG, Ahn SH, Chang HY, Han KH. The clinical implication of single nucleotide polymorphisms in deoxycytidine kinase in chronic hepatitis B patients treated with lamivudine. J Med Virol 2016;88:820-7. [PMID: 26400223 DOI: 10.1002/jmv.24393] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
716 Lang Kuhs KA, Kuniholm MH, Pfeiffer RM, Chen S, Desai S, Edlin BR, Peters MG, Plankey M, Sharp GB, Strickler HD, Villacres MC, Quinn TC, Gange SJ, Prokunina-Olsson L, Greenblatt RM, O'Brien TR. Interferon Lambda 4 Genotype Is Not Associated with Recurrence of Oral or Genital Herpes. PLoS One 2015;10:e0138827. [PMID: 26431156 DOI: 10.1371/journal.pone.0138827] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
717 Robinson MW, Aranday-Cortes E, Gatherer D, Swann R, Liefhebber JM, Filipe Ada S, Sigruener A, Barclay ST, Mills PR, Patel AH, McLauchlan J. Viral genotype correlates with distinct liver gene transcription signatures in chronic hepatitis C virus infection. Liver Int 2015;35:2256-64. [PMID: 25800823 DOI: 10.1111/liv.12830] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
718 Rady NH, Darwish RK, Mogahed EA, Mandour IA, Abo Youssef H, Sharaf SAA, El-karaksy HM. Potential genetic markers for prediction of treatment response in Egyptian children infected with HCV genotype 4. Cytokine 2015;75:349-55. [DOI: 10.1016/j.cyto.2015.04.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
719 Zheng H, Li M, Chi B, Wu X, Wang J, Liu D. IL28B rs12980275 variant as a predictor of sustained virologic response to pegylated-interferon and ribavirin in chronic hepatitis C patients: A systematic review and meta-analysis. Clinics and Research in Hepatology and Gastroenterology 2015;39:576-83. [DOI: 10.1016/j.clinre.2015.01.009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
720 Bernieh B. Viral hepatitis in hemodialysis: An update. J Transl Int Med. 2015;3:93-105. [PMID: 27847896 DOI: 10.1515/jtim-2015-0018] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 4.0] [Reference Citation Analysis]
721 Gardiner CM. NK cell function and receptor diversity in the context of HCV infection. Front Microbiol 2015;6:1061. [PMID: 26483779 DOI: 10.3389/fmicb.2015.01061] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
722 Korean Society for AIDS. The 2015 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans. Infect Chemother 2015;47:205-11. [PMID: 26483998 DOI: 10.3947/ic.2015.47.3.205] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
723 Thompson AJ, Holmes JA. Treating hepatitis C - what's new? Aust Prescr 2015;38:191-7. [PMID: 26843711 DOI: 10.18773/austprescr.2015.068] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
724 Finotti G, Tamassia N, Calzetti F, Fattovich G, Cassatella MA. Endogenously produced TNF-α contributes to the expression of CXCL10/IP-10 in IFN-λ3-activated plasmacytoid dendritic cells. J Leukoc Biol 2016;99:107-19. [PMID: 26382296 DOI: 10.1189/jlb.3VMA0415-144R] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
725 Coppola N, Pisaturo M, Sagnelli C, Onorato L, Sagnelli E. Role of genetic polymorphisms in hepatitis C virus chronic infection. World J Clin Cases 2015; 3(9): 807-822 [PMID: 26380828 DOI: 10.12998/wjcc.v3.i9.807] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
726 Enache EL, Sin A, Bancu L, Ramière C, Diaz O, André P, Enache LS. Duplex High-Resolution Melting Assay for the Simultaneous Genotyping of IL28B rs12979860 and PNPLA3 rs738409 Polymorphisms in Chronic Hepatitis C Patients. Int J Mol Sci 2015;16:22223-42. [PMID: 26389885 DOI: 10.3390/ijms160922223] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
727 Real LM, Herrero R, Rivero-Juárez A, Camacho Á, Macías J, Vic S, Soriano V, Viedma S, Guardiola JM, Fibla J, Rivero A, Pineda JA, Caruz A. IFNL4 rs368234815 polymorphism is associated with innate resistance to HIV-1 infection. AIDS 2015;29:1895-7. [PMID: 26372394 DOI: 10.1097/QAD.0000000000000773] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
728 Tamaki N, Kurosaki M, Higuchi M, Takada H, Nakakuki N, Yasui Y, Suzuki S, Tsuchiya K, Nakanishi H, Itakura J. Genetic Polymorphisms of IL28B and PNPLA3 Are Predictive for HCV Related Rapid Fibrosis Progression and Identify Patients Who Require Urgent Antiviral Treatment with New Regimens. PLoS One. 2015;10:e0137351. [PMID: 26352693 DOI: 10.1371/journal.pone.0137351] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
729 Kogiso T, Hashimoto E, Ikarashi Y, Kodama K, Taniai M, Torii N, Egawa H, Yamamoto M, Tokushige K. Spontaneous clearance of HCV accompanying hepatitis after liver transplantation. Clin J Gastroenterol. 2015;8:323-329. [PMID: 26342292 DOI: 10.1007/s12328-015-0602-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
730 Webb GJ, Hirschfield GM. Using GWAS to identify genetic predisposition in hepatic autoimmunity. J Autoimmun. 2016;66:25-39. [PMID: 26347073 DOI: 10.1016/j.jaut.2015.08.016] [Cited by in Crossref: 76] [Cited by in F6Publishing: 80] [Article Influence: 9.5] [Reference Citation Analysis]
731 Thanapirom K, Suksawatamnuay S, Sukeepaisarnjaroen W, Tangkijvanich P, Treeprasertsuk S, Thaimai P, Wasitthankasem R, Poovorawan Y, Komolmit P. Association between CXCL10 and DPP4 Gene Polymorphisms and a Complementary Role for Unfavorable IL28B Genotype in Prediction of Treatment Response in Thai Patients with Chronic Hepatitis C Virus Infection. PLoS One 2015;10:e0137365. [PMID: 26339796 DOI: 10.1371/journal.pone.0137365] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
732 Akamatsu S, Hayes CN, Ochi H, Uchida T, Kan H, Murakami E, Abe H, Tsuge M, Miki D, Akiyama R, Hiraga N, Imamura M, Aikata H, Kawaoka T, Kawakami Y, Chayama K. Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A. J Hepatol 2015;63:554-63. [PMID: 25849245 DOI: 10.1016/j.jhep.2015.03.033] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
733 Balagopal A, Thomas DL. Editorial Commentary: Who is "Special" Now? Clin Infect Dis 2015;61:826-8. [PMID: 25977267 DOI: 10.1093/cid/civ382] [Reference Citation Analysis]
734 Lapalus M, Laouenan C, Cardoso AC, Estrabaud E, Carvalho-Filho RJ, Zhang Q, Lada O, Appourchaux K, Mouri F, Boyer N, Bedossa P, Asselah T, Martinot-Peignoux M, Marcellin P. Precore/Core promoter variants to predict significant fibrosis in both HBeAg positive and negative chronic hepatitis B. Liver Int 2015;35:2082-9. [PMID: 25612083 DOI: 10.1111/liv.12787] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
735 Hajarizadeh B, Grady B, Page K, Kim AY, McGovern BH, Cox AL, Rice TM, Sacks-Davis R, Bruneau J, Morris M, Amin J, Schinkel J, Applegate T, Maher L, Hellard M, Lloyd AR, Prins M, Geskus RB, Dore GJ, Grebely J; InC3 Study Group. Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study. J Viral Hepat 2015;22:708-17. [PMID: 25580520 DOI: 10.1111/jvh.12384] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
736 Florian J, Mishra P, Arya V, Harrington P, Connelly S, Reynolds K, Sinha V. Direct-acting antiviral drugs for the treatment of chronic hepatitis C virus infection: Interferon free is now. Clin Pharmacol Ther 2015;98:394-402. [DOI: 10.1002/cpt.185] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
737 Heim MH. Interferon signaling. Signaling Pathways in Liver Diseases 2015. [DOI: 10.1002/9781118663387.ch16] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
738 Read SA, Tay ES, Shahidi M, O'Connor KS, Booth DR, George J, Douglas MW. Hepatitis C Virus Driven AXL Expression Suppresses the Hepatic Type I Interferon Response. PLoS One 2015;10:e0136227. [PMID: 26313459 DOI: 10.1371/journal.pone.0136227] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
739 Akuta N, Sezaki H, Suzuki F, Kawamura Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Arase Y. Relationships between serum asunaprevir concentration and alanine aminotransferase elevation during daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. J Med Virol. 2016;88:506-511. [PMID: 26292191 DOI: 10.1002/jmv.24360] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [